Document:

Exhibit 10.55

 

[* *] Portions of the this exhibit have been omitted pursuant to a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

 

FIRST AMENDED AND RESTATED PRODUCTS PURCHASE AGREEMENT

 

THIS FIRST AMENDED AND RESTATED PRODUCTS PURCHASE AGREEMENT (this “Agreement”), is entered into and effective as of the 8th day of May, 2013 (the “Effective Date”), by and between Rockwell Medical, Inc., a Michigan  corporation (“Rockwell”), and DaVita Healthcare Partners Inc., a Delaware corporation (“DaVita”) on behalf of itself and the DaVita Facilities (as defined in Recital B).  Capitalized terms used herein and not otherwise defined herein shall have the meaning set forth in Article XVIII.

 

RECITALS

 

A.                                    Rockwell is in the business of manufacturing and selling dialysis products and supplies, including the dialysis products and supplies set forth on Exhibit A attached hereto and incorporated herein by this reference (each, a “Product”, and collectively, the “Products”).

 

B.                                    DaVita owns (in whole or in part) or manages dialysis and vascular access facilities, clinics, and units located throughout the United States and its territories (each, a “DaVita Facility”, and collectively, the “DaVita Facilities”).

 

C.                                    Rockwell and DaVita entered into that certain Products Purchase Agreement, effective as of February 16, 2011 (the “Original Agreement”), whereby Rockwell agreed to sell certain products to DaVita and the DaVita Facilities, subject to all of the terms and conditions of the Original Agreement.

 

D.                                    Rockwell and DaVita desire to enter into this Agreement in order to: (i) amend and restate (and supersede and replace) the Original Agreement, effective as of the Effective Date, and (ii) set forth the terms and conditions on which: (A) DaVita, on behalf of itself and the DaVita Facilities, will purchase and acquire the Products from Rockwell, and (B) Rockwell will supply and sell the Products to DaVita and the DaVita Facilities.

 

In consideration of the foregoing premises and mutual covenants, agreements, representations, and warranties contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

 

ARTICLE I

 

PURCHASE AND SALE OF PRODUCTS AND REPORTS

 

1.1                               Sale and Purchase. During the Term (as defined in Section 2.2) and subject to the terms and conditions of this Agreement, Rockwell will sell, supply, convey, transfer, assign, and deliver the Products to DaVita and the DaVita Facilities in such quantities as DaVita or the DaVita Facilities may order from time to time.

 

1.2                               Product Commitment.  DaVita covenants and agrees that at [* *] of the DaVita Facilities (the “Committed DaVita Facilities”) will use their best efforts to purchase all of their requirements for acid concentrate (i.e., CitraPure®, Dri-Sate® Dry Acid or RenalPure® Liquid Acid) and bicarbonate (i.e., RenalPure® Bicarbonate Powder or Sterilyte® Liquid Bicarbonate) from Rockwell

 

 

each calendar year during the Term (the “Product Commitment”).  [* *]  Rockwell’s sole and exclusive remedy against DaVita and the DaVita Facilities for any breach by the DaVita Committed Facilities of the Product Commitment shall be to terminate this Agreement, and in such event Rockwell shall not be entitled to any other relief or remedy whatsoever, including any monetary damages, against DaVita or any of the DaVita Facilities.  Rockwell understands and acknowledges that the DaVita Facilities not included in the Committed DaVita Facilities (the “Non-Committed DaVita Facilities”) have not promised or committed to purchase any particular quantity of any of the Products or any particular percentage of their requirements for items such as the Products, and that each of the Non-Committed DaVita Facilities may purchase other products from other vendors and suppliers performing some or all of the same functions as the Products.

 

1.3                               Monthly Reports.  Each month during the Term, Rockwell shall deliver a report to DaVita in accordance with DaVita’s specifications, which specifications will be given to Rockwell by DaVita.  Each monthly report, at a minimum, shall (a) show all purchases of the Products made by each DaVita Facility by Product or Product categories, (b) include year-to-date purchase figures for each DaVita Facility, and (c) include any other information reasonably requested by DaVita relating to each DaVita Facility’s purchases of the Products pursuant to this Agreement.

 

1.4                               Notice of Changes to Product Labeling.  If, at any time during the Term, Rockwell or any applicable Governmental Authority determines that there must be an amendment, change, revision, or modification to the product labeling, safety information, or any other information relating to any particular Product (a “Product Labeling Event”), Rockwell shall within five (5) Business Days of any such Product Labeling Event, deliver a written notice to DaVita which: (a) describes in reasonable detail any such Product Labeling Event, (b) explains in reasonable detail the reasons and the causes for any such Product Labeling Event, and (c) includes a copy of such amendment, change, revision, or modification to the product labeling, safety information, or any other information relating to any such particular Product (the “Product Label Change Notice”).  Rockwell shall respond to any questions, inquiries, or requests for additional information that DaVita or any DaVita Facility may have with respect to any Product Label Change Notice and shall assist DaVita and the DaVita Facilities in understanding how, if at all, any Product Labeling Event may affect or have an impact on DaVita’s or any DaVita Facilities’ use of the Products.

 

ARTICLE II

 

TERM AND TERMINATION

 

2.1                               Term.  This Agreement shall commence on the Effective Date, and shall continue in effect until December 31, 2018 (the “Initial Term”), unless sooner terminated in accordance with the provisions of this Article II.

 

2.2                               Renewal.  If, upon the expiration of the Initial Term, the parties hereto have not negotiated, executed, and delivered (a) a new agreement relating to the subject matter hereof or (b) an extension of this Agreement, this Agreement shall continue until the earlier of: (i) either party hereto providing ninety (90) days prior written notice of termination to the other party hereto or (ii) the parties hereto entering into a new agreement relating to the subject matter hereof or an extension of this Agreement (the Initial Term, together with any such extension shall be referred to as the “Term”).

 

2.3                               DaVita Termination Rights.  This Agreement may be terminated by DaVita as follows:

 

(a)                                 Immediately in the event of a breach by Rockwell of any of its covenants or obligations set forth in Articles VI or IX; or

 

2

 

(b)                                 Upon thirty (30) days prior written notice to Rockwell, in the event of a breach by Rockwell of any representation, warranty, covenant, or obligation of Rockwell contained in this Agreement (other than the covenants or obligations set forth in Articles VI or IX), and Rockwell fails to cure such breach within thirty (30) days following the date of such notice; or

 

(c)                                  Immediately upon the occurrence of any of the following: (i) Rockwell files a voluntary petition in bankruptcy seeking protection from creditors (a “Bankruptcy Filing”); or (ii) Rockwell fails to contest an involuntary Bankruptcy Filing made against it or, despite contesting such involuntary Bankruptcy Filing, fails to obtain its dismissal within sixty (60) days from its filing; or (iii) a trustee or custodian is appointed for a substantial portion of or all of the assets of Rockwell; or (iv) Rockwell fails to pay its debts as they become due or admits its inability to do so (each of the foregoing, an “Insolvency Event”); or

 

(d)                                 Immediately in the event there is a change in Rockwell’s status which excludes it from participation in any Federal health care program, as defined under 42 U.S.C. § 1320a-7b(f).

 

2.4                               Rockwell Termination Rights.  This Agreement may be terminated by Rockwell as follows:

 

(a)                                 Immediately in the event of a breach by DaVita of any of its covenants or obligations set forth in Article IX; or

 

(b)                                 Upon thirty (30) days prior written notice to DaVita, in the event of a breach by DaVita of any representation, warranty, covenant, or obligation of DaVita contained in this Agreement (other than the covenants or obligations set forth in Article IX or Section 17.1), and DaVita fails to cure such breach within thirty (30) days following the date of such notice; or

 

(c)                                  Immediately upon the occurrence of an Insolvency Event with respect to DaVita; or

 

(d)                                 Upon at least nine (9) months prior written notice to DaVita in the event that Rockwell decides to either: [* *]; or

 

(e)                                  Upon sixty (60) days advance written notice to DaVita in the event of a breach by DaVita of Section 17.1, and DaVita fails to cure such with breach within sixty (60) days following the date of such notice; or

 

(f)                                   Immediately in the event there is a change in DaVita’s status which excludes it from participation in any Federal health care program, as defined under 42 U.S.C. § 1320a-7b(f).

 

2.5                               Effect of Termination.  The expiration of this Agreement or the earlier termination of this Agreement for any reason will not release either party hereto from any liability or obligation which, at the time of the expiration of this Agreement or the earlier termination of this Agreement for any reason, has already accrued or which thereafter may accrue in respect to any act or omission prior to the expiration of this Agreement or the earlier termination of this Agreement for any reason.

 

ARTICLE III

 

PURCHASE PRICE AND OTHER PRICING COVENANTS

 

3.1                               Purchase Price.  The purchase price for each Product is set forth on Exhibit A (each, a “Purchase Price” and collectively, the “Purchase Prices”).  The Purchase Price includes [* *] to the states

 

3

 

set forth on Exhibit B attached hereto (the “Territory”).  In the event that DaVita or any DaVita Facility requires any Product to be shipped outside of the Territory, DaVita and Rockwell shall [* *].  All orders for each Product by DaVita or any DaVita Facility shall be subject to [* *] set forth on Exhibit C attached hereto.  In the event that DaVita or any DaVita Facility desires to order an amount of any Product [* *].

 

3.2                               Taxes.  Rockwell covenants and agrees that neither DaVita nor any DaVita Facility shall be liable for any taxes including any excise, gross receipts, gross earnings, gross value, property, income taxes measured on Rockwell’s income, or other taxes, other than applicable sales taxes, with respect to the purchase and sale of the Products.  [* *].

 

3.3                               Pricing Covenant.  Rockwell represents and warrants to DaVita that the Purchase Price for each Product and all other terms of sale offered to DaVita and the DaVita Facilities for each Product [* *].

 

3.4                               Price Increase.  At any time on or after [* *], Rockwell may [* *] submit a written notice to DaVita requesting a meeting with DaVita to discuss and negotiate in good faith possible adjustments to the Purchase Price of any of the Products [* *].  The parties shall meet at a mutually agreeable time and location within fifteen (15) days of such meeting request.  During such meeting, if Rockwell requests an increase to the Purchase Price of a Product, it shall deliver to DaVita within five (5) days of such meeting or at such meeting, reasonably detailed documentation which documents and indicates that [* *].  In the event the parties are not able to reach a mutually agreeable adjustment to the Purchase Price of any Product for which Rockwell requested an adjustment within thirty (30) days of the meeting, then either party hereto shall have the right to terminate this Agreement upon ninety (90) days’ prior written notice to the other party hereto.

 

ARTICLE IV

 

PURCHASE ORDERS; DELIVERY; DEDICATED CUSTOMER SERVICE REPRESENTATIVE

 

4.1                               Purchase Orders and Delivery.  Each Product shall be delivered by Rockwell to DaVita or any DaVita Facility, as applicable, pursuant to the terms of each purchase order submitted by DaVita or any such DaVita Facility, as applicable. DaVita or any DaVita Facility may submit an order for the purchase of any of the Products via facsimile at [* *].  Rockwell shall provide accurate and on-time deliveries of all orders placed, in accordance with any reasonable special instructions that may be included in the purchase order [* *].

 

4.2                               Dedicated Customer Service Representatives.  Rockwell hereby agrees and covenants that it shall provide DaVita with reasonable access to one or more dedicated customer service representatives (each, a “Service Representative”) who shall be available to promptly respond to and address any issues that DaVita or any DaVita Facility may have with respect to any of the Products or any of Rockwell’s obligations set forth in this Agreement (the “Customer Services”).  Rockwell further agrees and covenants that each Service Representative shall perform the Customer Services in the highest professional manner.

 

4.3                               Return Goods Policy. Rockwell hereby represents and warrants to DaVita that attached hereto as Exhibit D is a true, correct, and complete copy of Rockwell’s “Return Goods Policy” (the “Return Goods Policy”).  Notwithstanding anything to the contrary set forth in the Return Goods Policy, DaVita or a DaVita Facility, as applicable, reserves the right to inspect all Products and to reject any or all of the Products which are, in DaVita’s or a DaVita Facility’s, as applicable, reasonable discretion, incorrectly shipped by Rockwell, defective, damaged, contaminated, or otherwise not in compliance with

 

4

 

the warranties granted or assigned hereunder.  Any return pursuant to this Section 4.3 by DaVita or any DaVita Facility, as applicable, shall be sent back to Rockwell [* *].  Upon the return of any Product by DaVita or any DaVita Facility, as applicable, to Rockwell pursuant to this Section 4.3, [* *].    DaVita and each DaVita Facility shall also have the right to return any Product pursuant to the terms and conditions set forth in the Return Goods Policy which do not conflict with this Section 4.3.  Rockwell shall provide DaVita with at least thirty (30) days prior written notice of any changes to the Return Goods Policy.

 

ARTICLE V

 

PAYMENT TERMS

 

All purchases by DaVita or any DaVita Facility of Products pursuant to this Agreement shall be paid on terms [* *].  DaVita or any DaVita Facility, as applicable, may withhold payment on the portion of any invoice for which DaVita or any such DaVita Facility, as applicable, has a bona fide dispute if it: (a) pays all undisputed amounts, (b) notifies Rockwell of such invoice dispute, and (c) provides to Rockwell a reconciliation of charges and any documentation necessary to support its claimed adjustment.  The parties hereto agree to use their commercially reasonable efforts to resolve any invoice dispute within thirty (30) days of Rockwell’s receipt of any such invoice dispute notice from DaVita or any DaVita Facility, as applicable.

 

ARTICLE VI

 

FAILURE TO SUPPLY

 

In the event of Rockwell’s failure or inability to supply any Product(s) within and for the time period required by DaVita or any DaVita Facility, as applicable, including as a result of a force majeure event (e.g., act of God, fire, casualty, flood, war, act of terrorism, strike, lockout, labor trouble, failure of public utilities, injunction, epidemic, riot, insurrection, or any other circumstances beyond the reasonable control of Rockwell) (a “Failure to Supply Event”), Rockwell covenants and agrees that it shall (a) give notice as promptly as is practicable under the circumstances to DaVita of such Failure to Supply Event, unless an order of a regulatory agency or other action arising out of patient safety concerns requires the giving of shorter notice; [* *].  Rockwell further covenants and agrees that during the period that a Failure to Supply Event is occurring, none of the Committed DaVita Facilities shall be subject to the Product Commitment.

 

ARTICLE VII

 

INVENTORY RESERVE COVENANTS

 

Rockwell agrees and covenants to DaVita that it shall, at all times during the Term, to allow for the continuous and uninterrupted supply of each of the Products to DaVita and the DaVita Facilities: (a) maintain and reserve for use exclusively by DaVita and the DaVita Facilities an amount of inventory of each Product equal [* *] and (b) have outstanding purchase orders with its suppliers for raw materials and products in amount sufficient to allow Rockwell to manufacture an amount of each such Product equal to [* *].

 

5

 

ARTICLE VIII

 

ADDITIONAL PRODUCTS AND REPLACEMENT PRODUCTS

 

8.1                               Additional Products.  Throughout the Term, Rockwell shall provide to DaVita and the DaVita Facilities the right to purchase or lease all current or new products manufactured, utilized, licensed, sold, or distributed by Rockwell or any of its Affiliates (including products and product lines acquired by Rockwell or any of its Affiliates as a result of an acquisition, merger, or other transaction involving Rockwell or any of its Affiliates) that are or that become Commercially Available and which are not already covered by this Agreement or by any other agreement, whether written or oral, between the parties hereto (such products are collectively referred to as “Additional Products” and individually as an “Additional Product”).  Rockwell agrees to include DaVita in all of its and its Affiliates distributions of customer announcements regarding Rockwell’s or its Affiliates’ Additional Products.  The purchase price for any Additional Product(s) shall be negotiated by the parties hereto in good faith and the agreed upon purchase price shall be memorialized in writing as a supplement or amendment to this Agreement.  Rockwell covenants and agrees that it shall only make an offer for the sale of any Additional Product(s) to DaVita’s Vice-President of Clinical Operations, Chief Medical Officer, or Group Vice-President, and not to any DaVita Facility directly; provided that the purchase of any Additional Product(s) by DaVita or any DaVita Facility through a Rockwell product catalog made generally available to the dialysis community shall not be a breach by Rockwell of this Section 8.1.  If Rockwell or any of its Affiliates acquires any Additional Product(s) as a result of an acquisition, merger, or other transaction involving Rockwell or any of its Affiliates with a Person with which DaVita or a DaVita Facility, as applicable, already has a purchase or rebate arrangement whether written or oral (a “Prior Agreement”), Rockwell or such Affiliate covenants and agrees that it shall continue to abide by all of the terms and conditions of such Prior Agreement or if DaVita requests, any such Additional Product(s) shall be included in this Agreement on terms to be negotiated and determined by the parties hereto as provided in this Section 8.1.

 

8.2                               Replacement Products.  If at anytime during the Term, Rockwell or any of its Affiliates introduces a product or offering that is a replacement for an existing Product covered by this Agreement, whether developed by Rockwell or any of its Affiliates or acquired by Rockwell or any of its Affiliates in connection with any transaction (a “Replacement Product”), Rockwell will allow (or will cause its Affiliate to allow) DaVita or any DaVita Facility, as applicable, to purchase such Replacement Product at the same price as the Product it is replacing or is ultimately intended to replace.

 

ARTICLE IX

 

CONFIDENTIAL INFORMATION COVENANTS

 

9.1                               Confidential Information.

 

(a)                                 No Disclosure of Confidential Information.  The Non-Disclosing Party (as defined in Section 18.5) agrees that in connection with the transactions contemplated by this Agreement and the relationship of the parties hereto, it will have access to Confidential Information of the Disclosing Party (as defined in Section 18.5) and that such Confidential Information is vital, sensitive, confidential, and proprietary to the Disclosing Party.  Therefore, the Non-Disclosing Party agrees that during the Term and for the longest time permitted under applicable law after the expiration of this Agreement or the earlier termination of this Agreement for any reason, that it will (i) hold any Confidential Information delivered or communicated to it by the Disclosing Party in the strictest confidence, including taking all reasonable precautions to prevent the inadvertent disclosure of any such Confidential Information to any unauthorized third party or parties and (ii) not, at any time without the Disclosing Party’s express written consent, which consent may be withheld by the Disclosing Party in its sole and absolute discretion (A) disclose, reproduce, display, perform, record, broadcast, transmit, distribute, modify, translate, combine with other information or materials, create derivative works based on, exploit commercially, or otherwise use any such Confidential Information in any manner or medium whatsoever, (B) disclose or publicize any such Confidential Information or the terms of this Agreement to any third party or parties, or (C)

 

6

 

discuss with or otherwise disclose or reveal to any third party or parties any information relating to the Disclosing Party’s business or the Non-Disclosing Party’s duties or responsibilities to the Disclosing Party, regardless of whether such information constitutes Confidential Information.  Notwithstanding anything to the contrary herein, the Non-Disclosing Party shall have the right to disclose any of the terms or provisions of this Agreement upon any determination by the Non-Disclosing Party that such disclosure is necessary in connection with the compliance by the Non-Disclosing Party with any legal requirement, including applicable obligations and requirements pursuant to federal and state securities laws and listing standards.

 

(b)                                 Retention and Destruction of Confidential Information.  The Non-Disclosing Party shall not take or retain any Confidential Information that is in written, email, computerized, model, sample, or other form capable of physical delivery, upon or after the expiration of this Agreement or the earlier termination of this Agreement for any reason without the prior written consent of the Disclosing Party, which consent may be withheld by the Disclosing Party in its sole and absolute discretion.  At any time upon the request of the Disclosing Party, the Non-Disclosing Party shall promptly redeliver to the Disclosing Party or destroy all written materials containing or reflecting any information contained in the Confidential Information (including all copies, extracts, or other reproductions) and agree to destroy all documents, memoranda, notes, and other writings whatsoever (including all copies, extracts, or other reproductions), prepared by the Non-Disclosing Party based on the information contained in the Confidential Information.  Notwithstanding the return or destruction of the Confidential Information, the Non-Disclosing Party will continue to abide by its obligations of confidentiality and other obligations hereunder.

 

(c)                                  Exceptions to Confidential Information.  Notwithstanding anything to the contrary herein, Confidential Information shall not include any information that (i) was already known to the Non-Disclosing Party at the time of disclosure by the Disclosing Party free of any restriction, (ii) is generally available to the public or becomes publicly known through no wrongful act of the Non-Disclosing Party, or (iii) is received by the Non-Disclosing Party from a third-party who has a legal right to provide such information to the Non-Disclosing Party.

 

(d)                                 Use of Trademarks and Other Intellectual Property.  Each party hereto agrees not to internally or externally use, release, publish, or distribute any materials or information (including advertising and promotional materials) containing the names, tradenames, trademarks, or other intellectual property right of the other party hereto without the express prior written consent of such other party hereto.

 

(e)                                  Disclosures of Confidential Information Required By Law.  In the event that the Non-Disclosing Party is required by law (e.g., by oral questions, interrogatories, request for information or documents, subpoena, civil investigative demand, or any other similar process) to disclose any Confidential Information, the Non-Disclosing Party agrees that it shall provide the Disclosing Party with prompt written notice of any such disclosure of any such Confidential Information that is required by law (prior to making such disclosure and in no event later than five (5) days after the receipt of such request(s)) and shall consult with the Disclosing Party as to the advisability of taking legally advisable steps to resist or narrow any such disclosure of any such Confidential Information that is required by law.  If disclosure of any Confidential Information is required by law, the Non-Disclosing Party will (i) furnish only that portion of any such Confidential Information which, in the reasonable opinion of the Non-Disclosing Party’s counsel, after consultation with the Disclosing Party’s counsel, it is legally obligated to disclose and (ii) use its best efforts to obtain an order or other reliable assurances that confidential and non-public treatment will be accorded to any such Confidential Information that is required to be disclosed by law.

 

7

 

(f)                                   Employees, Agents, Representatives, Etc.  For purposes of this Section 9.1, any Confidential Information received by any director, officer, member, manager, partner, employee, agent, subcontractor, advisor, or representative of the Non-Disclosing Party pursuant to the terms and conditions of this Agreement shall be deemed received by the Non-Disclosing Party and any breach by such persons of this Section 9.1 shall be deemed a breach by the Non-Disclosing Party of this Agreement.

 

9.2                               Enforcement.  The Non-Disclosing Party agrees that money damages would not be an adequate remedy for any breach of this Article IX.  Therefore, in the event of a breach or threatened breach of the provisions of this Article IX by the Non-Disclosing Party, the Disclosing Party may, in addition to other rights and remedies existing in its favor, apply to any court of competent jurisdiction for specific performance, injunctive relief, or any other relief in order to enforce or prevent any violation of the provisions of this Article IX (without proving monetary damages, posting a bond, or other security).

 

ARTICLE X

 

REPRESENTATIONS AND WARRANTIES OF ROCKWELL

 

Rockwell hereby represents and warrants to DaVita as follows:

 

10.1                        Standing and Authority.  Rockwell has the requisite corporate power, right, and authority to enter into this Agreement and to consummate the transactions contemplated hereby.  Rockwell’s execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action on the part of Rockwell.

 

10.2                        Execution; Delivery; Binding Effect.  This Agreement has been duly executed and delivered by Rockwell, and constitutes the legal, valid, and binding obligation of Rockwell, enforceable against Rockwell in accordance with its terms.

 

10.3                        No Conflicts.  Neither the execution, delivery, or performance of this Agreement by Rockwell nor the consummation of the transactions contemplated in this Agreement, shall (a) conflict with, contravene, or result in a breach of any statute or administrative regulation, or of any law, rule, regulation, ordinance, order, writ, injunction, judgment, or decree of any Governmental Authority or of any arbitration award to which Rockwell is a party or by which any of the properties or assets of Rockwell are or may be bound or (b) conflict with, contravene, or violate any agreement, understanding, or arrangement to which Rockwell is a party or by which any of the properties or assets of Rockwell are or may be bound.

 

10.4                        Title.  Rockwell possesses good and marketable title to all of the Products free and clear of any and all liens, mortgages, charges, security interests, pledges, or other encumbrances or adverse claims of any nature, whether arising by agreement, operation of law, or otherwise (collectively, “Liens”).  Rockwell has the right to convey and in connection with the transactions contemplated by this Agreement will convey to DaVita and the DaVita Facilities, as applicable, good and marketable title to all of the Products acquired hereunder, free and clear of any and all Liens.

 

10.5                        Licenses, Permits, and Compliance with Laws.  Rockwell has all rights, licenses, permits, and consents necessary to sell the Products to DaVita and the DaVita Facilities and to perform its obligations hereunder during the Term.  Rockwell is and has at all times been in and during the Term shall be in compliance with all federal, state, and local laws, statutes, rules, and regulations applicable to its business and the performance of its obligations under this Agreement.  No Product delivered hereunder during the Term is or will be adulterated or misbranded within the meaning of the FFDCA, or within the meaning of any applicable state or municipal law, or is or will be a product which may not be introduced

 

8

 

into interstate commerce.  During the Term, Rockwell shall immediately inform DaVita following its receipt of any information which states that the integrity or legal status of any Product provided hereunder has been called into question by any retailer, wholesaler, or state or federal authority, or that any such Product sold to DaVita or any DaVita Facility hereunder is suspected of being counterfeit, stolen, adulterated, misbranded, or otherwise an unlawful product and shall provide DaVita with prompt written confirmation of any such event, including copies of any and all documents related thereto.  DaVita’s and the DaVita Facilities’ use of the Products in accordance with their intended use shall not infringe upon any ownership rights of any other Person or upon any patent, copyright, trademark, or other intellectual property or proprietary right or trade secret of any third party.

 

10.6                        Products.  Each Product purchased during the Term (a) is and shall be manufactured in accordance with its packaging, (b) is and shall be manufactured, handled, stored, and transported in accordance with all applicable United States, state, and local laws and regulations pertaining thereto, including to the extent applicable, the FFDCA and implementing regulations and FDA approved Good Manufacturing Practices, (c) meets all specifications for effectiveness and safety as required by the FDA, (d) is fit for the indications described in its labeling, and (e) is labeled in compliance with all applicable laws.  Each Product is and will (i) be of the kind and quantity specified herein, (ii) be of safe and merchantable quality, (iii) be free of defects in design, materials, manufacture, or workmanship when delivered, (iv) [* *], and (v) conform to its specifications as written or published, unless otherwise agreed to by the parties hereto.  In the event any Product or any component of a Product is not manufactured by Rockwell, Rockwell hereby assigns or agrees to assign (to the extent assignable) to DaVita all such manufacturer warranties, copies of which shall be provided by Rockwell to DaVita upon request.

 

10.7                        Expired Product.  Rockwell will use its best efforts not to ship to DaVita or any DaVita Facility expired Product [* *], unless agreed to in writing by DaVita.  In the event that Rockwell ships to DaVita or any DaVita Facility expired Product [* *], DaVita shall have the right to return such Product to Rockwell at Rockwell’s sole cost and expense.

 

10.8                        Health Care Programs.  Rockwell is not currently (a) named on any of the following lists (i) HHS/OIG List of Excluded Individuals/Entities, (ii) GSA List of Parties Excluded from Federal Programs, or (iii) OFAC “SDN and Blocked Individuals” or (b) under investigation or otherwise aware of any circumstances which would result in Rockwell being excluded from participation in any Federal health care program, as defined under 42 U.S.C. §1320a-7b(f).

 

All warranties granted or assigned under this Article X will continue in full force and effect notwithstanding transfer of title to any Product to or by DaVita or any DaVita Facility to any other DaVita Facility.  All warranties granted under this Agreement shall survive inspection, acceptance, and payment of the Products.

 

ARTICLE XI

 

REPRESENTATIONS AND WARRANTIES OF DAVITA

 

DaVita hereby represents and warrants to Rockwell as follows:

 

11.1                        Standing and Authority.  DaVita has the requisite corporate power, right, and authority to enter into this Agreement and to consummate the transactions contemplated hereby.  DaVita’s execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action on the part of DaVita.

 

9

 

11.2                        Execution; Delivery; Binding Effect.  This Agreement has been duly executed and delivered by DaVita, and constitutes the legal, valid, and binding obligation of DaVita, enforceable against DaVita in accordance with its terms.

 

11.3                        No Conflicts.  Neither the execution, delivery, or performance of this Agreement by DaVita nor the consummation of the transactions contemplated in this Agreement, shall (a) conflict with, contravene, or result in a breach of any statute or administrative regulation, or of any law, rule, regulation, ordinance, order, writ, injunction, judgment, decree of any Governmental Authority, or of any arbitration award to which DaVita is a party or by which any of the properties or assets of DaVita are or may be bound or (b) conflict with, contravene, or violate any provision of any agreement, understanding, or arrangement to which DaVita is a party or by which any of the properties or assets of DaVita are or may be bound.

 

11.4                        Compliance with Laws.                 DaVita has all rights, licenses, permits, and consents necessary to perform its obligations hereunder during the Term.  DaVita is and has at all times been in and during the Term shall be in compliance with all federal, state, and local laws, statutes, rules, and regulations applicable to its business and the performance of its obligations under this Agreement.

 

11.5                        Health Care Programs.  DaVita is not currently (a) named on any of the following lists (i) HHS/OIG List of Excluded Individuals/Entities, (ii) GSA List of Parties Excluded from Federal Programs, or (iii) OFAC “SDN and Blocked Individuals” or (b) under investigation or otherwise aware of any circumstances which would result in DaVita being excluded from participation in any Federal health care program, as defined under 42 U.S.C. §1320a-7b(f).

 

ARTICLE XII

 

INDEMNIFICATION AND INSURANCE

 

12.1                        Indemnification of DaVita.  Rockwell agrees to defend, indemnify, and hold DaVita, its Affiliates, and the DaVita Facilities and each of their respective directors, officers, members, managers, partners, employees, and agents (collectively, the “DaVita Indemnitees”) harmless from and against any and all causes of action (at law or in equity), actions, claims, costs, suits, liabilities, judgments, settlements, demands, losses, damages, proceedings, or expenses of all kinds (including reasonable attorneys’ fees, witnesses’ fees, investigation expenses, and any other expenses incident thereto) (collectively, “Losses”) that the DaVita Indemnitees may sustain or incur as a result of: (a) any breach of any representation or warranty made by Rockwell in this Agreement or in materials furnished by Rockwell for DaVita’s and the DaVita Facilities’ use; (b) any breach by Rockwell of any of its covenants or obligations in this Agreement; (c) the use of any Product by DaVita or any DaVita Facility in accordance with any such Products’ labeling and instructions for use; (d) any defect in the design or manufacture of any Product (including claims for property damage, loss of life, and bodily injury); (e) any Recall (as defined in Article XIII) with respect to any Product; or (f) any negligent, reckless, wanton, malicious, or other tortious conduct by Rockwell in connection with the transactions contemplated by this Agreement.  Notwithstanding the foregoing, in no event shall Rockwell have an obligation to defend, indemnify, or hold any of the DaVita Indemnitees harmless hereunder to the extent any Losses were caused by the sole negligence or willful misconduct of any such DaVita Indemnitees.

 

12.2                        Indemnification of Rockwell.  DaVita agrees to defend, indemnify, and hold Rockwell and its Affiliates and each of their respective directors, officers, members, managers, partners, employees, and agents (collectively, the “Rockwell Indemnitees”) harmless from and against any and all Losses that the Rockwell Indemnitees may sustain or incur as a result of: (a) any breach of any representation or warranty made by DaVita in this Agreement; (b) any breach by DaVita of any of its covenants or

 

10

 

obligations in this Agreement; (c) the use of any Product by DaVita or any DaVita Facility not in accordance with any such Products’ labeling and instructions for use; (d) any DaVita Facilities’ negligence or misconduct in the “Administration” of a Product to its patients; or (e) any negligent, reckless, wanton, malicious, or other tortious conduct by DaVita in connection with the transactions contemplated by this Agreement.  For purposes of this Section 12.2, the “Administration” of a Product by a DaVita Facility shall mean the dispensing and handling by such DaVita Facility and its employees of such Product and the actual administration of such Product to patients by such DaVita Facility and its employees, but shall exclude physician prescriptions of such Product to patients.  Notwithstanding the foregoing, in no event shall DaVita have an obligation to defend, indemnify, or hold any of the Rockwell Indemnitees harmless hereunder to the extent any Losses were caused by the sole negligence or willful misconduct of any such Rockwell Indemnitees.

 

12.3                        Indemnification Procedure for Third Party Claims.  If any DaVita Indemnitee or any Rockwell Indemnitee entitled to indemnification under this Article XII (the “Indemnified Party”) receives notice of the assertion of any claim, or the commencement of any suit, action, or proceeding by any Person who is not a party hereto or an Affiliate of a party hereto (a “Third Party Claim”) against such Indemnified Party, the Indemnified Party shall give written notice regarding such Third Party Claim to the party hereto that is required to provide indemnification under this Article XII (the “Indemnifying Party”) within thirty (30) days after learning of such Third Party Claim.  The Indemnifying Party shall have the right, upon written notice to the Indemnified Party (the “Defense Notice”) within thirty (30) days after receipt from the Indemnified Party of notice of such Third Party Claim, which Defense Notice by the Indemnifying Party shall specify the counsel it will appoint to defend such Third Party Claim (the “Defense Counsel”), to conduct at its expense the defense against such Third Party Claim in its own name, or if necessary in the name of the Indemnified Party; provided, however, that: (a) the Indemnified Party shall have the right to approve the Defense Counsel, which approval shall not be unreasonably withheld, conditioned, or delayed by the Indemnified Party and (b) as a condition precedent to the Indemnifying Party’s right to assume control of such defense, the Indemnifying Party must first enter into an agreement with the Indemnified Party (in form and substance reasonably satisfactory to the Indemnified Party) pursuant to which the Indemnifying Party agrees to be fully responsible for any and all Losses relating to such suit Third Party Claim and unconditionally guarantees the payment and performance of any and all Losses which may arise with respect to such Third Party Claim, subject to the terms and conditions set forth in this Section 12.  The Indemnifying Party shall not have the right to assume control of, but may participate in, and the Indemnified Party shall have the sole right to assume control of any Third Party Claim which: (i) seeks a temporary restraining order, a preliminary or permanent injunction, or specific performance against the Indemnified Party, (ii) involves criminal or quasi-criminal allegations against the Indemnified Party, (iii) if unsuccessful would set a precedent that would materially interfere with, or have a material adverse effect on, the business or financial condition of the Indemnified Party, or (iv) imposes liability in the part of the Indemnified Party for substantially all of which the Indemnified Party is not entitled to indemnification under this Article XII.  If the Indemnifying Party is permitted to assume and control the defense of any Third Party Claim and elects to do so, the Indemnified Party shall have the right to employ counsel separate from counsel employed by the Indemnifying Party in any such Third Party Claim and to participate in the defense thereof, but the fees and expenses of such counsel employed by the Indemnified Party shall be at the expense of the Indemnified Party unless (A) the employment thereof has been specifically authorized by the Indemnifying Party in writing, (B) the Indemnified Party has been advised by counsel that a conflict of interest exists between the Indemnifying Party and the Indemnified Party, or (C) the Indemnifying Party has failed to assume the defense and employ counsel, in which case the fees and expenses of the Indemnified Party’s counsel shall be paid by the Indemnifying Party.  No Indemnifying Party shall consent to the entry of any judgment or enter into any settlement of any Third Party Claim without the prior written consent of the Indemnified Party if (w) such judgment or settlement would lead to liability or create any financial or other obligation on the part of the Indemnified Party for which the Indemnified

 

11

 

Party is not entitled to indemnification hereunder, (x) such judgment or settlement would result in the finding or admission of any violation of any federal, state, or local law, statute, ordinance, or regulation, (y) such judgment or settlement does not include as an unconditional term thereof the giving by each claimant or plaintiff to each Indemnified Party of a release from all liability in respect to such Third Party Claim, or (z) as a result of such judgment or settlement, injunctive or other equitable relief would be imposed against the Indemnified Party.  In the event that the Indemnifying Party fails to give the Defense Notice within thirty (30) days of receiving notice of a Third Party Claim from the Indemnified Party, it shall be deemed to have elected not to conduct the defense of such Third Party Claim, or in the event the Indemnifying Party does deliver a Defense Notice within thirty (30) days of receiving notice of such Third Party Claim from the Indemnified Party and thereby elects to not conduct the defense of such Third Party Claim, then in either such event the Indemnified Party shall have the right to conduct and control the defense of such Third Party Claim in good faith and to compromise and settle such Third Party Claim or consent to the entry of a judgment of such Third Party Claim in good faith without the prior consent of the Indemnifying Party.  A failure by the Indemnified Party to give timely, complete, or accurate notice as provided in this Section 12.3 will not affect the rights or obligations of the Indemnifying Party except and only to the extent that, as a result of such failure, the Indemnifying Party entitled to receive such notice was deprived of its right to recover any payment under its applicable insurance coverage or was otherwise directly and materially damaged as a result of such failure to give timely notice.

 

12.4                        Indemnification Procedure for Direct Claims.  In the event an applicable Indemnified Party should have an indemnification claim against an applicable Indemnifying Party hereunder which does not involve a Third Party Claim (a “Direct Claim”), the applicable Indemnified Party shall transmit to the applicable Indemnifying Party a written notice containing an estimate of the Losses attributable to such Direct Claim and the basis of the applicable Indemnified Party’s request for indemnification under this Agreement within thirty (30) days after learning of such Direct Claim (the “Direct Indemnification Notice”).  If the applicable Indemnifying Party does not notify the applicable Indemnified Party in writing within thirty (30) days from its receipt of the Direct Indemnification Notice that the applicable Indemnifying Party disputes a Direct Claim(s) specified by the applicable Indemnified Party in the Direct Indemnification Notice, such Direct Claim(s) specified by the applicable Indemnified Party in the Direct Indemnification Notice shall be deemed a liability of the applicable Indemnifying Party hereunder and the applicable Indemnifying Party shall be liable for any and all Losses in connection with such Direct Claim(s) specified by the applicable Indemnified Party in the Direct Indemnification Notice.  If the applicable Indemnifying Party has timely disputed a Direct Claim(s) specified by the applicable Indemnified Party in the Direct Indemnification Notice as provided in this Section 12.4, such dispute shall be resolved by litigation in accordance with the terms and conditions of Sections 19.3, 19.4, and 19.5. A failure by the applicable Indemnified Party to give timely, complete, or accurate notice as provided in this Section 12.4 will not affect the rights or obligations of the applicable Indemnifying Party except and only to the extent that, as a result of such failure, the applicable Indemnifying Party entitled to receive such notice was deprived of its right to recover any payment under its applicable insurance coverage or was otherwise directly and materially damaged as a result of such failure to give timely notice.

 

12.5                        Insurance.  Each party hereto agrees that it shall secure and maintain in full force and effect throughout the Term (and following the expiration of this Agreement or the earlier termination of this Agreement for any reason, to cover any claims or liabilities arising from this Agreement) commercial general liability insurance, which includes contractual liability coverage, product liability (only in the case of Rockwell) and workers’ compensation insurance, to cover any claims or liabilities arising from this Agreement.  Such commercial general liability insurance shall be in an amount reasonably satisfactory to the other party hereto.  Any limits on either party’s insurance coverage shall not be construed to create a limit on its liability with respect to any of its obligations hereunder.  Each party hereto shall name the other party as an additional insured on such party’s commercial general liability insurance policy.  Such commercial general liability insurance policy shall provide at least thirty (30)

 

12

 

days prior written notice to the other party hereto of the cancellation, non-renewal, or substantial modification thereof.  Each party hereto shall supply certificates of insurance to the other party hereto upon the other party’s request.

 

ARTICLE XIII

 

RECALL

 

In the event the FDA initiates a mandatory recall (i.e., the correction or removal of a Product) or Rockwell believes in its sole discretion that it may be necessary to conduct a recall (i.e., the correction or removal of a Product), field market withdrawal, stock recovery, or other similar action with respect to any of the Products (a “Recall”), Rockwell shall immediately notify DaVita of such Recall.  The parties hereto agree that the final decision as to and control of the handling of any Recall shall be in Rockwell’s sole discretion; provided that Rockwell conducts any such Recall in accordance with any and all applicable legal requirements and general guidance issued by the FDA.  In the event that Rockwell does not conduct a Recall, clearly and without dispute, in accordance with all applicable legal requirements and general guidance issued by the FDA, DaVita shall have the right to take any and all actions it determines necessary to comply with such applicable legal requirements and general guidance issued by the FDA, [* *].   DaVita shall provide all reasonable assistance requested by Rockwell in connection with a Recall.  In the event of a Recall with respect to any Product(s), Rockwell shall reimburse DaVita for: [* *].  DaVita and Rockwell shall maintain records of all sales of the Products and customers who received such Products so as to enable Rockwell to adequately administer a Recall with respect to any of the Products in accordance with applicable legal requirements and general guidance issued by the FDA.  In the event of a Recall, neither party hereto shall make any statement to the press or public concerning such Recall without first notifying the other party hereto and obtaining such other party’s prior written approval of any such statement, which approval shall not be unreasonably withheld, conditioned, or delayed.  Any return by DaVita or any DaVita Facility pursuant to this Article XIII shall be sent back to Rockwell, [*   *].

 

ARTICLE XIV

 

OPEN RECORDS AND DISCOUNTS

 

14.1                        Open Records.  To the extent required by §1861(v)(1)(I) of the Social Security Act, the parties hereto will allow the U.S. Department of Health and Human Services, the U.S. Comptroller General, and their duly authorized representatives, access to this Agreement and any records necessary to verify the nature and extent of costs incurred pursuant to this Agreement during the Term and for four (4) years following the last date any Products are furnished by Rockwell to DaVita or any DaVita Facility under this Agreement.  If Rockwell carries out its obligations under this Agreement through a subcontract worth Ten Thousand Dollars ($10,000) or more over a twelve (12) month period with a related organization, the subcontract shall also contain an access clause to permit access by the U.S. Department of Health and Human Services, the U.S. Comptroller General, and their duly authorized representatives to the related organization’s books and records.  Nothing in this Section 14.1 is intended to waive any right either party hereto may have under any applicable laws or regulations to retain in confidence information included in records so requested.

 

14.2                        Discounts.   Any discounts, rebates, incentives, or other reductions in price issued by Rockwell to DaVita or any DaVita Facility under this Agreement may constitute a discount within the meaning of 42 U.S.C. §1320a-7b(b)(3)(A).  DaVita and the DaVita Facilities may have an obligation to properly disclose and appropriately reflect any such discounts, rebates, incentives, or other reductions in price to any state or federal program that provides cost or charge based reimbursement to DaVita or any such DaVita Facility for the items to which such discounts, rebates, incentives, or other reductions in

 

13

 

price apply.  In order to assist DaVita’s and the DaVita Facilities’ compliance with any such obligations, Rockwell agrees that it shall fully and accurately report all discounts, rebates, incentives, or other reductions in price on the invoices, coupons, or statements submitted to DaVita or any DaVita Facility and inform DaVita or any such DaVita Facility of their obligations to report such discounts, rebates, incentives, or other reductions in price.  In the event the value of any discounts, rebates, incentives, or other reductions in price are not known at the time of sale, Rockwell shall fully and accurately report the existence of such discounts, rebates, incentives, or other reductions in price on the invoices, coupons, or statements submitted to DaVita or any DaVita Facility, inform DaVita or any DaVita Facility of their obligations to report such discounts, rebates, incentives, or other reductions in price, and when the value of such discounts, rebates, incentives, or other reductions in price becomes known, provide DaVita or any DaVita Facility with documentation of the calculation of such discounts, rebates, incentives, or other reductions in price and identifying the specific Products purchased to which such discounts, rebates, incentives, or other reductions in price will be applied.  Rockwell shall also provide to DaVita or any DaVita Facility any other information that DaVita or any DaVita Facility may request that is necessary for them to obtain in order to comply with any such obligations, and Rockwell shall refrain from doing anything which would impede DaVita or any DaVita Facility from meeting its obligations under this Section 14.2 or any Medicare regulation.

 

ARTICLE XV

 

ACCESS AND POLICIES AND PROCEDURES

 

Rockwell acknowledges, agrees, and covenants that: (a) all of DaVita’s applicable vendor relations policies and procedures and any updates thereto (the “Policies and Procedures”) that will be in effect during the Term will be available for viewing by Rockwell during the Term by going to http://www.davita.com/about/vendor-policies and (b) Rockwell shall abide by the Policies and Procedures during the Term.  Rockwell further acknowledges, agrees, and covenants that it must obtain DaVita’s prior written approval of: (i) all proposed educational, marketing, presentation, and promotional materials and (ii) all presentations that are in the case of subparagraphs (i) or (ii) related to any of the products or services offered by Rockwell, including the Products (the “Materials”), that are to be given or made by Rockwell to: (A) DaVita or any DaVita Facility or (B) any patient of DaVita or any DaVita Facility, which approval may only be given in writing by DaVita’s Vice President, Clinical Operations or his or her authorized representative.  DaVita’s Vice President, Clinical Operations or his or her authorized representative agrees to use his or her commercially reasonable efforts to notify Rockwell of his or her decision with respect to the approval of the Materials within ten (10) Business Days following the receipt of a request by Rockwell to approve the Materials; provided that if DaVita’s Vice President, Clinical Operations or his or her authorized representative fails to notify Rockwell of his or her decision with respect to the approval of the Materials within such ten (10) Business Day period, such request to approve the Materials will be deemed denied.  Rockwell further acknowledges, agrees, and covenants that absent a specific request from DaVita or any DaVita Facility, none of Rockwell’s agents, representatives, or employees shall: (x) contact any patient of DaVita or any DaVita Facility or (y) be permitted access at any time to DaVita or any DaVita Facility; provided that nothing in this Article XV shall prohibit Rockwell from contacting any patient of DaVita or any patient of a DaVita Facility in a manner that is consistent with the Policies and Procedures or as required by any applicable federal, state, or local law.

 

ARTICLE XVI

 

AUDIT

 

If DaVita disagrees with any computation or statement delivered by Rockwell to DaVita or any DaVita Facility under this Agreement, DaVita may, within thirty (30) days after the receipt of such

 

14

 

computation or statement, audit any such computation or statement.  DaVita shall conduct any such audit during such times as may be mutually agreed to by the parties hereto.  In the event that DaVita’s audit results in a number different from that set forth in the computation or statement delivered by Rockwell to DaVita or any DaVita Facility, DaVita shall deliver a written notice (an “Objection Notice”) to Rockwell setting forth in reasonable detail any and all items of disagreement related to such computation or statement.  If DaVita does not deliver an Objection Notice within such thirty (30) day period, the calculations set forth in any such computation or statement shall be deemed final, conclusive, and binding on the parties hereto.  Rockwell and DaVita will use their commercially reasonable efforts to resolve any disagreements relating to any computation or statement, but if they do not obtain a final resolution within twenty (20) days after Rockwell has received the Objection Notice, then either Rockwell or DaVita may refer the items in dispute to a nationally recognized firm of independent public accounts as to which DaVita and Rockwell mutually agree (the “Firm”), to resolve any remaining disagreements.  Rockwell and DaVita will direct the Firm to render a determination within twenty (20) days of its retention, and Rockwell and DaVita and their respective agents and employees will cooperate with the Firm during its engagement.  The determination of the Firm will be conclusive and binding upon DaVita and Rockwell, and DaVita or Rockwell, as applicable, will make any payment owed to other party hereto within five (5) Business Days of the Firm’s determination.  The Firm shall execute a confidentiality agreement in a form reasonably acceptable to Rockwell and DaVita.  [* *].

 

ARTICLE XVII

 

ADDITIONAL ACKNOWLEDGEMENTS AND AGREEMENTS OF THE PARTIES

 

17.1                        Discontinuation Event.  DaVita agrees that: (a) in the event a Committed DaVita Facility intends on discontinuing its purchase of the Products from Rockwell (a “Discontinuation Event”), it shall [* *].  DaVita further agrees that in the event a Discontinuation Event occurs as to multiple Committed DaVita Facilities in a geographic county, group of nearby counties, or subdivisions of a county (a “Market”), it shall use its commercially reasonable efforts to implement such Discontinuation Event as to such Committed DaVita Facilities in such Market in a manner which assists Rockwell in minimizing the negative effect it would experience as a result of such Discontinuation Event.  In the event of a breach by DaVita of the provisions of this Section 17.1, Rockwell’s sole and exclusive remedy shall be to terminate this Agreement pursuant to Section 2.4(e).

 

17.2                        Business Model Change.  Rockwell agree to [* *] and to use commercially reasonable efforts to [* *].  DaVita acknowledges that in the event Rockwell wishes to [* *], it will use its commercially reasonable efforts to [* *]; provided that if DaVita uses its commercially reasonable efforts to [* *], DaVita shall have no liability whatsoever to Rockwell, including any direct, indirect, consequential, exemplary, or punitive damages, [* *].

 

17.3                        Mixer Training.  Rockwell agrees to furnish, [* *], complete and appropriate training regarding the use and maintenance of the Dri-Sate® Acid Mixer used for mixing Dri-Sate® Dry Acid and CitraPure® Dry Acid, to such number of personnel of DaVita and the DaVita Facilities as DaVita shall designate.  [* *].

 

17.4                        Bicarbonate Mixer.  Upon mutual written agreement between the parties hereto, Rockwell will [* *].

 

15

 

ARTICLE XVIII

 

CERTAIN DEFINED TERMS

 

The following terms as used herein have the following meaning:

 

18.1                        “Affiliate” means, with respect to a Person, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such Person.  The term “control”, including the terms “controlling”, “controlled by”, and “under common control with” for the purposes of the definition of “Affiliate”, means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract, or otherwise.

 

18.2                        [* *]

 

18.3                        “Business Day” means a day other than Saturday, Sunday, or a public holiday on which banks are authorized or required to be closed under the laws of the State of Colorado.

 

18.4                        “Commercially Available” means any product that is approved by the FDA and manufactured, utilized, sold, or distributed anywhere in the United States by Rockwell or any of its Affiliates.

 

18.5                        “Confidential Information” means information not generally known outside the disclosing party or any of its Affiliates (collectively, the “Disclosing Party”) (unless as a result of a breach of any of the non-disclosing party’s or any of its Affiliates’(collectively, the “Non-Disclosing Party’s”) obligations imposed by this Agreement) or which is identified as confidential by the Disclosing Party to the Non-Disclosing Party concerning the Disclosing Party’s business and technical information, whether in written, computerized, oral, tangible or intangible, or other form, including: (a) the terms and provisions of this Agreement, (b) any and all trade secrets concerning the business, customers, and affairs of the Disclosing Party, product specifications, data, know-how, formulae, compositions, processes, designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current, and planned research and development, current and planned manufacturing and distribution methods and processes, customer lists, current and anticipated customer requirements, price lists, market studies, business plans, clinical practices and patient protocols, computer software and programs (including object code and source code), database technologies, systems, improvements, devices, discoveries, concepts, methods, and information of the Disclosing Party and any other information of the Disclosing Party, however documented, that is a trade secret under applicable law, (c) any and all information concerning the business and affairs of the Disclosing Party, including historical financial statements, financial projections and budgets, rebates, discounts, payment terms, pricing, historical and projected sales, capital spending budgets and plans, contractual arrangements, the names and background of key personnel, contractors, agents, customers, suppliers, and potential suppliers, personnel training and techniques and materials, purchasing methods and techniques, however documented, (d) the names and addresses, records and charts, and any other information concerning the Disclosing Party’s patients, and (e) any and all notes, analysis compilations, studies, summaries, and other materials prepared by or for the Disclosing Party containing or based, in whole or in part, upon any information included in the foregoing.

 

18.6                        [* *].

 

18.7                        “FDA” means the United States Food and Drug Administration and any successor thereto.

 

16

 

18.8                        “FFDCA” means the United States Federal Food, Drug and Cosmetic Act of 1938 and all regulations promulgated thereunder.

 

18.9                        “Governmental Authority” means any multi-national, national, state, provincial, local, governmental, judicial, public, quasi-public, administrative, regulatory or self-regulatory authority, agency, commission, board, organization, or instrumentality.

 

18.10                 “Person” means any individual or any group of individuals or any general partnership, limited partnership, limited liability partnership, limited liability company, professional limited liability company, corporation, joint venture, trust, business trust, cooperative or association or any other organization that is not a natural person and any combination of any such entity or organization and any natural persons acting in concert, and the heirs, executors, administrators, legal representatives, successors and assigns of any “person” where the context so permits.

 

18.11                 “Sale of DaVita” means any transaction or series of transactions pursuant to which any Person or group of related Persons in the aggregate acquire(s): (a) securities of DaVita possessing the voting power to elect a majority of DaVita’s board of directors (whether by merger, consolidation, reorganization, combination, sale or transfer of DaVita’s securities, securityholder or voting agreement, power of attorney, or otherwise) or (b) all or substantially all of DaVita’s assets.

 

18.12                 “Sale of Rockwell” means any transaction or series of transactions pursuant to which any Person or group of related Persons in the aggregate acquire(s): (a) securities of Rockwell possessing the voting power to elect a majority of Rockwell’s board of directors (whether by merger, consolidation, reorganization, combination, sale or transfer of Rockwell’s securities, securityholder or voting agreement, proxy, power of attorney, or otherwise) or (b) all or substantially all of Rockwell’s assets.

 

18.13                 “Transfer” means (a) any Sale of Rockwell, (b) Sale of DaVita, or (c) any sale, transfer, assignment, pledge, mortgage, exchange, hypothecation, grant of a security interest, or other direct or indirect disposition or encumbrance of an interest (including by operation of law) or the rights thereof.  The term “Transferred,” and other forms of the word “Transfer” shall have correlative meanings.

 

ARTICLE XIX

 

MISCELLANEOUS

 

19.1                        Entire Agreement; Amendments. This Agreement, including its recitals and exhibits, constitutes the entire agreement between the parties hereto and supersedes any and all prior representations, warranties, statements, promises, agreements, and understandings between the parties hereto, whether oral or written, relating to the subject matter hereof, and no party hereto shall be bound by nor charged with any written or oral representations, warranties, statements, promises, agreements, or understandings not specifically set forth in this Agreement.  No amendments or modifications of the terms of this Agreement, including any conflicting or additional terms contained in any sales order, purchase order, acknowledgment form, or other written document submitted by either party hereto, shall be binding on either party hereto unless reduced to writing and signed by a duly authorized representative of each party hereto.

 

19.2                        Notices.  All notices given pursuant to this Agreement shall be sent by: (a) certified mail, return receipt requested, in which case notice will be deemed delivered three (3) Business Days after deposit, postage prepaid in the United States mail; (b) a nationally recognized overnight courier, in which 

 

17

 

case notice will be deemed delivered one (1) Business Day after deposit with such courier; or (c) personal delivery, in which case notice will be deemed delivered upon delivery.  The address of Rockwell is Rockwell Medical, Inc., 30142 Wixom Road, Wixom, Michigan 48383, Attention: Chief Executive Officer and the address of DaVita is DaVita Healthcare Partners Inc., 1111 Bayhill Drive, Suite 285, San Bruno, California 94066, Attention: Group Vice-President with a copy to DaVita Healthcare Partners Inc., 2000 16th St., Denver, Colorado 80202, Attention: Chief Legal Officer.  The addresses in this Section 19.2 may be changed by written notice to the other party hereto, provided that no notice of a change of address will be effective until actual receipt of such notice.

 

19.3                        Choice of Law.  All issues and questions concerning the construction, validity, enforcement, and interpretation of this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the laws of the State of Delaware.

 

19.4                        WAIVER OF JURY TRIAL.  EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS OR EVENTS CONTEMPLATED HEREBY OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN), OR ACTIONS OF ANY PARTY HERETO.  THE PARTIES HERETO EACH AGREE THAT ANY AND ALL SUCH CLAIMS AND CAUSES OF ACTION SHALL BE TRIED BY THE COURT WITHOUT A JURY.  EACH OF THE PARTIES HERETO FURTHER WAIVES ANY RIGHT TO SEEK TO CONSOLIDATE ANY SUCH LEGAL PROCEEDING IN WHICH A JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER LEGAL PROCEEDINGS IN WHICH A JURY TRIAL CANNOT OR HAS NOT BEEN WAIVED.

 

19.5                        Attorneys Fees.  In the event of any legal proceeding between the parties hereto with respect to this Agreement, the enforceability of any of its provisions, or any alleged or actual breach of this Agreement by any party hereto, the prevailing party shall be entitled to recover reasonable attorney’s fees and all other costs and expenses incurred in connection with pursuing any action with respect thereto, in addition to any other relief to which such party may be entitled.  The term “prevailing party” shall mean with respect to each claim asserted in a complaint the party in whose favor final judgment after appeal (if any) is rendered with respect to each such claim asserted in the complaint.

 

19.6                        Non-Limitation of Rights and Remedies.  Except as otherwise expressly provided herein, the various rights and remedies provided herein shall be cumulative and in addition to any other rights and remedies the parties hereto may be entitled to pursue at law or equity.  The exercise of one or more of such rights or remedies shall not impair the right of either party hereto to exercise any other right or remedy at law or equity.

 

19.7                        Waiver.   No waiver by any party hereto, whether express or implied, of its rights under any provision hereto shall constitute a waiver of the party’s rights under such provisions at any other time or a waiver of the party’s rights under any other provision hereto.  No failure by any party hereto to take any action against any breach of this Agreement or default by another party hereto shall constitute a waiver of the former party’s right to enforce any provision of this Agreement or to take action against any such breach or default or any subsequent breach or default by the other party hereto.  To be effective any waiver must be in writing and signed by the waiving party.

 

19.8                        Severability.  In the event that any provision of this Agreement shall be held to be invalid or unenforceable in any respect, such provision shall be enforced to the fullest extent permitted by law 

 

18

 

and the remaining provisions of this Agreement shall remain in full force and effect.   If any such invalid portion constitutes a material term of this Agreement, the parties hereto shall meet and in good faith seek to mutually agree to modify this Agreement so as to retain, if possible, the overall essential terms of this Agreement.

 

19.9                        Conflicts.  To the extent that any provision of any sales order, purchase order, invoice, or any other document, or the terms of any of Rockwell’s general policies, terms and conditions, procedures or catalogs, conflict with or alter any term of this Agreement, this Agreement shall govern and control.

 

19.10                 Assignment and Transfer.  This Agreement will be binding upon and inure to the benefit of the parties hereto.  This Agreement may not be Transferred by any party hereto without the prior written consent of the other party hereto which consent shall not be unreasonably withheld, conditioned, or delayed; provided however that nothing in this Agreement shall or is intended to limit the ability of: (a) DaVita to Transfer this Agreement, in whole or in part, without the consent of Rockwell to: (i) any Affiliate of DaVita; (ii) any buyer in connection with a Sale of DaVita; or (iii) any lenders of DaVita as collateral for borrowings or (b) Rockwell to Transfer this Agreement, in whole or in part, without the consent of DaVita to: (A) any newly formed Affiliate of Rockwell in connection with a corporate reorganization of Rockwell that does not involve a Sale of Rockwell to any Person that is not a party hereto or (B) any lenders of Rockwell as collateral for borrowings; provided that any such lenders or any of its Affiliates are not engaged in the business of manufacturing, selling, or distributing products used in the provision of dialysis services.

 

19.11                 Relationship of the Parties. This Agreement is not intended to create and shall not be construed as creating between Rockwell and DaVita the relationship of Affiliate, principal and agent, joint venture, partnership, or any other similar relationship, the existence of which is hereby expressly denied.  Neither party hereto shall have (nor shall it hold itself out as having) any right, power, or authority to make or incur any legally binding agreement, obligation, representation, warranty, or commitment on behalf of the other party hereto or to direct any action of, or activity by the other party hereto or any of its officers, directors, members, managers, employees, or agents.

 

19.12                 Counterparts; Facsimile/PDF Signatures. This Agreement may be executed in any number of counterparts and any party hereto may execute any such counterpart, each of which when executed and delivered shall be deemed to be an original and all of which counterparts taken together shall constitute but one and the same instrument.  This Agreement shall become binding when one or more counterparts taken together shall have been executed and delivered by each of the parties hereto.  It shall not be necessary in making proof of this Agreement or any counterpart hereof to produce or account for any of the other counterparts.  The parties hereto agree that facsimile transmission or PDF of original signatures shall constitute and be accepted as original signatures.

 

19.13                 Headings and Interpretation.  All Section and Article headings contained in this Agreement are for convenience of reference only, do not form a part of this Agreement, and shall not affect in any way the meaning or interpretation of this Agreement.  Words used herein, regardless of the number and gender specifically used, shall be deemed and construed to include any other number, singular or plural, and any other gender, masculine, feminine, or neuter as the context requires.  The words “include”, “includes”, and “including”, and words of similar import, shall be deemed to be followed by the phrase “without limitation”.   Unless the context expressly by its terms requires otherwise, (a) any reference to any law herein shall be construed as referring to such law as from time to time enacted, repealed, or amended, (b) any reference herein to any Person shall be construed to include such Person’s permitted successors and assigns, (c) the words “herein”, “hereof”, and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any 

 

19

 

particular provision hereof, and (d) all references herein to Sections, Articles, or Exhibits shall be construed to refer to Sections, Articles, or Exhibits of this Agreement.

 

19.14                 Joint Preparation.  Each party hereto: (a) has participated in the preparation of this Agreement; (b) has read and understands this Agreement; and (c) has been represented by counsel of its own choice in the negotiation and preparation of this Agreement.  Each party hereto represents that this Agreement is executed voluntarily and should not be construed against any party hereto solely because it drafted all or a portion hereof.

 

19.15                 Time of Essence.  Rockwell’s obligation to meet the delivery dates or any other time periods set forth herein is of the essence.

 

19.16                 Survival.  Notwithstanding anything to the contrary that may be contained elsewhere in this Agreement, this Article XIX and Articles II, VI, IX, X, XI, XII, and XIII shall survive, and remain in full force and effect, following the expiration of this Agreement or the earlier termination of this Agreement for any reason.

 

19.17                 Business Day.  If any payment is due or any time period for giving notice or taking action expires on a day that is not a Business Day, the payment shall be due and payable on and the time period for giving such notice or taking such action shall automatically be extended to the next succeeding Business Day.

 

19.18                 Public Announcements.  Except as otherwise required pursuant to any applicable federal or state securities laws or stock listing requirements, no party hereto shall make any public announcement of any kind or any filing with respect to the other party hereto or any of the transactions provided for herein without the prior written consent of the other party hereto.  Except as otherwise required pursuant to any applicable federal or state securities laws or stock listing requirements, any press release or other announcement or notice regarding the other party hereto or any of the transactions contemplated by this Agreement shall be by joint press release mutually agreed to in writing by the parties hereto.

 

[SIGNATURE PAGE FOLLOWS]

 

20

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be effective as of the Effective Date.

 

	
ROCKWELL:
    	
DAVITA:
    
	
 
    	
 
    
	
 
    	
 
    
	
ROCKWELL   MEDICAL, INC.
    	
DAVITA   HEALTHCARE PARTNERS INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/   Robert Chioini
    	
 
    	
By:
    	
/s/   LeAnne Zumwalt
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    
	
Print   Name:
    	
Robert   Chioini
    	
 
    	
Print   Name:
    	
LeAnne   Zumwalt
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    
	
Title:
    	
CEO
    	
 
    	
Title:
    	
Group   VP
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Approved   as to form: 
    
	
 
    	
 
    
	
 
    	
DAVITA   HEALTHCARE PARTNERS INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Print   Name:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Title:
    	
 
    
											

 

[SIGNATURE PAGE TO FIRST AMENDED AND RESTATED PRODUCTS PURCHASE AGREEMENT]

 

 

EXHIBIT A

 

PRODUCTS AND PURCHASE PRICE

 

Price Quote Standard Formulas

 

	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CATALOG #
    	
 
    	
DESCRIPTION
    	
 
    	
PACKAGING
    	
 
    	
UNIT PRICE
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
25   Gallon Case
    	
 
    	
Case
    	
 
    	
[*   *]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
55   Gallon Drum
    	
 
    	
Drum
    	
 
    	
[*   *]
    
	
[*   *]
    	
 
    	
 
    	
 
    	
4   Gal/cs 3.785lt/gal
    	
 
    	
Case
    	
 
    	
[*   *]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
25   Gallon Case
    	
 
    	
Case
    	
 
    	
[*   *]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
55   Gallon Drum
    	
 
    	
Drum
    	
 
    	
[*   *]
    
	
[*   *]
    	
 
    	
 
    	
 
    	
4   Gal/cs 3.785lt/gal
    	
 
    	
Case
    	
 
    	
[*   *]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
2.1   Gallon Bag 20/cs
    	
 
    	
Case
    	
 
    	
[*   *]
    
	
[*   *]
    	
 
    	
 
    	
 
    	
15   Gallon Bag 4/cs
    	
 
    	
Case
    	
 
    	
[*   *]
    
	
[*   *]
    	
 
    	
 
    	
 
    	
25   Gallon Bag 2/cs
    	
 
    	
Case
    	
 
    	
[*   *]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
4   Gallon Case
    	
 
    	
Case
    	
 
    	
[*   *]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*   *]
    	
 
    	
 
    	
 
    	
4   Gallon Case
    	
 
    	
Case
    	
 
    	
[*   *]
    
	
[*   *]
    	
 
    	
 
    	
 
    	
50lb Bag
    	
 
    	
Bag
    	
 
    	
[*   *]
    
	
[*   *]
    	
 
    	
 
    	
 
    	
25lb   Bag
    	
 
    	
Bag
    	
 
    	
[*   *]
    

 

NOTES:

·                  Dry Acid Mixers for Dri-Sate® and CitraPure® Dry Acid:

 

DSMIX-50                                   Dry Acid Mixer, 50 Gal                                                           [*   *]

DSMIX-100                            Dry Acid Mixer, 100 Gal                                                    [*   *]

 

·                  Drum prices include [*   *].

 

[* *].

 

A-1

 

EXHIBIT B

 

TERRITORY

 

The purchase price for the Products as set forth on Exhibit A is applicable in the following [*   *]:

 

[*   *]

 

[*   *]

 

B-1

 

EXHIBIT C

 

ROCKWELL SHIPPING AND ORDER REQUIREMENTS

 

GENERAL GUIDELINES APPLICABLE TO ALL PRODUCTS (DRI-SATE® DRY ACID CONCENTRATE, RENALPURE® LIQUID ACID CONCENTRATE, RENALPURE® BICARBONATE POWDER, STERILYTE® LIQUID BICARBONATE, CITRAPURE®  DRY ACID and LIQUID ACID CONCENTRATE and CLEANING AGENTS)

 

1.              Lead time from the initial order from a DAVITA dialysis clinic to the first delivery is [*  *].

2.              If DAVITA fails to maintain adequate inventory of a particular Product [*   *], resulting in ROCKWELL shipping the Products via a third party carrier, [*   *].

3.              [*             *] shall pay all return freight costs due to Products shipped in error and/or Products damaged prior to receipt by DAVITA; otherwise, [*   *] shall pay [*  *].

4.              Orders for Products must be received via facsimile at [*  *], otherwise a charge of [*   *] will be applied [*   *]. Each of DAVITA’s dialysis clinics shall [*   *].

5.              ROCKWELL shall [*          *].

6.              ROCKWELL shall [*          *].

 

NOTE:       The minimum order requirement in the aggregate for all Products combined (liquid and dry acid concentrate, bicarbonate powder, SteriLyte and cleaning agents) is [*   *].

 

SPECIFIC ADDITIONAL GUIDELINES FOR CERTAIN PRODUCTS

 

DRY ACID CONCENTRATE

 

1.                                      Special formulas of Dry Acid Concentrate, if approved, [*          *].

 

LIQUID ACID CONCENTRATE

 

1.                                      Special formulas of Liquid Acid Concentrate, if approved, [*          *].

2.                                      With respect to Liquid Acid Concentrate, DAVITA will be responsible for a [*        *].

 

C-1

 

EXHIBIT D

 

RETURN GOODS POLICY

 

See Item 3 of Exhibit C.

 

D-1Exhibit 10.1

 

COLLABORATION AGREEMENT

DATED AS OF JULY 15, 2013

 

BY AND AMONG

 

AUXILIUM UK LTD AND

 

AUXILIUM INTERNATIONAL HOLDINGS, INC.

 

AND

 

SWEDISH ORPHAN BIOVITRUM AB (publ)

 

Confidential treatment requested under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2.  The confidential portions of this exhibit have been omitted and are marked accordingly.  The confidential portions have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

 

 

TABLE OF CONTENTS

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
ARTICLE 1
    	
DEFINITIONS
    	
1
    
	
 
    	
 
    	
 
    
	
ARTICLE 2
    	
LICENSES
    	
15
    
	
 
    	
 
    	
 
    
	
2.1
    	
Grant   to Sobi
    	
15
    
	
2.2
    	
Grant   to Auxilium
    	
15
    
	
2.3
    	
Additional   Licensing Provisions
    	
16
    
	
2.4
    	
Performance   by Affiliates, Subcontractors and Sublicensees
    	
16
    
	
2.5
    	
Exclusivity
    	
17
    
	
2.6
    	
Sobi   Restrictive Covenants
    	
18
    
	
2.7
    	
BTC   Step-In Rights
    	
19
    
	
 
    	
 
    	
 
    
	
ARTICLE 3
    	
GOVERNANCE
    	
19
    
	
 
    	
 
    	
 
    
	
3.1
    	
Joint   Steering Committee
    	
19
    
	
3.2
    	
Joint   Steering Committee Membership
    	
21
    
	
3.3
    	
Joint   Steering Committee Meetings
    	
21
    
	
3.4
    	
Decision-Making
    	
21
    
	
3.5
    	
Alliance   Managers
    	
22
    
	
3.6
    	
Committees
    	
22
    
	
3.7
    	
Transition   Committee
    	
22
    
	
3.8
    	
Limits   on JSC and Committee Authority
    	
23
    
	
3.9
    	
Disbanding   the JSC
    	
23
    
	
3.10
    	
Actions
    	
23
    
	
3.11
    	
Exchange   of Information
    	
23
    
	
3.12
    	
Minutes   of Committee Meetings
    	
24
    
	
 
    	
 
    	
 
    
	
ARTICLE 4
    	
DEVELOPMENT
    	
24
    
	
 
    	
 
    	
 
    
	
4.1
    	
Overview
    	
24
    
	
4.2
    	
Objectives   Under the Development Plan
    	
25
    
	
4.3
    	
Development   Plan and Development Budget
    	
26
    
	
4.4
    	
Development   Costs
    	
27
    
	
4.5
    	
Records,   Reports and Information
    	
28
    
	
4.6
    	
Ownership   and Transfer of Development Data
    	
28
    
	
4.7
    	
Right   to Audit
    	
29
    
	
4.8
    	
Medical   Science Liaisons
    	
29
    
	
4.9
    	
Other   Materials
    	
29
    
	
 
    	
 
    	
 
    
	
ARTICLE 5
    	
REGULATORY
    	
29
    
	
 
    	
 
    	
 
    
	
5.1
    	
Regulatory   Data and Regulatory Materials
    	
29
    
	
5.2
    	
Regulatory   Filings and Regulatory Approvals
    	
30
    
	
5.3
    	
Communications
    	
32
    
	
5.4
    	
No   Other Regulatory Filings
    	
32
    
	
5.5
    	
Adverse   Event Reporting; Safety Data Exchange and Medical Inquiries
    	
32
    
	
5.6
    	
Regulatory   Authority Communications Received by a Party
    	
33
    
	
5.7
    	
Recall,   Withdrawal, or Market Notification of Product
    	
35
    
	
5.8
    	
Regulatory   Diligence
    	
36
    

 

i

 

TABLE OF CONTENTS

(continued)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
ARTICLE 6
    	
COMMERCIALIZATION
    	
37
    
	
 
    	
 
    	
 
    
	
6.1
    	
Commercialization   in the Field in the Territory
    	
37
    
	
6.2
    	
Commercialization   Plan
    	
37
    
	
6.3
    	
Sobi’s   Performance
    	
38
    
	
6.4
    	
Reports
    	
39
    
	
6.5
    	
Compliance
    	
39
    
	
6.6
    	
Sales   Representatives
    	
39
    
	
6.7
    	
Promotional   Materials
    	
40
    
	
6.8
    	
Product   Trademarks and Product Trade Dress
    	
40
    
	
6.9
    	
Commercialization   Data
    	
42
    
	
6.10
    	
Global   Branding Strategy
    	
43
    
	
 
    	
 
    	
 
    
	
ARTICLE 7
    	
SUPPLY
    	
44
    
	
 
    	
 
    	
 
    
	
7.1
    	
General
    	
44
    
	
7.2
    	
Development   Supply
    	
44
    
	
7.3
    	
Commercial   Supply
    	
44
    
	
7.4
    	
Exclusive   Source
    	
44
    
	
7.5
    	
Packaging   and Labeling; Certain Other Manufacturing Activities
    	
45
    
	
7.6
    	
Forecasting   and Ordering
    	
46
    
	
7.7
    	
Invoicing,   and Manufacturing Standard Cost Audit
    	
48
    
	
7.8
    	
Shipping   and Delivery
    	
48
    
	
7.9
    	
Quality   and Compliance
    	
49
    
	
7.10
    	
Disputes   and Remedies
    	
50
    
	
7.11
    	
Shortages
    	
51
    
	
7.12
    	
Manufacturing   Supply Assurance
    	
51
    
	
7.13
    	
Product   Specification and Manufacturing Changes
    	
51
    
	
7.14
    	
Termination   of Supply Obligations
    	
51
    
	
7.15
    	
Auxilium   Notice
    	
51
    
	
 
    	
 
    	
 
    
	
ARTICLE 8
    	
PAYMENTS
    	
52
    
	
 
    	
 
    	
 
    
	
8.1
    	
Milestone   Payments
    	
52
    
	
8.2
    	
Royalties
    	
52
    
	
8.3
    	
Royalty   Reports and Payments
    	
54
    
	
8.4
    	
Third   Party Royalties and Other Payments
    	
55
    
	
8.5
    	
Taxes   and Withholding
    	
56
    
	
8.6
    	
Currency   Conversion
    	
57
    
	
8.7
    	
General   Payment Procedures
    	
57
    
	
8.8
    	
Late   Payments
    	
57
    
	
8.9
    	
Legal   Restrictions
    	
57
    
	
8.10
    	
Records;   Audits
    	
57
    
	
 
    	
 
    	
 
    
	
ARTICLE 9
    	
INTELLECTUAL PROPERTY MATTERS
    	
58
    
	
 
    	
 
    	
 
    
	
9.1
    	
Ownership   of Intellectual Property
    	
58
    

 

ii

 

TABLE OF CONTENTS

(continued)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
9.2
    	
Disclosures;   Disputes Regarding Inventions
    	
59
    
	
9.3
    	
Patent   Filings, Prosecution and Maintenance
    	
59
    
	
9.4
    	
Defense   and Enforcement of Patents
    	
62
    
	
9.5
    	
Patent   Term Extensions
    	
64
    
	
9.6
    	
Patent   Marking
    	
64
    
	
 
    	
 
    	
 
    
	
ARTICLE 10
    	
REPRESENTATIONS, WARRANTIES AND COVENANTS
    	
64
    
	
 
    	
 
    	
 
    
	
10.1
    	
Mutual   Representations and Warranties
    	
64
    
	
10.2
    	
Additional   Representations, Warranties and Covenants of Auxilium
    	
65
    
	
10.3
    	
Additional   Representations, Warranties and Covenants of Sobi as of the Effective Date
    	
67
    
	
10.4
    	
Additional   Covenants of Sobi
    	
68
    
	
10.5
    	
Disclaimer
    	
68
    
	
10.6
    	
No   Other Representations or Warranties
    	
69
    
	
 
    	
 
    	
 
    
	
ARTICLE 11
    	
LIABILITY AND INDEMNIFICATION
    	
69
    
	
 
    	
 
    	
 
    
	
11.1
    	
Indemnification   by Auxilium
    	
69
    
	
11.2
    	
Indemnification   by Sobi
    	
69
    
	
11.3
    	
Indemnification   Procedures
    	
70
    
	
11.4
    	
Limitation   of Liability
    	
71
    
	
11.5
    	
Insurance
    	
72
    
	
 
    	
 
    	
 
    
	
ARTICLE 12
    	
CONFIDENTIALITY
    	
72
    
	
 
    	
 
    	
 
    
	
12.1
    	
Confidential   Information
    	
72
    
	
12.2
    	
Confidentiality   Obligations
    	
73
    
	
12.3
    	
Permitted   Disclosure and Use
    	
73
    
	
12.4
    	
Notification
    	
74
    
	
12.5
    	
Publicity;   Filing of this Agreement
    	
74
    
	
12.6
    	
Publication
    	
75
    
	
12.7
    	
Use   of Names
    	
75
    
	
12.8
    	
Survival
    	
75
    
	
 
    	
 
    	
 
    
	
ARTICLE 13
    	
TERM AND TERMINATION
    	
75
    
	
 
    	
 
    	
 
    
	
13.1
    	
Term
    	
75
    
	
13.2
    	
Termination   for Material Breach
    	
75
    
	
13.3
    	
Termination   as a Result of Bankruptcy
    	
76
    
	
13.4
    	
Termination   by Auxilium
    	
76
    
	
13.5
    	
Termination   by Sobi
    	
76
    
	
 
    	
 
    	
 
    
	
ARTICLE 14
    	
EFFECTS OF TERMINATION
    	
77
    
	
 
    	
 
    	
 
    
	
14.1
    	
Effects   of Termination
    	
77
    
	
14.2
    	
Sobi   Rights In Lieu of Termination
    	
79
    
	
14.3
    	
Accrued   Rights
    	
79
    
	
14.4
    	
Survival
    	
79
    

 

iii

 

TABLE OF CONTENTS

(continued)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
14.5
    	
Rights   in Bankruptcy
    	
79
    
	
14.5
    	
Continuing   Obligations
    	
79
    
	
 
    	
 
    	
 
    
	
ARTICLE 15
    	
DISPUTE RESOLUTION
    	
80
    
	
 
    	
 
    	
 
    
	
15.1
    	
Disputes
    	
80
    
	
15.2
    	
Arising   Between the Parties
    	
80
    
	
15.3
    	
Dispute   Resolutions
    	
80
    
	
15.4
    	
Patent   and Trademark Dispute Resolution
    	
80
    
	
15.5
    	
Injunctive   Relief
    	
80
    
	
 
    	
 
    	
 
    
	
ARTICLE 16
    	
MISCELLANEOUS
    	
80
    
	
 
    	
 
    	
 
    
	
16.1
    	
Entire   Agreement; Amendment
    	
80
    
	
16.2
    	
Force   Majeure
    	
81
    
	
16.3
    	
Notices
    	
81
    
	
16.4
    	
No   Strict Construction; Interpretation
    	
82
    
	
16.5
    	
Assignment
    	
82
    
	
16.6
    	
Further   Actions
    	
82
    
	
16.7
    	
Severability
    	
82
    
	
16.8
    	
No   Waiver
    	
82
    
	
16.9
    	
Independent   Contractors
    	
83
    
	
16.10
    	
English   Language; Governing Law
    	
83
    
	
16.11
    	
Counterparts
    	
83
    

 

iv

 

TABLE OF CONTENTS

 

	
 
    	
Page
    
	
 
    	
 
    
	
List   of Schedules
    	
 
    
	
1.7   
    	
Auxilium   Patents
    	
 
    
	
1.73   
    	
Territory
    	
 
    
	
2.4.2   
    	
Sobi   Sublicensees
    	
 
    
	
4.1.1(a)   
    	
Ongoing   Studies
    	
 
    
	
4.1.1(b)   
    	
Real   World Study
    	
 
    
	
4.4.5   
    	
Stability   Testing
    	
 
    
	
6.2.1   
    	
Initial   Commercialization Plan
    	
 
    
	
6.3.1(b)   
    	
Minimum   Annual Finished Product Sales Commitments
    	
 
    
	
6.3.4   
    	
Assigned   Contracts
    	
 
    
	
7.5.1   
    	
Artwork   and Labels
    	
 
    
	
7.5.2   
    	
Analytical   Release Testing
    	
 
    
	
7.6   
    	
Initial   Forecast
    	
 
    
	
10.2.6   
    	
Trademark   Registrations
    	
 
    
	
12.5.1   
    	
Press   Release
    	
 
    

 

1

 

COLLABORATION AGREEMENT

 

This Collaboration Agreement (this “Agreement”), dated as of July 15, 2013 (the “Effective Date”), is made by and among AUXILIUM UK LTD, a United Kingdom limited company, jointly and severally with Auxilium International Holdings, Inc., a Delaware corporation, (together referred to as “Auxilium”), and Swedish Orphan Biovitrum AB (publ), a Swedish corporation (“Sobi”).  Auxilium and Sobi are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, Auxilium has developed and is currently further developing a pharmaceutical product hereinafter defined as the Product for the treatment of Dupuytren’s Contracture and Peyronie’s Disease;

 

WHEREAS, Auxilium International Holdings, Inc. owns certain intellectual property rights related to the Product;

 

WHEREAS, AUXILIUM UK LTD owns certain distribution and other rights related to the Product in the Territory;

 

WHEREAS, Sobi has significant experience in the commercialization of pharmaceutical products in the Territory; and

 

WHEREAS, Sobi and Auxilium desire to establish a collaboration for the further development and commercialization of the Product in the Field in the Territory.

 

NOW THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows:

 

ARTICLE 1
 DEFINITIONS

 

As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined elsewhere in this Agreement:

 

1.1                               “Affiliate” means any Person directly or indirectly controlled by, controlling or under common control with, a Party, but only for so long as such control shall continue.  For purposes of this definition, “control” (including, with correlative meanings, “controlled by”, “controlling” and “under common control with”) shall be presumed to exist with respect to a Person in the event of the possession, direct or indirect, of (i) the power to direct or cause the direction of the management and policies of such Person (whether through ownership of securities, by contract or otherwise), or (ii) at least fifty percent (50%) of the voting securities or other comparable equity interests.  The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case, such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct or cause the direction of the

 

1

 

management and policies of such Person.  For the avoidance of doubt, neither of the Parties shall be deemed to be an “Affiliate” of the other.

 

1.2                               “Analytical Release Testing” means all activities associated with carrying out the analytical testing necessary for the release of the Product in the Territory.  Such activities shall include:  transferring test methods, developing and validating new analytical tests required in the Territory, amending the release specifications to be in compliance with local Laws, conducting the release testing of the Product in the Territory (including raw materials, intermediates, drug substance, drug product and sterile diluents).  For clarity, preparation of reference standards to be used for Analytical Release Testing includes analytical tests other than release testing (e.g., mass spectrophotometry, isoelectrofocusing, N- and C-terminal sequencing, amino acid analysis, etc.), which activities shall also be deemed Analytical Release Testing hereunder.

 

1.3                               “Auxilium Invention” means an Invention that is Invented solely or jointly with a Third Party, by an employee of Auxilium or its Affiliates or a Person under an obligation of assignment to Auxilium or its Affiliates.

 

1.4                               “Auxilium Know-How” means all Know-How that is (i) Controlled by Auxilium (or its Affiliates) as of the Effective Date or at any time during the Term or (ii) an Auxilium Invention or a Joint Invention, in each case of (i) or (ii), which is necessary or reasonably useful for the Development or Commercialization of the Product in the Field in the Territory; provided, however that “Auxilium Know-How” shall not include any Auxilium Manufacturing Know-How.  For clarity, “Auxilium Know-How” shall not include the Auxilium Patents or the Auxilium Manufacturing Patents.

 

1.5                               “Auxilium Manufacturing Know-How” means all Know-How that is (i) Controlled by Auxilium (or its Affiliates) as of the Effective Date or (ii) an Auxilium Invention or a Joint Invention, in each case of (i) or (ii) which is necessary or reasonably useful for Manufacture of the Product in the Territory for Commercialization in the Field in the Territory, including any CMC Information.

 

1.6                               “Auxilium Manufacturing Patent” means any Patent that is (i) Controlled by Auxilium (or its Affiliates) as of the Effective Date or (ii) an Auxilium Collaboration Patent, in each case of (i) or (ii), which is necessary or reasonably useful for the Manufacture of the Product in the Territory for Commercialization in the Field in the Territory; provided, however, that an “Auxilium Manufacturing Patent” shall not include any Auxilium Patent.

 

1.7                               “Auxilium Patent” means any Patent in the Territory that is (i) Controlled by Auxilium (or its Affiliates) as of the Effective Date, including the Patents listed in Schedule 1.7, or (ii) that comes under the Control of Auxilium during the Term (including an Auxilium Collaboration Patent), in each case of (i) or (ii) which is necessary or reasonably useful for the Development or Commercialization of the Product in the Field in the Territory.

 

1.8                               “Auxilium Technology” means the Auxilium Patents and Auxilium Know-How.

 

2

 

1.9                               “BTC License Agreement” means that certain Second Amended and Restated Development and License Agreement, dated as of August 31, 2011, by and between Auxilium and BioSpecifics Technologies Corp. (“BTC”).

 

1.10                        “Bulk Product” means the finished form of the Product including a sterile diluent containing NaCl and CaCl2, packaged in unlabeled vials.

 

1.11                        “Commercialize”, “Commercializing” or “Commercialization” means all activities directed to the marketing, promotion, selling or offering for sale of a Finished Product for an indication, including planning, market research, Pre-Marketing, advertising, educating, marketing, promoting, importing, exporting, distributing and post-marketing safety surveillance and reporting.  For clarity, “Commercialization” shall not include any activities related to Manufacturing or Development of the Product.

 

1.12                        “Commercially Reasonable Efforts” means, with respect to a Party’s obligations under this Agreement, including to Commercialize the Finished Product, those efforts and resources consistent with the usual practices of such Party in pursuing the development or commercialization of its own pharmaceutical products that are of similar market potential as such Finished Product, taking into account all relevant factors including product labeling, market potential,  financial return, medical and clinical considerations, regulatory environment and competitive market conditions, all as measured by the facts and circumstances at the time such efforts are due.  Without limiting the foregoing, Commercially Reasonable Efforts requires, with respect to such obligations, that the Party: (i) promptly assign responsibility for such obligation to specific employee(s) who are held accountable for progress and monitor such progress on an on-going basis, (ii) set annual objectives for carrying out such obligations, and (iii) allocate resources designed to advance progress with respect to such objectives.

 

1.13                        “Competitive Product” means (i) any pharmaceutical product containing [***] or [***], or (ii) any pharmaceutical product indicated for use [***].

 

1.14                        “Control” means, when used in reference to intellectual property, other intangible property, or materials, that a Party owns or has a license or sublicense to such intellectual property, other intangible property or materials, and has the ability to grant a license or sublicense or other right to use such intellectual property, other intangible property or materials, as applicable, as provided for herein, without (i) requiring the consent of a Third Party or (ii) violating the terms of any agreement or other arrangement with any Third Party.

 

1.15                        “Cover(ed)” means, with respect to any Patent and the subject matter at issue, that, but for a license granted under a Valid Claim of such Patent, the manufacture, development, use, sale, offer for sale or importation of the subject matter at issue would infringe such Valid Claim, or in the case of a Patent that is a patent application, would infringe a Valid Claim in such patent application if it were to issue as a patent.

 

1.16                        “Develop”, “Developing” or “Development” means all activities relating to research, non-clinical, preclinical and clinical trials, toxicology testing, statistical analysis and

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

3

 

reporting, necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining all Regulatory Approvals in the Field in the Territory, including all registries required for any Pricing Approvals and all other development-related activities that are deemed by the JSC to be commercially useful, but shall not include any activities related to Commercialization or Manufacture.

 

1.17                        “Development Activities” means those Development activities undertaken by or on behalf of a Party or its Affiliates with respect to the Product in the Field consistent with the applicable Development Plan.

 

1.18                        “Development Costs” means the costs and expenses incurred by a Party or its Affiliates attributable to, or reasonably allocable to, the Development of the Product, including costs of conducting Phase IV Clinical Trials (as well as other post-Regulatory Approval filing date studies (including physician-initiated studies and registries required for any Pricing Approvals)).  “Development Costs” shall include (i) Out-of-Pocket Costs and (ii) internal costs (e.g., staff or administrative) that are attributable or reasonably allocable to the Development of the Product.  For clarity, Development Costs shall exclude Regulatory Costs.

 

1.19                        “Dollar” means a U.S. dollar, and “$” shall be interpreted accordingly.

 

1.20                        “Drug Substance” means the collagenases derived from Clostridium histolyticum.

 

1.21                        “EMA” means the European Medicines Agency or its successor.

 

1.22                        “European Union” or “EU” means the countries of the European Union, as it is constituted as of the Effective Date, which consists of Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom or such other countries included in the Territory as of the Effective Date that after the Effective Date become members of the EU.

 

1.23                        “Facility” means, as applicable, a Party’s Manufacturing facility and such other facilities used by such Party (or those of its Affiliates or Third Party contractors) in the manufacture, packaging, labeling or storage of (a) Product or (b) materials utilized in the manufacture, packaging or labeling of Product, in each case, with respect to the Product for Development or Commercialization in the Field in the Territory hereunder.

 

1.24                        “FDA” means the U.S. Food and Drug Administration or its successor.

 

1.25                        “FD&C Act” means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder.

 

1.26                        “Field” means the treatment in humans of (i) Dupuytren’s Contracture, (ii) Peyronie’s Disease and (iii) such other indications as the Parties agree to include hereunder, if any.  For purposes of clarity, the “Field” shall not include any new indications for the Product other than as set forth in the foregoing clauses (i) and (ii) and any New Indications.

 

4

 

1.27                        “Finished Product” means the Product, including without limitation the diluent, in its full packaging and final presentation form ready for release to end-users.

 

1.28                        “First Commercial Sale” means, with respect to a Finished Product, the first sale of such Finished Product in a given country or other regulatory jurisdiction in the Territory by or on behalf of Sobi, its Affiliates or its permitted distributors to a Third Party, after receipt of Regulatory Approval (including Pricing Approval, to the extent required for sale of a Product in a given country or regulatory jurisdiction, and any necessary labeling negotiations that may be required after Regulatory Approval and such Pricing Approval) for such Finished Product in such country or regulatory jurisdiction.

 

1.29                        “General Development Activities” means all Development Activities other than Territory Development Activities.

 

1.30                        “Good Clinical Practices” or “GCP” means all applicable Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials, including, as applicable, (i) as set forth in European Commission Directive 2001/20/EC relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, and brought into law by European Commission Directive 2005/28/EC laying down the principles and detailed guidelines for good clinical practice for investigational medicinal products, (ii) the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (“ICH”) Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for trials on medicinal products in the EU, (iii) the Declaration of Helsinki (2004) as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto, (iv) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards) and 312 (Investigational New Drug Application), as may be amended from time to time, and (v) the equivalent Laws in any relevant country, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.

 

1.31                        “Good Laboratory Practices” or “GLP” means all applicable Good Laboratory Practice standards, including, as applicable, (i) as set forth in European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices, as may be amended from time to time as well as any Rules Governing Medicinal Products in the European Community Vol. III, ISBN 92.825 9619-2 (ex - OECD principles of GLP), (ii) the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and (iii) the equivalent Laws in any relevant country, each as may be amended and applicable from time to time.

 

1.32                        “Good Manufacturing Practices” or “GMP” means all applicable Good Manufacturing Practices including, (i) the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the quality standards appropriate for their intended use, as defined in European Commission Directive 2003/94/EC

 

5

 

laying down the principals and guidelines of good manufacturing practice, (ii) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Sections 210, 211, 601 and 610, (iii) the Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products, (iv) the principles detailed in the ICH Q7A guidelines, and (v) the equivalent Laws in any relevant country, each as may be amended and applicable from time to time.

 

1.33                        “Governmental Authority” means any multinational, federal, state, local, municipal or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal), in each case, having jurisdiction over the applicable subject matter.

 

1.34                        “IND” means the equivalent application of an Investigational New Drug Application to the equivalent agency of the FDA in the Territory, such as a clinical trial application (“CTA”) or a clinical trial exemption (“CTX”), the filing of which is necessary to commence or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction.

 

1.35                        “Invented” means the acts of (an) inventor(s), as determined in accordance with applicable Laws relating to inventorship set forth in the patent Laws of the United States (Title 35, United States Code), in discovering, conceiving and completing an Invention.

 

1.36                        “Invention” means any writing, invention, discovery, improvement, technology or other Know-How (in each case, whether patented or not) that is not existing as of the Effective Date and is Invented under this Agreement during the Term.

 

1.37                        “Joint Invention” means an Invention that is Invented jointly by an employee of, or Person under an obligation of assignment to, each of Auxilium and Sobi or their respective Affiliates.

 

1.38                        “Joint Steering Committee” or “JSC” means the joint steering committee formed by the Parties as described in Section 3.1.

 

1.39                        “Know-How” means any proprietary data, results, material(s), technology, and nonpublic information of any type whatsoever, in any tangible or intangible form, including know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulations, formulae, materials or compositions of matter of any type or kind (patentable or otherwise), software, algorithms, marketing reports and plans, market research, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, toxicological, preclinical and clinical test data), analytical and quality control data, stability data, other study data and procedures.

 

1.40                        “Laws” means all applicable laws, statutes, rules, regulations, directives, decisions, ordinances, guidelines and other pronouncements of any Governmental Authority.

 

1.41                        “Manufacture” or “Manufacturing” means all activities related to the manufacturing of the Bulk Product, or any ingredient thereof, including manufacturing for clinical use or commercial sale, a named patient program, in-process and Bulk Product testing,

 

6

 

release of Bulk Product, quality assurance activities related to manufacturing and release of Bulk Product, Packaging and Labeling, handling and storage of Bulk Product and ongoing stability tests and regulatory activities related to any of the foregoing.

 

1.42                        “Manufacturing Development Activities” means development of test methods, stability testing, formulation development, process development, quality assurance activities, quality control activities, qualification and validation activities, analytic process development, manufacturing process validation, scale-up, and all other activities, including CMC-related activities, necessary for or related to the Manufacture of the Product for use in the Field.

 

1.43                        “Manufacturing Standard Cost” means the standard cost per Unit of Product, calculated annually.  This includes the cost of raw materials, labor, and other direct and identifiable variable costs and appropriate costs for equipment pools, plant operations and plant support services.  The costs for plant operations and support services would include utilities, maintenance, engineering, safety, human resources, finance, plant management and other similar activities, as well as, shipping costs to a finished goods warehouse.  The plant operations and support services costs would be allocated to the Product consistent with generally accepted accounting principles in the United States (“GAAP”), based on budgeted volumes produced by or on behalf of Auxilium.

 

1.44                        “Marketing Authorization Application” or “MAA” means an application to the appropriate Regulatory Authority for approval to sell the Finished Product (but excluding Pricing Approval) in any particular country or regulatory jurisdiction, including any amendments, updates and variations thereto and any such application filed with the EMA pursuant to the centralized procedure or with the applicable Regulatory Authority of a country in the Territory in accordance with the decentralized or mutual recognition procedures or any other national approval procedure.

 

1.45                        “Medical Science Liaison” means an individual who is employed by or on behalf of Sobi or its Affiliates and who provides educational services and other educational efforts directed towards the medical and/or scientific community.

 

1.46                        “Net Sales” means the gross amount invoiced by or on behalf of Sobi or any of its Affiliates or sublicensees (or any permitted distributors) on account of sales of the Finished Product, less the following deductions specifically and solely related to the Finished Product and actually allowed consistent with GAAP:

 

(a)                                 customary trade, cash or quantity discounts actually paid, granted or accrued, to the extent not already reflected in the amount invoiced, including cash rebates to customers;

 

(b)                                 excise, import and sales taxes, customs, duties, and other fees of a similar nature to the extent included in the price and separately itemized on the invoice or otherwise documented to Auxilium’s reasonable satisfaction (but specifically excluding, for clarity, any income taxes assessed against the income arising from such sale);

 

7

 

(c)                                  outbound freight, shipment and insurance costs to the extent included in the price and separately itemized on the invoice or otherwise documented to Auxilium’s reasonable satisfaction;

 

(d)                                 amounts actually paid, granted or accrued on (i) returns in accordance with Sobi’s returned goods policy provided to Auxilium or (ii) recalls; and

 

(e)                                  compulsory payments and rebates directly related to the sale of the Finished Product paid to a Governmental Authority pursuant to governmental regulations by reason of any national or local health insurance program or similar program.

 

For clarity, (i) Net Sales shall not be reduced by the amount of any commissions paid to individuals, whether they are associated with independent sales agencies or regularly employed by Sobi, its Affiliate or sublicensee (or any agent, distributee, or designee thereof), or for a cost of collection or any other amount not specifically set forth in (a) through (e) above and (ii) the amount of any discounts, rebates or allowances granted or taken with respect to the total sales to a customer for multiple products of Sobi, its Affiliate or sublicensee (or any agent, distributee, or designee thereof) shall not be deducted in calculating Net Sales.  Any of the items set forth above that would otherwise be deducted from the invoice price in the calculation of Net Sales but which are separately charged to, and paid by, Third Parties shall not be deducted from the invoice price in the calculation of Net Sales.  In the case of any sale or transfer of the Finished Product other than in an arm’s length transaction exclusively for cash, such as barter, counter-trade, sampling, or named patient program, Net Sales shall be determined by referencing Net Sales at which substantially similar quantities of the Finished Product are sold in an arm’s length transaction for cash.

 

Notwithstanding the foregoing, amounts billed by Sobi, its Affiliates, its sublicensees or any permitted distributors for the sale of Finished Product among Sobi, its Affiliates, its sublicensees or any permitted distributor for resale shall not be included in the computation of Net Sales hereunder.  Net Sales shall be accounted for in accordance with GAAP, consistently applied.  Sobi, its Affiliates, its sublicensees (and any permitted distributor) will sell the Finished Product as a stand-alone product and will not sell the Finished Product as part of a bundle with other products or offer package deals to customers that include the Finished Product, except to the extent required to obtain sales contracts with government entities, and in such case, the price of the Finished Product relevant for the calculation of Net Sales will be the average price in the preceding calendar quarter of the Finished Product sold separately less the average discount of all products sold as part of the package.

 

Within fifteen (15) days of the end of each calendar year, Sobi shall provide Auxilium with a report that itemizes any permitted deductions from Net Sales that were not included in Sobi’s invoices for sales of the Product because such deductions could not be determined at the time such invoices were originally issued (“Additional Net Sales Deductions”).  Any permitted Additional Net Sales Deductions shall reduce the Net Sales for the calendar year ending immediately preceding such report.

 

1.47                        “New Indication” means any indication for the Product outside the Field.

 

8

 

1.48                        “Out-of-Pocket Costs” means costs and expenses paid to Third Parties (or payable to Third Parties and accrued in accordance with GAAP), other than Affiliates or employees, by either Party.

 

1.49                        “Patents” means patents and patent applications and all substitutions, divisions, continuations, continuations-in-part, any patent issued with respect to any such patent applications, any reissue, reexamination, utility models or designs, renewal or extension (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all counterparts thereof in any country.

 

1.50                        “Patent Term Extension” means any term extensions, supplementary protection certificates, Regulatory Exclusivity and equivalents thereof offering Patent protection beyond the initial term with respect to any issued Patents.

 

1.51                        “Person” shall mean any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.

 

1.52                        “Phase IV Clinical Trials” means certain post-marketing studies to delineate additional information about a pharmaceutical product’s risks, benefits, and optimal use (including health economic outcome studies, pricing and reimbursement studies, as well as product registries), commenced after receipt of regulatory approval for a product in the indication for which such trial is being conducted.

 

1.53                        “Pre-Marketing” means all sales and marketing activities undertaken prior to and in preparation for the launch of the Finished Product in the Territory.  Pre-Marketing shall include market research, key opinion leader development, advisory boards, medical education, disease-related public relations, health economic outcome studies, market access and reimbursement evaluations, sales force training and other pre-launch activities prior to the First Commercial Sale of the Finished Product in a given country or other regulatory jurisdiction in the Territory.

 

1.54                        “Pricing Approval” means the approval, agreement, determination or decision from a Governmental Authority establishing the price and/or reimbursement for the Product for sale in a given country or regulatory jurisdiction, as required by applicable Laws in such country or other regulatory jurisdiction prior to the sale of the Product in such country or regulatory jurisdiction.

 

9

 

1.55                        “Product” means, in all cases excluding any dermal formulations labeled for topical administration, any dosage strength of the pharmaceutical product consisting of the lyophilized form of injectable collagenases derived from Clostridium histolyticum [***].

 

1.56                        “Product Approval” means the approval of a Governmental Authority necessary for the marketing and sale of the Finished Product in a given country or regulatory jurisdiction, which may include the approval of an MAA (but shall not include any Pricing Approvals).

 

1.57                        “Product Complaint” means any written, verbal or electronic expression of dissatisfaction regarding any Finished Product sold by or on behalf of Sobi (or any of its Affiliates, sublicensees or permitted distributors) in the Territory, including reports of actual or suspected product tampering, contamination, mislabeling or inclusion of improper ingredients.

 

1.58                        “Product Specifications” means those Manufacturing, performance, quality - control release, and Packaging and Labeling specifications for the Finished Product in the Territory, which are initially as set forth in the applicable Product Approval for the Finished Product, as such specifications may be amended from time to time pursuant to the terms of this Agreement.

 

1.59                        “Promotional Materials” means all written, printed, audio, video or graphic or other electronic advertising, promotional, educational, branded, and communication materials (other than the Finished Product labels and package inserts) for marketing, advertising, educating, and promoting of the Finished Product in the Field in the Territory, for use (i) by a Sales Representative or a Medical Science Liaison or (ii) in advertisements, web sites or direct mail pieces.

 

1.60                        “Quality Agreement” means the quality agreement relating to the Unit of Product between Sobi and Auxilium.

 

1.61                        “Regulatory Approvals” means all necessary approvals (including INDs, Product Approvals, Pricing Approvals, import permits, and, in each case any supplements and amendments thereto), licenses, registrations or authorizations of any Governmental Authority, necessary for the Development, manufacture, distribution, use, promotion and sale of the Product in a given country or regulatory jurisdiction.

 

1.62                        “Regulatory Authority” means, in a particular country or regulatory jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval in such country or regulatory jurisdiction, including, without limiting the foregoing, (i) in the U.S., the FDA, and (ii) in the European Union, the EMA, the European Commission and relevant national medicines regulatory authorities.

 

1.63                        “Regulatory Costs” shall include (a) Out-of-Pocket Costs and (b) internal costs (e.g., staff or administrative) that are attributable or reasonably allocable to the preparation of Regulatory Materials, and maintenance of Regulatory Approvals, for the Bulk Product or Finished Product in the Field in the Territory.  For clarity, Regulatory Costs shall exclude Development Costs

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

10

 

1.64                        “Regulatory Data” means any and all research data, pharmacology data, chemistry, manufacturing and control data, preclinical data, pricing and reimbursement data, clinical data and all other documentation submitted, or required to be submitted, to Regulatory Authorities in association with regulatory filings for the Product (including any applicable Drug Master Files (“DMFs”), Chemistry, Manufacturing and Control (“CMC”) data, or similar documentation).

 

1.65                        “Regulatory Exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by any Governmental Authority with respect to the Product other than a Patent right, including without limitation, in the European Union, Regulation (EC) No 726/2004 and Directive 2001/83/EC (as amended).

 

1.66                        “Regulatory Materials” means regulatory applications, submissions, notifications, communications, correspondence, registrations, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority that are necessary in order to Develop, Manufacture, obtain marketing authorization, market, sell or otherwise Commercialize the Product in a particular country or regulatory jurisdiction.  Regulatory Materials include INDs, MAAs, presentations, responses, and applications for other Product Approvals.

 

1.67                        “Royalty Term” means the period of time beginning on the Effective Date and ending upon the ten (10) year anniversary of the Effective Date (the “Initial Term”), and shall thereafter be automatically renewed for sequential two (2) year periods (each a “Renewal Term”) unless a notice of non-renewal is provided in writing to the other Party at least six (6) months prior to the expiration of the Initial Term or the then current Renewal Term.

 

1.68                        “Sales Representative” means an individual who is employed by or on behalf of Sobi (or its Affiliates, sublicensees or subcontractors) and who performs details, engages in market access discussions and/or other promotional efforts with respect to the Finished Product.

 

1.69                        “Sobi Applied Know-How” means all Know-How that is (i) (a) Controlled by Sobi (or its Affiliates) as of the Effective Date or comes under the Control of Sobi (or its Affiliates) during the Term (other than as a result of the licenses granted by Auxilium to Sobi under this Agreement) and (b) incorporated by Sobi into any Finished Product prior to any termination or expiration of this Agreement (provided, however, that such Know-How is necessary or reasonably useful for the Development or Manufacture of Bulk Product or Commercialization of Finished Product) or (ii) a Sobi Invention.

 

1.70                        “Sobi Applied Patent” means any Patent that (i) (a) is Controlled by Sobi (or its Affiliates) as of the Effective Date or comes under the Control of Sobi (or its Affiliates) during the Term (other than as a result of the licenses granted by Auxilium to Sobi under this Agreement) and (b) that claims any Sobi Applied Know-How or (ii) is a Sobi Collaboration Patent.

 

1.71                        “Sobi Applied Technology” means the Sobi Applied Know-How and the Sobi Applied Patents.

 

11

 

1.72                        “Sobi Invention” means an Invention that is Invented, solely or jointly with a Third Party, by an employee of Sobi or its Affiliates or a Person under an obligation of assignment to Sobi or its Affiliates.

 

1.73                        “Territory” means the countries listed on Schedule 1.73, unless and until this Agreement is terminated with respect to any such country in accordance with the terms of this Agreement.

 

1.74                        “Territory Development Activities” means those Development Activities that are (i) necessary solely for obtaining or maintaining Regulatory Approval for the Product in the Field in any given country in the Territory and (ii) post-Regulatory Approval filing date Development Activities for the Product in any given country in the Field in the Territory.  Notwithstanding the foregoing, in the event that Sobi requests that Auxilium perform certain Development Activities, within the Territory, which are not necessary solely for obtaining or maintaining Regulatory Approval in the Territory, and Auxilium agrees at its sole discretion to perform such activities within the Territory, then such activities as are conducted in any given country in the Territory shall be deemed Territory Development Activities.  For clarity, those Development Activities which Auxilium proposes (absent Sobi’s request) to conduct in the Territory shall not be included in the definition of Territory Development Activities, and shall therefore be deemed General Development Activities. For purposes of clarity, Territory Development Activities includes any studies required to obtain any Pricing Approval.

 

1.75                        “Third Party” means any Person other than Auxilium or Sobi or their respective Affiliates.

 

1.76                        “Unit of Product” means one 0.9 mg vial of the current lyophilized form of injectable collagenases derived from Clostridium histolyticum and one 3 mL vial of sterile diluent containing NaCl and CaCl2.

 

1.77                        “U.S.” means the United States of America and its possessions and territories.

 

1.78                        “Valid Claim” means (a) a claim of an issued and unexpired Auxilium Patent, Joint Collaboration Patent or a Sobi Collaboration Patent that (i) has not been rejected, revoked or held to be invalid or unenforceable by a court or other authority of competent jurisdiction, from which decision no appeal can be further taken or (ii) has not been finally abandoned, disclaimed or admitted to be invalid or unenforceable through reissue or disclaimer; or (b) a claim included in a pending patent application of an Auxilium Patent, a Joint Collaboration Patent or a Sobi Collaboration Patent (whether filed before or after the Effective Date) that (i) has not been pending for more than seven (7) years from the effective date of filing for such patent application (provided, however that for purposes of clarity, in the event such pending claim subsequently issues in an issued patent, then such claim shall again be a Valid Claim as of the date of issuance of such patent) or (ii) has not been finally determined to be unallowable by the applicable governmental authority (from which no appeal is or can be taken).

 

1.79                        Interpretation.  Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a) “include”, “includes” and “including” are not

 

12

 

limiting; (b) “hereof”, “hereto”, “herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement; (c) words of one gender include the other gender; (d) words using the singular or plural number also include the plural or singular number, respectively; (e) references to a contract or other agreement mean such contract or other agreement as from time to time amended, modified or supplemented; (f) references to a Person are also to its permitted successors and assigns; (g) references to an “Article”, “Section”, “Exhibit” or “Schedule” refer to an Article or Section of, or an Exhibit or Schedule to, this Agreement, unless expressly stated otherwise; (h) references to a law include any amendment or modification to such law and any rules and regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules and regulations occurs, before or after the date of this Agreement; and (i) Dupuytren’s Contracture is analogous to Dupuytren’s Disease as such term is used in the BTC License Agreement.

 

1.80                        Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement:

 

	
Term
    	
 
    	
Section
    
	
“Abandoned   Collaboration Patents”
    	
 
    	
9.3.2
    
	
“Abandoned Joint   Inventions”
    	
 
    	
9.3.2
    
	
“Additional Diluent”
    	
 
    	
7.3
    
	
“Additional Diluent Supply   Price”
    	
 
    	
7.3
    
	
“Additional Net Sales   Deductions”
    	
 
    	
1.46
    
	
“Aggregate Quarterly   Supply Price”
    	
 
    	
8.3
    
	
“Agreement”
    	
 
    	
Preamble
    
	
“Alliance Manager”
    	
 
    	
3.5
    
	
“Assigned Contracts”
    	
 
    	
6.3.4
    
	
“Audit”
    	
 
    	
8.10
    
	
“Auxilium”
    	
 
    	
Preamble
    
	
“Auxilium Collaboration   Patents”
    	
 
    	
9.1.1
    
	
“Bankrupt Party”
    	
 
    	
14.6
    
	
“Breaching Party”
    	
 
    	
13.2
    
	
“BTC”
    	
 
    	
1.9
    
	
“CDS”
    	
 
    	
5.1.1
    
	
“Certificate of   Analysis”
    	
 
    	
7.9.2(a)
    
	
“Claim”
    	
 
    	
11.1
    
	
“CMC”
    	
 
    	
1.64
    
	
“Commercial Supply   Price”
    	
 
    	
7.3
    
	
“Commercialization   Budget”
    	
 
    	
6.2.3(e)
    
	
“Commercialization   Data”
    	
 
    	
6.9
    
	
“Commercialization   Plan”
    	
 
    	
6.2.1
    
	
“Committee”
    	
 
    	
3.6
    

 

13

 

	
“Confidential Information”
    	
 
    	
12.1
    
	
[***]
    	
 
    	
[***]
    
	
“Controlling Party”
    	
 
    	
9.4.1(a)
    
	
“CTA”
    	
 
    	
1.34
    
	
“CTX”
    	
 
    	
1.34
    
	
“Default”
    	
 
    	
10.2.13
    
	
“Development Budget”
    	
 
    	
4.3.1(c)
    
	
“Development Data”
    	
 
    	
4.6
    
	
“Development Plan”
    	
 
    	
4.3.1
    
	
“Development Supply   Price”
    	
 
    	
7.2
    
	
“Disbanding Notice”
    	
 
    	
3.8
    
	
“Disclosing Party”
    	
 
    	
12.1
    
	
“DMFs”
    	
 
    	
1.64
    
	
“Effective Date”
    	
 
    	
Preamble
    
	
“Executive Officer”
    	
 
    	
15.2
    
	
“Finished Product   Designation”
    	
 
    	
7.6.3
    
	
“Finished Product Designation   Acceptance Date”
    	
 
    	
7.6.3
    
	
“Forecast”
    	
 
    	
7.6.1
    
	
“Forecast Date”
    	
 
    	
7.6.1
    
	
“GAAP”
    	
 
    	
1.43
    
	
“Global Branding   Strategy”
    	
 
    	
6.10
    
	
“ICH”
    	
 
    	
1.30
    
	
“Indemnification Claim   Notice”
    	
 
    	
11.3.1
    
	
“Indemnified Party” and   “Indemnifying Party”
    	
 
    	
11.3.1
    
	
“Indemnitee” and   “Indemnitees”
    	
 
    	
11.3.1
    
	
“Infringement Claim”
    	
 
    	
9.4.1
    
	
“Initial   Commercialization Plan”
    	
 
    	
6.2.1
    
	
“Initial Term”
    	
 
    	
1.67
    
	
“Joint Collaboration   Patents”
    	
 
    	
9.1.1
    
	
“Latent Defects”
    	
 
    	
7.9.2(b)
    
	
“Losses”
    	
 
    	
11.1
    
	
“Milestone Notification   Notice”
    	
 
    	
8.1
    
	
“Milestone Payments”
    	
 
    	
8.1
    
	
“Notice of   Non-Conformance”
    	
 
    	
7.9.2(a)
    
	
“OOS”
    	
 
    	
7.9.3
    
	
“Packaging and   Labeling”
    	
 
    	
7.5.1
    
	
“Party” or “Parties”
    	
 
    	
Preamble
    
	
“Patent Challenge”
    	
 
    	
13.4
    
	
“Product Trade Dress”
    	
 
    	
6.8.1
    
	
“Product Trademark”
    	
 
    	
6.8.1
    
	
“Promotional   Commercialization Data”
    	
 
    	
6.9
    
	
“Purchase Order”
    	
 
    	
7.6.3
    
	
“Real World Study”
    	
 
    	
4.1.1
    
	
“Receiving Party”
    	
 
    	
12.1
    
	
“Recovery”
    	
 
    	
9.4.2(c)(iv)
    
	
“Redacted Agreement”
    	
 
    	
12.5.2
    

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

14

 

	
“Renewal Term”
    	
 
    	
1.67
    
	
“Royalty Payment”
    	
 
    	
8.2.1
    
	
“Royalty Rates”
    	
 
    	
8.2.1
    
	
“Sobi”
    	
 
    	
Preamble
    
	
“Sobi Collaboration   Patents”
    	
 
    	
9.1.1
    
	
“Sobi Funded Patent Rights”
    	
 
    	
9.3.1
    
	
“Success Amount”
    	
 
    	
8.2.2
    
	
“Success Event”
    	
 
    	
8.2.2
    
	
“Term”
    	
 
    	
13.1
    
	
“VAT”
    	
 
    	
8.5.1
    

 

ARTICLE 2
 LICENSES

 

2.1                               Grant to Sobi.

 

2.1.1                     General Grant to Sobi.  Subject to the terms and conditions of this Agreement, Auxilium hereby grants to Sobi during the Term (i) a co-exclusive (with Auxilium and its Affiliates) license or sublicense, as applicable, with the right to sublicense solely in accordance with Section 2.4.2, under the Auxilium Technology and the Joint Collaboration Patents, to perform Territory Development Activities, and (ii) an exclusive (even as to Auxilium and its Affiliates), payment-bearing license or sublicense, as applicable, with the right to sublicense solely in accordance with Section 2.4.2, under the Auxilium Technology and the Joint Collaboration Patents, to Commercialize the Product in the Field in the Territory.

 

2.1.2                     Additional Grant to Sobi.  Subject to the terms and conditions of this Agreement, including in particular Section 6.8, Auxilium hereby grants to Sobi during the Term an exclusive license or sublicense, as applicable, with the right to sublicense solely in accordance with Section 2.4.2, to use the Product Trademark and Product Trade Dress solely to the extent necessary to Commercialize the Finished Product in the Field in the Territory.  Auxilium hereby grants to Sobi during the Term and from and after the expiration or termination by Sobi for breach by Auxilium of this Agreement, a non-exclusive, royalty-free, irrevocable, perpetual, worldwide license under any Joint Collaboration Patents for any and all uses; provided, that in the event of a termination of this Agreement by Sobi for breach of Auxilium such license shall not include any rights with respect to the Product, Bulk Product or Finished Product.

 

2.2                               Grant to Auxilium.

 

2.2.1                     General Grant to Auxilium.  Subject to the terms and conditions of this Agreement, Sobi, together with its Affiliates, hereby grants to Auxilium during the Term a non-exclusive royalty-free license or sublicense, as applicable, with the right to sublicense, under the Sobi Applied Technology, to Develop, Manufacture or Commercialize the Product, Bulk Product or Finished Product.

 

15

 

2.2.2                     Additional Grant to Auxilium.  Subject to the terms and conditions of this Agreement, Sobi, together with its Affiliates, hereby grants to Auxilium (i) a non-exclusive, paid-up, irrevocable, perpetual, worldwide license or sublicense, as applicable, with the right to sublicense, under the Sobi Applied Technology, to develop (including obtaining and maintaining regulatory approval), make, use, import, export, offer for sale and sell pharmaceutical products containing injectable collagenases derived from Clostridium histolyticum for sale anywhere in the world (other than the sale of the Finished Product in the Field in the Territory), (ii) from and after the expiration or termination of this Agreement (on a country-by-country basis), a non-exclusive, paid-up, irrevocable, perpetual, worldwide license or sublicense, as applicable, with the right to sublicense, under the Sobi Applied Technology, to develop (including obtaining and maintaining regulatory approval), make, use, import, export, offer for sale and sell the Product, Bulk Product or Finished Product in the Field in such country in the Territory.

 

2.3                               Additional Licensing Provisions.

 

2.3.1                     Negative Covenant.  Each Party covenants that it will not use or practice any of the other Party’s Patent rights or other intellectual property rights licensed (or sublicensed, as applicable) to it under this ARTICLE 2 except for the purposes expressly permitted in the applicable license grant.

 

2.3.2                     No Implied Licenses; Retained Rights.  Except as explicitly set forth in this Agreement, neither Party grants any license, express or implied, under its intellectual property rights to the other Party, whether by implication, estoppel or otherwise.

 

2.4                               Performance by Affiliates, Subcontractors and Sublicensees.

 

2.4.1                     Performance by Affiliates.  The Parties recognize that each Party may perform some or all of its obligations under this Agreement through Affiliates; provided, however, that each Party shall remain responsible for and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.  Each Party hereby expressly waives any requirement that the other Party exhaust any right, power or remedy, or proceed against an Affiliate, for any obligation or performance hereunder prior to proceeding directly against such Party.  Wherever in this Agreement the Parties delegate responsibility to Affiliates, the Parties agree that such entities may not make decisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way.

 

2.4.2                     Subcontractors and Sublicensees.  As of the Effective Date, Sobi has entered into the sublicenses that will apply to the Product as set forth on Schedule 2.4.2. Sobi shall remain responsible for, and shall guarantee, the performance of such existing sublicensees.  Sobi shall have the right to grant sublicenses to any sublicensee under all of its rights under the license granted pursuant to Section 2.1, or to subcontract the performance of its obligations hereunder, at any given time during the Term in any part of the Territory; provided however that with respect to each such sublicense not set forth on Schedule 2.4.2 or subcontract, as the case may be: (i) with respect to each sublicensee, Auxilium shall be notified in writing at least twenty 

 

16

 

(20) business days in advance of the grant (including a description of the rights to be granted, the identity of the sublicensee and the countries involved) and, if such sublicensee is not an Affiliate of Sobi, Sobi shall obtain the prior written consent of Auxilium thereto, such consent not to be unreasonably withheld; (ii) Sobi shall ensure that each of its sublicensees and subcontractors accepts and complies with all applicable terms and conditions of this Agreement, and Sobi shall remain responsible for, and shall guarantee, the performance of its sublicensees and subcontractors hereunder, except to the extent otherwise provided in any contractual arrangements set forth on Schedule 2.4.2; and (iii) any such sublicense or subcontract shall (a) be subject and subordinate to the terms and conditions of this Agreement, (b) be subject to an appropriate written agreement that imposes on any such sublicensee or subcontractor all applicable terms, conditions and obligations under this Agreement, including the reporting, audit, inspection and confidentiality provisions hereunder, (c) contain a provision prohibiting such sublicensee or subcontractor from further sublicensing and subcontracting and (d) not in any way diminish, reduce or eliminate any of Sobi’s obligations under this Agreement.  For the avoidance of doubt, Sobi will remain directly responsible for all amounts owed to Auxilium under this Agreement.  Sobi hereby expressly waives any requirement that Auxilium exhaust any right, power or remedy, or proceed against a sublicensee or subcontractor for any obligation or performance hereunder prior to proceeding directly against Sobi.

 

2.5                               Exclusivity.

 

2.5.1                     Sobi.  Sobi hereby covenants not to research, develop (including submitting any applications for regulatory approval), manufacture or commercialize, during the Term, any Competitive Product [***], either on its own, with or through any Affiliate, or in collaboration with a Third Party, in each case other than with respect to the Commercialization of the Finished Product in the Field in the Territory pursuant to this Agreement.  Notwithstanding the foregoing, the limitations set forth in this Section 2.5.1 shall not apply to any New Indication.

 

2.5.2                     Auxilium.  Auxilium hereby covenants that it shall not (and shall cause its Affiliates not to), during the Term manufacture or commercialize any Competitive Product in the Field in the Territory, either on its own, with or through any Affiliate, or in collaboration with a Third Party, and in each case other than with respect to the Development of Bulk Product and Commercialization of the Finished Product in the Field in the Territory pursuant to this Agreement.  Notwithstanding the foregoing, the limitations set forth in this Section 2.5.2 shall not apply to any New Indication.  Should Auxilium or its Affiliates, during the Term, develop (including submitting any applications for regulatory approval), manufacture or commercialize any Competitive Product in the Field, either Party may initiate discussions regarding the commercial viability of such Competitive Product in the Field in the Territory and should Auxilium, following such discussions, desire to develop or commercialize such Competitive Product in the Field in the Territory, Auxilium shall offer the exclusive rights to such Competitive Product in the Field in the Territory to Sobi, the details of which shall be negotiated in good faith between the Parties.

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

17

 

2.6                               Sobi Restrictive Covenants.

 

2.6.1                     Ex-Territory Activities.  Sobi hereby covenants and agrees that it shall not (and shall cause its Affiliates, sublicensees and subcontractors not to), either itself or through a Third Party, market, promote or actively offer for sale the Finished Product outside of the Territory in or outside of the Field.  Without limiting the generality of the foregoing, with respect to countries outside of the Territory, Sobi shall not (i) engage in any advertising activities relating to the Finished Product directed to customers outside the Territory, or (ii) solicit orders from any prospective purchaser located outside the Territory.  If Sobi receives any order from a prospective purchaser located in a country outside of the Territory, Sobi shall immediately refer that order to Auxilium and shall not accept any such order or deliver or tender (or cause to be delivered or tendered) any Finished Product under such order.  If Sobi should reasonably know that a customer or distributor is engaged itself or through a Third Party in the sale or distribution of the Finished Product outside of the Territory, then Sobi shall (a) within two (2) business days of gaining knowledge of such activities notify Auxilium regarding such activities and provide all information that Auxilium may request concerning such activities and (b) take all reasonable steps (including cessation of sales to such customers) necessary to limit such sale or distribution outside the Territory, unless otherwise agreed in writing by the Parties.

 

2.6.2                     Ex-Field Activities.  Sobi hereby covenants and agrees that it shall not (and shall cause its Affiliates, its sublicensees and subcontractors not to), either itself or through a Third Party, Commercialize the Finished Product in the Territory for use outside the Field, provided however under this Agreement that the Parties recognize i) that Sobi can not control if the Finished Product is prescribed by a healthcare physician for off-label use, ii) that Sobi would not always be able to determine for which intended use the Finished Product is ordered by a customer, and iii) any such off-label prescription outside Sobi’s reasonable knowledge or control shall not be deemed a breach of this Agreement.  Without limiting the generality of the foregoing, Sobi shall not (i) engage in any advertising activities relating to the Finished Product directed to use outside the Field, or (ii) solicit orders from any prospective purchaser for use of the Finished Product outside the Field in the Territory.  If Sobi receives any order from a prospective purchaser for use of the Finished Product outside the Field, Sobi shall immediately refer that order to Auxilium and shall not accept any such order or deliver or tender (or cause to be delivered or tendered) any Finished Product under such order, unless otherwise agreed in writing by the Parties.  If Sobi should reasonably know that a customer or distributor, or a customer’s distributor or customer, is engaged in the sale or distribution of the Finished Product for use outside the Field, then Sobi shall (a) within two (2) business days of gaining knowledge of such activities notify Auxilium regarding such activities and provide all information that Auxilium may request concerning such activities and (b) take all reasonable steps (including cessation of sales to such customer) necessary to limit such sale or distribution for use outside the Field, unless otherwise agreed in writing by the Parties.

 

2.6.3                     Sobi Contracts.  In the event that Sobi (or any of its Affiliates) enters into any agreements with a sublicensee or subcontractor (including, any distributors or wholesalers) for the Commercialization of Finished Product, it shall include in any and all said agreements provisions substantially similar to those set forth in Sections 2.6.1 and 2.6.2, such that such sublicensee or subcontractor shall only be authorized to market, distribute and sell the Finished Product within the Field within the applicable countries in the Territory, and shall be prohibited 

 

18

 

from marketing, distributing or selling the Finished Product outside the Field or outside the Territory. For clarity, regardless the aforementioned, no agreement shall stipulate terms which are not compliant with applicable competition law.

 

2.6.4                     Within-Territory Activities.  Auxilium hereby covenants and agrees that it shall not (and shall cause its Affiliates, sublicensees and subcontractors not to), either itself or through a Third Party, market, promote or actively offer for sale the Finished Product into countries within the Territory for use in the Field.  Without limiting the generality of the foregoing, with respect to such countries within the Territory, Auxilium shall not (i) engage in any advertising activities relating to the Finished Product for use in the Field directed solely to customers located in such countries, or (ii) solicit orders from any prospective purchaser located in such countries. If Auxilium receives any order from a prospective purchaser located in a country inside of the Territory, Auxilium shall immediately refer that order to Sobi.

 

2.6.5                     Auxilium Contracts.  In the event that Auxilium (or any of its Affiliates) enters into any agreements with a subcontractor (including, any distributors or wholesalers) or a sublicensee for the Commercialization of Finished Product, it shall include in any and all said agreements provisions substantially similar to those set forth in Section 2.6.4, such that such subcontractor or sublicensee, as applicable, shall only be authorized to market, distribute and sell the Finished Product: (i) within countries outside the Territory or (ii) within the Territory, for use outside the Field as otherwise provided in this Agreement.

 

2.6.6                     Jurisdictional Compliance.  It is the desire and intent of the Parties that the restrictive covenants contained in this Section 2.6 be enforced to the fullest extent permissible under the Laws and public policies applied in each jurisdiction in which enforcement is sought.  Auxilium and Sobi believe that the restrictive covenants in this Section 2.6 are valid and enforceable.  However, if any restrictive covenant should for any reason become or be declared by a competent court or competition authority to be invalid or unenforceable in any jurisdiction, such restrictive covenant shall be deemed to have been amended to the extent necessary in order that such provision be valid and enforceable, such amendment shall apply only with respect to the operation of such provision of this Section 2.6 in the particular jurisdiction in which such declaration is made.

 

2.7                               BTC Step-in Rights.  Auxilium agrees to use its Commercially Reasonable Efforts to obtain step-in rights for Sobi in the event of certain material breaches under the BTC License Agreement by Auxilium, wherein Sobi would have step-in rights under the terms of the BTC License Agreement substantially similar to those that Auxilium previously granted to Pfizer Inc.

 

ARTICLE 3
 GOVERNANCE

 

3.1                               Joint Steering Committee.  The Parties shall establish the JSC within thirty (30) days after the Effective Date.  The JSC shall perform the following functions:

 

19

 

3.1.1                     Review, coordinate and discuss the overall strategy for Developing the Product in the Field in the Territory, including reviewing, coordinating and discussing the overall strategy for seeking and maintaining Regulatory Approvals for the Finished Product in the Field in the Territory;

 

3.1.2                     Approve, manage and oversee the preparation and implementation of the Development Plan, if any, and any material amendments thereto, including reviewing the design of the clinical trial protocols and endpoints and overseeing the conduct of all clinical trials required as set forth in the Development Plan;

 

3.1.3                     Discuss any General Development Activities and Territory Development Activities to be conducted with respect to the Product in the Field in the Territory;

 

3.1.4                     Review any matters related to Regulatory Approvals for the Finished Product in the Field in the Territory, including the development and contents of all submissions to Regulatory Authorities in the Territory for Regulatory Approvals and all necessary filing and registration activities related thereto;

 

3.1.5                     Review and discuss the overall strategy for obtaining, maintaining and enforcing Patent protection and market and data exclusivity for the Product in the Field in the Territory;

 

3.1.6                     Review and discuss the overall strategy for Commercializing the Finished Product in the Field in the Territory;

 

3.1.7                     Review and discuss the Commercialization Plan, and any amendments or revisions thereto, which review shall be on an annual basis, on or before October 31st of each year during the Term, with a six (6) month review of any amendments or revisions thereto until three (3) years after the First Commercial Sale when such reviews shall become annual reviews only;

 

3.1.8                     Provide a forum for the Parties to discuss the Commercialization of the Finished Product in the Field in the Territory in the broader context of Auxilium’s Global Branding Strategy;

 

3.1.9                     Discuss a range of suggested prices and associated market access and reimbursement strategies at which the Finished Product will be sold to Third Parties in the Field in the Territory and any discount strategies and price increase/decrease strategies for the Finished Product in the Field in the Territory; provided that nothing contained herein shall limit or in any way restrict Sobi from having the final decision on setting the price or negotiating with pricing and reimbursement authorities in the countries within the Territory to determine at which price the Finished Product will be sold in the Field in the Territory;

 

3.1.10              Discuss safety stock of Drug Substance;

 

3.1.11              Be informed of any Packaging and Labeling strategies with respect to the Finished Product in the Field in the Territory;

 

20

 

3.1.12              Ensure guidance, consultancy and access by both Parties to CMC Information and data in support of filings, Facility inspections and Finished Product launch in the Territory;

 

3.1.13              Resolve disputes and other matters that are subject to JSC oversight;

 

3.1.14              Be informed on progress and issues concerning Manufacturing Development Activities and Territory-Specific Analytical Release Testing; and

 

3.1.15              Have such other responsibilities as may be assigned to the JSC pursuant to this Agreement or as may be mutually agreed upon by the Parties in writing from time to time.

 

3.2                               Joint Steering Committee Membership.  Auxilium and Sobi shall each designate three (3) representatives of appropriate seniority and experience to serve on the JSC by written notice to the other Party.  Either Party may designate substitutes for its representatives if one (1) or more of such Party’s designated representatives are unable to be present at a meeting.  From time to time each Party may replace its representatives by written notice to the other Party specifying the prior representative(s) and their replacement(s).  The JSC shall be co-chaired by a representative of each of Sobi and Auxilium.  One member of the JSC shall serve as secretary of the JSC at each JSC meeting, and the secretary shall alternate from meeting to meeting between a Sobi JSC member and an Auxilium JSC member.  The chairpersons shall be responsible for (i) calling meetings, (ii) preparing and issuing minutes of each such meeting in accordance with Section 3.12, and (iii) preparing and circulating an agenda for the upcoming meeting; provided that the chairpersons shall consider including any agenda items proposed by either Party no less than five (5) days prior to the next scheduled JSC meeting.

 

3.3                               Joint Steering Committee Meetings.  The JSC shall hold at least one (1) meeting per calendar quarter at such times during such calendar quarter for the first year following the Effective Date as it elects to do so, and thereafter, if the Parties mutually so decide, twice per year provided that the JSC shall meet more or less frequently as Sobi and Auxilium mutually agree upon as appropriate.  Meetings of the JSC shall be effective only if at least one (1) representative of each Party is present or participating.  The JSC may meet either (i) in person at either Party’s facilities or at such locations as the Parties may otherwise agree or (ii) by audio or video teleconference.  Other representatives of each Party involved with the Product may attend meetings as non-voting participants, subject to the confidentiality provisions set forth in ARTICLE 12.  Additional meetings of the JSC may also be held with the consent of each Party, as required to resolve disputes, disagreements or deadlocks in the other Committees or as otherwise required under this Agreement, and neither Party shall unreasonably withhold its consent to hold such additional meetings.  Each Party shall be responsible for all of its own expenses incurred in connection with participating in the JSC meetings or any of the other Committee meetings.

 

3.4                               Decision-Making.  The JSC may make decisions with respect to any subject matter that is subject to the JSC’s decision-making authority and functions as set forth in Section 3.1.  All decisions of the JSC shall be made by unanimous vote or written consent, with Sobi and Auxilium each having, collectively, among its respective members, one (1) vote in all decisions.  The JSC shall use commercially reasonable efforts to resolve the matters within its 

 

21

 

roles and functions or otherwise referred to it.  If the JSC cannot reach consensus on a given matter, then Auxilium shall have the final decision-making authority with respect to matters relating to Sections 3.1.1 (with respect to General Development Activities), 3.1.2 (with respect to General Development Activities), 3.1.3 (with respect to General Development Activities), 3.1.5, and 3.1.12, and Sobi shall have the final decision-making authority with respect to matters relating to Sections 3.1.1 (with respect to Territory Development Activities and Regulatory Approvals), 3.1.2 (with respect to Territory Development Activities), 3.1.3 (with respect to Territory Development Activities), 3.1.4, 3.1.6, 3.1.7, 3.1.8, and 3.1.9.  Notwithstanding the foregoing, (i) Sobi shall have the right to veto any decision by Auxilium where Auxilium exercises its decision-making authority and such Auxilium decision would result in Sobi being required to Develop the Product for Commercialization in the Territory, and (ii) Auxilium shall have the right to veto any decision by Sobi in the area of Development Activities where Sobi exercises its decision-making authority and Auxilium reasonably determines that such Sobi decision could negatively impact Auxilium’s development or commercialization of the Product outside the Territory.

 

3.5                               Alliance Managers.  Promptly following the Effective Date, each Party shall designate an individual to serve as the main point of contact for each Party to exchange information, facilitate communication and coordinate the Parties’ activities under this Agreement and to provide day-to-day support to the Committees (each, an “Alliance Manager”).  Each Alliance Manager shall be experienced in project management and shall have appropriate experience in the pharmaceutical industry.  The Alliance Managers shall attend all JSC meetings, and other meetings between the Parties as appropriate, and shall also work together to resolve any deadlock between the Parties; provided, however, that the Alliance Managers shall not be members of any Committee established pursuant to this Agreement.  Each Party may change its designated Alliance Manager from time to time upon written notice to the other Party.

 

3.6                               Committees.  From time to time, the JSC may establish and delegate duties to other sub-committees or directed teams (each, a “Committee”) to oversee particular projects or activities.  Each such Committee shall be constituted and shall operate as the JSC determines; provided that each Committee shall have equal representation from each Party.  Committees may be established on an ad hoc basis for purposes of a specific project, or on such other basis as the JSC may determine.  Each Committee and its activities shall be subject to the oversight, review and approval of, and shall report to, the JSC.  In no event shall the authority of a Committee exceed that of the JSC.  Any disputes among the members of a Committee shall be referred to the JSC for resolution in accordance with the terms of this Agreement.

 

3.7                               Transition Committee.  Within ten (10) days of the Effective Date, the Parties shall establish a Transition Committee and shall hold the first meeting (which may be via teleconference) of such committee to discuss and implement a Product transition plan, the details of which will be discussed by the Transition Committee but which shall include, among other things, a plan for transferring the Marketing Authorization and other Regulatory Filings to Sobi.  The Transition Plan will provide that the cost of the transition of the Product shall be borne by Sobi, provided that Auxilium will provide at its own expense a reasonable amount of training to Sobi on the Product in the Field, including medical information and marketing information.  The Transition Committee shall meet monthly for a period of six (6) months following the Effective Date.

 

22

 

3.8                               Limits on JSC and Committee Authority.  The JSC shall have only the powers assigned expressly to it in this ARTICLE 3 and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement.  In furtherance thereof, each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JSC and any other Committee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing.  Without limiting the generality of the foregoing, the JSC and any other Committee shall have no decision-making authority with respect to any matters related to (i) approving (or otherwise making decisions with respect to) matters related to obtaining, maintaining or enforcing Patent protection and market and data exclusivity for the Product, Bulk Product or Finished Product in the Field in the Territory (which matters shall be governed by ARTICLE 9), (ii) the Development of the Bulk Product outside the Field or outside of the Territory, (iii) the Commercialization of the Finished Product outside the Field or outside of the Territory and (iv) the Manufacture of the Bulk Product.  It is understood, however, that such matters can be discussed at the JSC especially as they may pertain to the Development of the Bulk Product or Commercialization of the Finished Product in the Territory.

 

3.9                               Disbanding the JSC.  At any time during the Term, and for any reason, Auxilium shall have the right to disband the JSC (and any Committees existing as of such time) upon written notice to Sobi, which notice shall be effective immediately upon receipt (“Disbanding Notice”).  Following the issuance of a Disbanding Notice and subject to this Section 3.9, (i) the JSC (and any Committees existing as of such time) shall immediately cease meeting and (ii) all decisions, obligations, rights and responsibilities within the purview of the JSC (and any Committees existing as of such time) shall henceforth be handled directly between the Parties with each Party maintaining its decision making authority, consistent with Section 3.4, in the event of any dispute.  If, at any time following the issuance of a Disbanding Notice, Auxilium wishes to reestablish the JSC, Auxilium shall notify Sobi in writing and, thereafter, the JSC shall be reestablished and function in accordance with the provisions of this ARTICLE 3.  For clarity, the disbanding of the JSC by Auxilium under this Section 3.9 shall have no impact on the consideration provided for or due to Auxilium under this Agreement.

 

3.10                        Actions.  In developing strategies, making decisions and exercising its rights under this Agreement (including acting through its representatives on any of the Committees and its Alliance Managers), each Party shall act in good faith and use its Commercially Reasonable Efforts to achieve the goals of the then-current Development Plan, if any, or Commercialization Plan.

 

3.11                        Exchange of Information.  Each Party shall keep the other Party reasonably and promptly informed as to its progress and activities relating to the Commercialization of the Finished Product in the Territory, including with respect to regulatory matters and meetings with Regulatory Authorities, by way of updates to appropriate Committees at their meetings or to the other Party in the event that the Committees are disbanded and as otherwise specified in this Agreement, or as reasonably requested from time to time by the other Party.  In connection therewith, Auxilium and Sobi shall provide each other with such information regarding such progress and activities under the Development Plan, if any, or the Commercialization Plan, or otherwise relating to the Finished Product, as the other Party may reasonably request from time to time.

 

23

 

3.12                        Minutes of Committee Meetings.  The Parties shall endeavor to finalize minutes of all Committee meetings within a reasonable time after the meeting (but in any event within forty five (45) days of such meeting) in accordance with the guidelines provided below:

 

3.12.1              Within  fifteen (15) days after a Committee meeting, the secretary of such Committee shall prepare and distribute to all members of such committee draft minutes of the meeting.  Such minutes shall provide a list of any issues yet to be resolved, either within such Committee or through the relevant resolution process.

 

3.12.2              The members of each Committee shall then have fifteen (15) days after receiving such draft minutes to collect comments thereon and provide them to the secretary of such Committee.

 

3.12.3              Upon the expiration of such second fifteen (15) day period, the Parties shall have an additional fifteen (15) days to discuss each other’s comments and finalize the minutes.  The secretary and chairperson(s) of such Committee, or alliance manager if so designated, shall each sign and date the final minutes.  The signature of such chairperson(s) and secretary upon the final minutes shall indicate each Party’s assent to the minutes.

 

ARTICLE 4
 DEVELOPMENT

 

4.1                               Overview.

 

4.1.1                     Overview of Development.  Subject to the terms and conditions of this Agreement, the Parties shall collaborate with respect to any required Development of the Bulk Product for use in the Field in the Territory as set forth herein.  Auxilium shall conduct the General Development Activities and, in accordance with the Development Plan, such portion of the Territory Development Activities as the Parties agree.  Sobi shall conduct, in accordance with the Development Plan, the Territory Development Activities, including bridging studies, clinical studies, those ongoing studies set forth on Schedule 4.1.1(a), Phase IV Clinical Studies (and other post-Regulatory Approval studies).  Notwithstanding the aforementioned, Auxilium shall maintain and remain as sponsor for the study set forth on Schedule 4.1.1(b) (the “Real World Study”).  The costs of the Real World Study are estimated on Schedule 4.1.1(b).  Auxilium will be responsible for the cost associated with the Real World Study described on Schedule 4.1.1(b) and Sobi will be responsible for any additional costs for such study. Auxilium will invoice Sobi the costs payable by Sobi hereunder, to be paid within thirty (30) days from the date of the invoice. Any major deviations of the Real World Study incurring significantly increased costs above the estimate set forth on Schedule 4.1.1(b) shall be approved by Sobi, including without limiting prolongation of the study, increased number of patients or sites or change of contract research organization performing such study.  In the event regulatory requirement to perform the Real World Study is withdrawn by the authorities and Auxilium wishes to terminate the Real World Study, Auxilium shall, at Sobi’s option, assign and transfer the Real World Study to Sobi. Auxilium shall use Commercially Reasonable Efforts to perform the General Development Activities and the Territory Development Activities as above for the Bulk Product for each indication in the Field (i.e., (i) Dupuytren’s Contracture, (ii) Peyronie’s Disease and (iii) such other New Indications as the Parties agree to include hereunder, if any).  Sobi shall use 

 

24

 

Commercially Reasonable Efforts to perform the Territory Development Activities for the Bulk Product for each indication in the Field (i.e., (a) Dupuytren’s Contracture, (b) Peyronie’s Disease and (c) such other New Indications as the Parties agree to include hereunder, if any) to enable obtaining and maintaining Regulatory Approval in the Territory for the Finished Product (solely for purposes of this clause (c) of this Section 4.1.1, the reference to “Finished Product” shall not include the specific concentrations of Product and diluent referenced in Unit of Product) for each such indication.

 

4.1.2                     General Development Activities; Regulatory Approvals Outside the Territory or Outside the Field.  The Parties hereby agree and acknowledge that nothing contained herein shall limit or otherwise restrict the ability of Auxilium or its sublicensees to (i) perform the General Development Activities as it sees fit and at its sole discretion, (ii) develop the Bulk Product for use or sale outside the Territory (whether or not in the Field) and (iii) obtain or maintain Regulatory Approvals for the Bulk Product or Finished Product outside the Territory (whether or not in the Field).  Without limiting the generality of the foregoing, the Development Plan shall not address (a) any General Development Activities or (b) any activities related to obtaining or maintaining Regulatory Approval for the Bulk Product or Finished Product in any country outside the Territory.  Any Development of the Bulk Product for obtaining or maintaining Regulatory Approval for the Finished Product within the Territory but outside the Field shall not be limited or restricted by this Agreement.

 

4.1.3                     Manufacturing Related Activities.

 

(a)                                 The Parties hereby agree and acknowledge that Auxilium shall be solely responsible for planning and performing all Manufacturing Development Activities.  Manufacturing Development Activities shall not be set forth in the Development Plan.

 

(b)                                 Subject to Section 7.5, the Parties shall agree as to the allocation of responsibility with respect to the performance of the developmental aspects of Analytical Release Testing; provided that, Sobi, as Marketing Authorization holder, shall have final decision-making authority in accordance with Section 3.4, with respect to such decisions.

 

4.1.4                     Certain Additional Restrictions.  Sobi agrees and acknowledges that it and its Affiliates and sublicensees shall not conduct any Development of the Bulk Product except in accordance with a Development Plan established pursuant to this Agreement.

 

4.2                               Objectives Under the Development Plan.

 

4.2.1                     Development Activities.  Each Party shall use Commercially Reasonable Efforts to carry out the Development Activities assigned to it, if any, under the Development Plan and in accordance with the time frames set forth in the Development Plan.

 

4.2.2                     Compliance.  Each Party shall conduct its Development Activities in accordance with sound and ethical business and scientific practices, and in compliance with all Laws, GMPs, GCPs and GLPs.

 

25

 

4.3                               Development Plan and Development Budget.

 

4.3.1                     General.  In connection with the Development of the Product for use in the Field in the Territory, the Parties shall conduct Territory Development Activities, if any, pursuant to a comprehensive development plan (the “Development Plan”).  The Development Plan shall set forth, among other things, and to the extent applicable, the following:

 

(a)                                 any preclinical studies, toxicology studies, pharmaco-economic studies, including any pricing and reimbursement analysis and studies, and other clinical studies (including Phase IV Clinical Trials, IIRs and Product registries), in each case, together with all protocols, endpoints and investigators conducting such studies, with respect to the Bulk Product in the Field in the Territory;

 

(b)                                 all regulatory plans and other elements of obtaining and maintaining Regulatory Approvals in the Field in each country in the Territory;

 

(c)                                  a detailed annual budget for all Development Costs and Regulatory Costs for the activities in the applicable Development Plan (the “Development Budget”);

 

(d)                                 subject to the provisions of Section 4.1.1, the allocation of the Development Activities to be conducted by each Party and the timeline for completing such Development Activities; and

 

(e)                                  the plans and timeline for preparing the necessary Regulatory Materials and for obtaining Regulatory Approval in the Field in the Territory.

 

4.3.2                     Initial Development Plan.  The initial Development Plan for the Bulk Product shall be prepared by the Parties taking into consideration any consultation with or guidance from any applicable Regulatory Authorities.  To the extent that future “national meetings” with the Regulatory Authorities in a specific country or territory within the Territory provide guidance with respect to the risk management plan or Development Activities in such country or territory, the Parties shall consider such guidance in updating and amending the Development Plan pursuant to Section 4.3.3.

 

4.3.3                     Updating and Amending Development Plan and Development Budget; Additional Development Activities.

 

(a)                                 On or before October 31st of each year during the Term, the JSC shall review, update and approve the Development Plan (including the Development Budget contained therein) which shall cover the Development Activities, if any, to be conducted during the upcoming calendar year, and the JSC shall, on at least a quarterly basis, review and update, as appropriate, the then-current Development Plan (including the Development Budget) to reflect any changes, reprioritizations of, or additions to the Development Plan.

 

(b)                                 From time to time during the Term, either Party may submit to the JSC any proposed expansion or other amendment of the Development Plan to cover additional Development Activities (or otherwise amend the Development Activities) with respect to the Bulk Product for use in the Field in the Territory for the JSC’s review and approval.  Once approved by the JSC, each amended Development Plan (including the Development Budget

 

26

 

contained therein) shall become effective and supersede the previous Development Plan and Development Budget as of the date of such approval or at such other time as decided by the JSC.

 

4.4                               Development Costs.

 

4.4.1                     General Development Activities.  Auxilium shall be responsible for one hundred percent (100%) of all Development Costs incurred by Auxilium with respect to any General Development Activities.

 

4.4.2                     Manufacturing Development Activities.  At Auxilium’s sole option, either Auxilium or Sobi shall be responsible for conducting Manufacturing Development Activities in order to qualify or validate the Product for sale in any jurisdiction where such activities are required after the Effective Date (whether for additional countries in the Territory or additional Manufacturing Development Activities required in a currently approved jurisdiction), provided that Sobi shall have the right to veto any decision by Auxilium where such decision would result in Sobi being required to perform Manufacturing Development Activities.  All Manufacturing Development Activities required after the Effective Date will be at Sobi’s sole expense and will be charged by Auxilium at [***].

 

4.4.3                     Territory Development Activities.  Sobi shall be solely responsible for one hundred percent (100%) of all Development Costs incurred by Sobi or Auxilium with respect to any Territory Development Activities (including, for clarity, any given General Development Activities which are deemed Territory Development Activities in accordance with Section 1.74).  Auxilium shall invoice Sobi for Development Costs it incurs in connection with performing any Territory Development Activities, which invoices Sobi shall pay within thirty (30) days of receipt thereof.

 

4.4.4                     Analytical Release Testing.  Sobi shall be solely responsible for one hundred percent (100%) of all Development Costs incurred by Sobi or Auxilium with respect to any Analytical Release Testing other than as set forth in Section 7.5.  Auxilium shall invoice Sobi for Development Costs it incurs in connection with performing any Analytical Release Testing, which invoices Sobi shall pay within thirty (30) days of receipt thereof.

 

4.4.5                     Stability Testing.  Auxilium shall conduct the stability testing set forth in Schedule 4.4.5.  To the extent that stability testing is required other than as set forth in Schedule 4.4.5, including without limitation qualifying a Third Party to perform such activities, then Sobi shall be responsible for performing such activities and shall be wholly responsible for, and bear one hundred percent (100%) of the costs related to such activities, including the cost to qualify such Third Party to perform such activities.

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

27

 

4.5                               Records, Reports and Information.

 

4.5.1                     General.  Each Party shall maintain current and accurate records of all work conducted by it under the Development Plan and all data and other information resulting from such work (which records shall include, as applicable, books, records, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof (e.g., samples of materials and other graphic or written data generated in connection with the Development Activities)).  Such records shall properly reflect all work done and results achieved in the performance of the Development Activities in sufficient detail and in good scientific manner appropriate for regulatory and patent purposes.  Each Party shall document all preclinical studies and clinical trials to be conducted pursuant to the Development Plan in formal written study reports according to applicable national and international (e.g., ICH, GMP, GCP and GLP) guidelines.  Each Party shall be given an adequate opportunity, in any event not less than ten (10) business days, to comment on and approve the drafts of reports resulting from activities conducted under the Development Plan.

 

4.5.2                     Status Updates in the Territory.  Each Party shall provide the JSC with reports detailing its respective Development Activities under the Development Plan and the results thereof at least five (5) business days prior to any JSC meeting, but in any event, on at least a calendar quarter basis.  Without limiting the foregoing, each Party shall promptly, but in any event within five (5) business days after receipt thereof, provide to the other Party copies of any material documents or correspondence received from any Regulatory Authority related to Development Activities.

 

4.6                               Ownership and Transfer of Development Data.  All data (including pre-clinical, clinical, technical, chemical, safety, and scientific data and information), know-how and other results generated by or resulting from or in connection with the conduct of Development Activities, including relevant laboratory notebook information, screening data, Regulatory Data and synthesis schemes, including descriptions in any form, data and other information (collectively, the “Development Data”), shall be owned solely and exclusively by the Party generating such data which shall be Confidential Information of such Party (and each Party shall require that all of its Affiliates, sublicensees and subcontractors assign any of such Affiliates’, sublicensees’ or subcontractors’ right, title and interest in and to such Development Data to such Party).  With respect to Development Data generated by a Party, such Party shall promptly provide the other Party with copies of reports and summaries thereof, in each case as such reports and summaries become available to such Party.  Sobi hereby grants Auxilium (and its Affiliates and designees), a right of reference to all Development Data owned by Sobi (or its Affiliates) for all uses in connection with the Product outside the Territory or outside the Field (including the development (including obtaining and maintaining Regulatory Approvals), manufacturing and commercialization thereof) or in the Territory after the expiration of the Term, which right of reference shall survive the expiration or termination of this Agreement.

 

28

 

4.7                               Right to Audit.  Each Party shall use Commercially Reasonable Efforts to ensure that the other Party’s authorized representatives and any Regulatory Authorities, to the extent permitted by Laws, may, during regular business hours and upon reasonable advance written notice, not more than [***] (except for cause), (i) examine and inspect its facilities or, subject to any Third Party confidentiality restrictions and other obligations, the facilities of any subcontractor, or any investigator site, used by it in the performance of Development of the Bulk Product in the Field in the Territory hereunder, and (ii) subject to Laws and any Third Party confidentiality restrictions and other obligations, inspect all data, documentation and work product relating to the activities performed by it, the subcontractor or investigator site, including the medical records of any patient participating in any clinical study, in each case generated pursuant to the said Development.  This right to inspect all data, documentation, and work product relating to the Bulk Product in the Field in the Territory may be exercised at any time during the Term upon reasonable notice (subject to each Party’s record retention policies then in effect), or such longer period as shall be required by Laws.  To the extent a Third Party’s facilities are the subject of an audit pursuant to this Section 4.7, the requesting Party shall (a) perform such audit in connection with the Party having contractual privity with such Third Party and (b) bear any costs charged by such Third Party associated with such audit.  For clarity, the Party having contractual privity with such Third Party shall have the right to accompany the requesting Party on any such audit of a Third Party facility; provided that neither Party shall have more than three (3) individual people present during the conduct of any such audit without the prior written consent of the Party being audited.

 

4.8                               Medical Science Liaisons.  Sobi shall be solely responsible for (i) any compensation that is payable to its Medical Science Liaisons (including with respect to any employee benefit plan) and (ii) the payment or withholding of any contributions, payroll taxes, or any other payroll-related item by or on behalf of Sobi (or its Affiliates or sublicensees) or any of its Medical Science Liaisons.  Sobi acknowledges and agrees that Auxilium does not and will not maintain or procure any worker’s compensation, healthcare, or other insurance for or on behalf of Sobi’s Medical Science Liaisons, all of which shall be Sobi’s sole responsibility.  For the avoidance of doubt, Sobi shall be solely responsible for any act or omission of its Medical Science Liaisons and for all probationary and termination actions taken by it with respect to its Medical Science Liaisons.

 

4.9                               Other Materials.    Auxilium shall provide Sobi with existing and new materials such as disease state and unbranded communication materials for educational and awareness purposes that are created and Controlled by Auxilium.

 

ARTICLE 5
 REGULATORY

 

5.1                               Regulatory Data and Regulatory Materials.

 

5.1.1                     Regulatory Materials.  Each Party shall, as soon as reasonably practicable after the same become available (to the extent that such Party is undertaking any 

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

29

 

preparation of the same), provide the other Party with copies of the Core Data Sheet (“CDS”), approved local prescriber, and patient-directed, labeling that are proposed or approved for the Commercialization of the Finished Product and Development of the Bulk Product in the Field in the Territory.

 

5.1.2                     Regulatory Data Generated by Auxilium and Sobi.  Within thirty (30) days after the Effective Date, Auxilium and Sobi shall meet and agree upon the portion of Regulatory Materials and Regulatory Data that is necessary for Sobi to perform its obligations hereunder.  Auxilium will use reasonable efforts to supply Sobi with such Regulatory Materials and Regulatory Data as Sobi may reasonably request from time to time.  During the Term, Auxilium and Sobi shall each promptly provide to the other copies of any further Regulatory Materials and Regulatory Data that either may generate or otherwise acquire.

 

5.1.3                     Use of Data by Sobi.  Sobi may only use the Regulatory Materials and Regulatory Data provided by Auxilium hereunder or generated by Sobi hereunder, and any other Development Data, for the purposes of (i) Commercializing the Finished Product in the Field in the Territory pursuant to this Agreement and (ii) obtaining and maintaining Regulatory Approval for the Finished Product in the Field in the Territory pursuant to this Agreement.

 

5.2                               Regulatory Filings and Regulatory Approvals.

 

5.2.1                     General Responsibilities; Ownership of Regulatory Approvals.  The Parties will use their Commercially Reasonable Efforts to transfer any Marketing Authorization Applications or Regulatory Approvals for the Product in the Territory to Sobi within 180 days following the Effective Date.  Subject to Section 5.2.5, Sobi shall be responsible for the preparation of all Regulatory Materials necessary or desirable for obtaining and maintaining such Regulatory Approvals in the Territory (including in connection with Patient Information Leaflets, labeling and packaging for the Finished Product in the Field and in the Territory) and Sobi shall submit such Regulatory Materials, Regulatory Approval and MAA’s, as applicable, to the applicable Governmental Authorities in the Territory.  Auxilium shall provide reasonably necessary and timely assistance to Sobi in connection with all activities undertaken by Sobi relating to the obtaining and maintaining of the Regulatory Approvals.  To the extent not prohibited by Laws, Sobi and Auxilium shall each be entitled to, and upon the reasonable request of the other Party required to, attend key meetings with the relevant Regulatory Authorities with respect to obtaining or maintaining the Product Approvals for the Finished Product in the Field in the Territory.  All Regulatory Approvals for the Finished Product in the Territory (other than those related solely to the Manufacture of the Product in the Territory, if any) shall be in the name of Sobi, and Sobi shall own all right, title and interest in and to all such Regulatory Approvals and all related Regulatory Materials.  In furtherance of the foregoing, Auxilium shall assign (and shall cause its Affiliates to assign), and hereby does assign, to Sobi any and all of its right, title, and interest in and to the Regulatory Materials for the Finished Product in the Territory.  The provisions of this Section 5.2.1 shall be subject to the provisions of Section 5.2.2.

 

30

 

5.2.2                     Certain Regulatory Approvals.

 

(a)                                 Pricing Approvals.  Notwithstanding the provisions of Section 5.2.1, to the extent that a given country or regulatory jurisdiction in the Territory requires Pricing Approval for sale of the Finished Product in the Field in such country or regulatory jurisdiction, Sobi shall (to the extent permitted by Laws) be solely responsible for (and shall use Commercially Reasonable Efforts toward) obtaining and maintaining Pricing Approvals in all such countries and regulatory jurisdictions in the Territory, in its own name.  In the event Sobi has not, by use of Commercially Reasonable Efforts, applied for Pricing Approvals for an indication in the Field in a country or regulatory jurisdiction in the Territory where Pricing Approvals are required for the sale of the Product in an indication in the Field within 24 months following the receipt of the Product Approval in such country or regulatory jurisdiction, then Auxilium shall be entitled to terminate this Agreement with respect to such indication and country or regulatory jurisdiction.  Sobi shall keep Auxilium informed on an ongoing basis of Sobi’s strategy for seeking, and the results it obtains in seeking, such Pricing Approvals in the Territory, including the results of any material discussion or other communication with relevant Governmental Authorities regarding such Pricing Approvals.  To the extent not prohibited by Laws, Auxilium shall be entitled to attend key meetings with the relevant Regulatory Authorities with respect to obtaining or maintaining Pricing Approvals for the Product in the Field in the Territory

 

(b)                                 Manufacturing Approvals and Manufacturing Related Sections.  Notwithstanding the provisions of Section 5.2.1, Auxilium shall be primarily responsible for preparing those portions of any Regulatory Materials related to the Manufacture of the Product for sale in the Field in the Territory, including any DMFs and CMC (or equivalent) sections of any Regulatory Materials, and will provide such Regulatory Materials to Sobi for use (with or without edit/modification) in compiling, supporting and maintaining regulatory filings in the Territory.

 

5.2.3                     Cost of Regulatory Activities.  All Regulatory Costs incurred by Sobi, or Auxilium, in connection with the transfer, preparation, filing, and maintenance of Regulatory Materials for the Product, and obtaining of Regulatory Approvals for the Finished Product, in the Field in the Territory shall be borne solely by Sobi.  Sobi shall be responsible for all Regulatory Costs involved in the maintenance of all Regulatory Approvals (other than Bulk Product Manufacturing-related Regulatory Approvals) for the Finished Product in the Field in the Territory.  Auxilium shall invoice Sobi for: (i) all Regulatory Costs it incurs in connection with the preparation of Regulatory Materials for, and obtaining of Regulatory Approvals in the Field in the Territory for the Finished Product and (ii) all Regulatory Costs it incurs in connection with the maintenance of Regulatory Approvals in the Field in the Territory for the Finished Product, which invoices Sobi shall pay within thirty (30) days of receipt thereof.

 

5.2.4                     Reporting and Review.  Each Party shall keep the other Party reasonably and regularly informed in connection with the preparation of all Regulatory Materials, Regulatory Authority review of Regulatory Materials, and Regulatory Approvals, in each case with respect to the Product for sale in the Field whether within the Territory or outside the Territory.  Each Party shall provide the other Party, in a timely manner, with copies and, where available, English translations of all notices, questions, and requests for information in tangible 

 

31

 

form which it receives from a Regulatory Authority with respect to the Finished Product for sale in the Field; provided, however that such Party shall have the right to redact any information to the extent not related to the Finished Product for sale in the Field.

 

5.2.5                     Consultation and Approval Prior to Regulatory Filings.  The Parties shall consult with each other on the strategy for pre-authorization activities (i.e., Regulatory Authority meetings and MAA filings) and post-authorization activities, with respect to Regulatory Approvals in the Territory for the Product in the Field in the Territory prior to the filing.  Without limitation of the foregoing, Sobi shall provide Auxilium with all proposed Regulatory Materials for review and comment prior to filing, and Sobi shall incorporate any comments received from Auxilium to the extent Auxilium provides comments within a reasonable timeframe proposed by Sobi and reasonably accepted by Auxilium; provided, however, that Auxilium shall have (i) final decision-making authority on the content of all Regulatory Materials related to the Manufacture of the Bulk Product for sale as Finished Product in the Field in the Territory and (ii) final decision-making authority on the content of all Regulatory Materials associated with the Bulk Product or Finished Product in the Field in the Territory in the event that Auxilium reasonably determines that such Regulatory Materials could adversely affect Development Activities or Commercialization of the Product outside of the Territory or Product Approval of the Product, Bulk Product or Finished Product outside the Territory.

 

5.3                               Communications.  The Parties shall cooperate in communicating with any Regulatory Authority having jurisdiction regarding the Bulk Product or Finished Product in the Field whether within the Territory or outside the Territory and each Party shall immediately notify the other in the event that such Party communicates, or intends to communicate, either on its own initiative in accordance with this Agreement or as a result of such a Regulatory Authority initiating contact with such Party in connection therewith.  Notwithstanding the foregoing, except as may be required by Laws, Sobi shall not, with respect to the Bulk Product or Finished Product communicate with (i) any Regulatory Authority having jurisdiction outside the Territory or (ii) any Regulatory Authority for use outside the Field, in each case, unless explicitly provided for in the Development Plan or requested or permitted in writing to do so by Auxilium, or unless so ordered by such Regulatory Authority, in which case Sobi shall immediately notify Auxilium of such order and shall, to the extent permitted by Laws, not take any further actions or communicate with such Regulatory Authority further until Auxilium has provided instruction as to how to proceed.  All communications with Regulatory Authorities regarding the Bulk Product and Finished Product in the Field in the Territory shall be undertaken as provided in this Agreement.

 

5.4                               No Other Regulatory Filings.  Except as otherwise expressly set forth in ARTICLE 5, Sobi (its sublicensees and its Affiliates) shall not file any Regulatory Materials or Regulatory Approvals for the Bulk Product or Finished Product or that are otherwise based on any Auxilium Technology or any Joint Collaboration Patents.

 

5.5                               Adverse Event Reporting; Safety Data Exchange and Medical Inquiries.

 

5.5.1                     Pharmacovigilance.  Sobi shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse events associated with the Bulk 

 

32

 

Product or Finished Product (solely for purposes of this Section 5.5, references to “Finished Product” shall not include the specific concentrations of Product and diluent referenced in Unit of Product) in the Field in the Territory (whether or not Product Approval has been achieved), in each case in accordance with Laws and this Agreement (and Sobi shall ensure that, in the Development of the Bulk Product, if any, and Commercialization of the Finished Product, it will record, investigate, summarize, notify, report and review all adverse events in accordance with Laws).  Auxilium is responsible for maintaining the global safety database for the Bulk Product and Finished Product and as such Auxilium (or its designee) shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse events associated with the Bulk Product or Finished Product in the countries outside the Territory.  Auxilium and Sobi will coordinate such that Sobi has reasonable and necessary access to such global safety database.  The safety units from each of the Parties shall meet and agree upon a written pharmacovigilance agreement for exchanging adverse event and other safety information relating to the Bulk Product and Finished Product.  A pharmacovigilance agreement for the period of transition of such responsibilities to Sobi shall be entered into as promptly as possible but in no event later than thirty (30) days from the date of this Agreement, and a final pharmacovigilance agreement shall be entered into by the Parties prior to the date that Sobi becomes the holder of the MAA.  Such written pharmacovigilance agreements shall ensure that adverse event and other safety information is exchanged according to a schedule that will permit each Party (and its designees or sublicensees) to comply with applicable Laws and regulatory requirements in their respective markets.

 

5.5.2                     Medical Inquiries for the Product.  Following the Effective Date, Sobi shall be responsible for handling all medical questions or inquiries in each such country in the Territory, including all Product Complaints, with regard to any Finished Product sold by or on behalf of Sobi (or any of its Affiliates or sublicensees) (including having a call center in connection therewith), in each case in accordance with Laws and this Agreement. Auxilium shall provide a copy of its standardized responses to medical inquires for the Product. Sobi shall submit a copy of any standardized responses to medical inquiries prior to use thereof for Auxilium’s review and comment.  Auxilium shall immediately forward any and all medical questions or inquiries which it receives with respect to any Finished Product sold by or on behalf of Sobi (or any of its Affiliates or sublicensees) in the Territory to Sobi in accordance with all Laws and Sobi shall immediately forward to Auxilium any and all medical questions or inquiries that it receives with respect to Finished Product (i) to Sobi’s knowledge not sold by or on behalf of Sobi (or any of its Affiliates or sublicensees) in the Territory or (ii) outside of the Territory, in each case in accordance with all Laws.  Notwithstanding the foregoing, Auxilium shall be primarily responsible for handling any Product Complaints related to Manufacturing, and Sobi shall refer all such Product Complaints to Auxilium.

 

5.6                               Regulatory Authority Communications Received by a Party.

 

5.6.1                     General.  Each Party shall immediately inform the other Party of notification of any action by, or notification or other information which it receives (directly or indirectly) from, any Regulatory Authority whether inside the Territory or outside the Territory which (i) raises any material concerns regarding the safety or efficacy of the Bulk Product or Finished Product; (ii) indicates or suggests a potential material liability of either Party to Third Parties in connection with the Bulk Product or Finished Product; (iii) is reasonably likely to lead 

 

33

 

to a recall, market withdrawal or market notification with respect to the Finished Product whether inside the Territory or outside the Territory; or (iv) relates to expedited and periodic reports of adverse events with respect to the Bulk Product or Finished Product whether inside the Territory or outside the Territory, or Product Complaints, and which may have an adverse impact on Regulatory Approval or the continued Commercialization of the Finished Product whether inside the Territory or outside the Territory.  Sobi shall be solely responsible for responding to any such communications relating to the Finished Product in the Field in the Territory and the Parties shall reasonably cooperate with and assist each other in complying with regulatory obligations, including by Auxilium providing to Sobi such information and documentation which is in Auxilium’s possession as may be necessary or reasonably helpful for Sobi to prepare a response to an inquiry from a Regulatory Authority in the Territory with respect to the Finished Product in the Field.  Each Party shall also promptly provide the other Party with a copy of all correspondence received from a Regulatory Authority whether inside the Territory or outside the Territory specifically regarding the matters referred to above.  Auxilium (or its designee) shall be solely responsible for any communications relating to the Bulk Product and Finished Product outside of the Territory.

 

5.6.2                     Disclosures.  In addition to its obligations under this Agreement, each Party shall disclose to the other Party (and in the case of Auxilium, Auxilium shall have the right to subsequently disclose to its designees) the following regulatory information:

 

(a)                                 Regulatory Actions.  All material information pertaining to actions taken by Regulatory Authorities whether inside the Territory or outside the Territory controlled by such Party, in connection with the Bulk Product or Finished Product in the Field, including any notice, audit notice, notice of initiation by Regulatory Authorities of investigations, inspections, detentions, seizures or injunctions concerning the Bulk Product or Finished Product in the Field whether inside the Territory or outside the Territory, notice of violation letter (i.e., an untitled letter), warning letter, service of process or other inquiry; provided, however, that a Party shall be entitled to redact those portions thereof to the extent not related to the Bulk Product or Finished Product in the Field.  Without limiting the generality of the foregoing, each Party shall promptly, but in any event within two (2) business days, inform the other Party of any inspections, proposed regulatory actions, investigations or requests for information or a meeting by any regulatory Authority with respect to the Bulk Product or Finished Product in the Field whether inside the Territory or outside the Territory.

 

(b)                                 Regulatory Non-compliance.  All information pertaining to notices from Regulatory Authorities whether inside the Territory or outside the Territory controlled by such Party of non-compliance with Laws in connection with the Bulk Product or Finished Product in the Field, including receipt of a warning letter or other notice of alleged non-compliance from any Regulatory Authority relating to the Bulk Product or Finished Product in the Field whether inside the Territory or outside the Territory; provided, however, that a Party shall be entitled to redact those portions thereof to the extent not related to the Bulk Product or Finished Product in the Field.

 

(c)                                  Certain Activities Outside the Territory.  Auxilium will provide reports of safety information related to the Bulk Product arising from all non-clinical toxicology studies and all clinical studies initiated outside of the Territory by Auxilium (or its Affiliates or 

 

34

 

by any Third Party on its or their behalf) related to the Bulk Product within (i) forty eight (48) hours in the case of safety related information and (ii) sixty (60) days of completion in all other cases, in each case, solely to the extent such information is Controlled by Auxilium (and solely to the extent Auxilium is permitted to disclose such information to Sobi pursuant to Laws or otherwise).  Auxilium will also provide Sobi with copies of all material regulatory filings made by Auxilium related to the Bulk Product or Finished Product in the Field outside of the Territory that may have a material impact on the Development of the Bulk Product and/or Commercialization of the Finished Product in the Field in the Territory.  Notwithstanding anything to the contrary contained in this Section 5.6.2(c), Sobi shall only be entitled to utilize any such data or other information provided pursuant to this Section 5.6.2(c) to satisfy its pharmacovigilance and safety reporting obligations hereunder in compliance with Laws (and for purposes of clarity, such information shall not be utilized for any other purposes, including to broaden the scope of any Regulatory Approval), and all such data and other information shall be considered “Confidential Information” of Auxilium.

 

(d)                                 BTC.  Sobi hereby agrees and acknowledges that Auxilium shall have the right to grant BTC a right of reference with respect to Regulatory Data.

 

5.7                               Recall, Withdrawal, or Market Notification of Product.

 

5.7.1                     Notification and Determination.  In the event that any Governmental Authority threatens or initiates any action to remove the Finished Product from the market whether inside the Territory or outside the Territory (in whole or in part), the Party receiving notice thereof shall notify the other Party of such communication immediately, but in no event later than one (1) business day, after receipt thereof.  Notwithstanding the foregoing, in all cases Sobi (acting as the holder of the Product Approval in the Territory) shall determine whether to initiate any recall, withdrawal or market notification of the Finished Product in the Field in the Territory, and Auxilium, as, between the Parties, holder of the Product Approval outside the Territory shall determine whether to initiate any such recall, withdrawal or market notification of the Finished Product outside the Territory, including the scope of such recall or withdrawal (e.g., a full or partial recall, or a temporary or permanent recall) or market notification; provided, however that before Sobi or Auxilium (as the case may be) initiates a recall, withdrawal or market notification, the Parties shall promptly meet and discuss in good faith the reasons therefor, provided that such discussions shall not delay any action that Sobi or Auxilium (as the case may be) reasonably believes has to be taken in relation to any recall, withdrawal or market notification.  In the event of any such recall, withdrawal or market notification, Sobi or Auxilium (as the case may be), as the distributor of the Finished Product, shall determine the necessary

 

35

 

actions to be taken, and, shall implement such action, with the other Party providing reasonable input (which the first Party shall in good faith consider and incorporate into any recall, withdrawal or market notification strategy) and reasonable assistance, to conduct such recall, withdrawal or market notification.  Without limiting the foregoing, Auxilium shall have the right to propose that a Finished Product recall, withdrawal or market notification should be initiated by Sobi, but Sobi, acting as the holder of the Product Approval in the Territory, shall make the final decision as to whether or not the recall, withdrawal or market notification will be initiated.  Sobi shall at all times utilize a batch tracing system which will enable the Parties to identify, on a prompt basis, customers within the Territory who have been supplied with Finished Product of any particular batch, and to recall such Finished Product from such customers as set forth in this Section 5.7.1.

 

5.7.2                     Cost Allocation.  All direct costs and expenses associated with implementing a recall, withdrawal or market notification with respect to the Finished Product in the Field in the Territory shall be allocated between Auxilium and Sobi as follows:

 

(a)                                 in the event, and to the extent, that the recall, withdrawal or market notification arises as a result of a material breach of this Agreement by Auxilium, including any Bulk Product Manufacturing breach, then Auxilium shall bear the costs and expenses, including all internal and Out-of-Pocket Costs of Sobi for implementing the recall, withdrawal or market notification (including an appropriate credit to Sobi against the payments of the applicable supply price pursuant to Section 7.7.1 for any Bulk Product that was incorporated into such recalled Finished Product which Sobi has paid for); and

 

(b)                                 in the event, and to the extent, that the recall, withdrawal or market notification arises out of the material breach of this Agreement by Sobi, then Sobi shall bear the costs and expenses for implementing the recall, withdrawal or market notification (and no credit will be given to Sobi against the payments of the applicable supply price pursuant to Section 7.7.1 for any Bulk Product that was incorporated into such recalled Finished Product which Sobi has paid for); and

 

(c)                                  in all other cases, all costs and expenses incurred by either Party for implementing the recall, withdrawal or market notification shall be borne equally by the Parties.

 

5.8                               Regulatory Diligence.

 

5.8.1                     Regulatory Approval in the Territory.  If at any time after eighteen (18) months from (x) the Effective Date, with respect to Dupuytren’s Contracture, (y) the date of Regulatory Approval in the EU for Peyronie’s Disease or (z) the date agreed to by the Parties, with respect to any New Indication, Sobi (i) has not filed for Regulatory Approval for the Finished Product and (ii) is not using Commercially Reasonable Efforts to obtain Regulatory Approval for the Finished Product, including performing Development Activities required for obtaining the Regulatory Approval, then Auxilium shall be entitled to terminate the Agreement with respect to such indication and country by providing written notice to Sobi.

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

36

 

5.8.2                     Sobi’s Determination Not to Proceed.  Without limitation of Section 5.8.1, in the event that Sobi determines at any time during the Term that it is not economically feasible to incur the costs necessary to obtain and/or maintain Regulatory Approval for the Finished Product in a given country and for any given indication in the Territory, Sobi shall promptly notify Auxilium in writing of such determination and Auxilium shall have the right to terminate this Agreement with respect to such indication and country.

 

ARTICLE 6
 COMMERCIALIZATION

 

6.1                               Commercialization in the Field in the Territory.  During the Term, Sobi shall be solely responsible for Commercializing the Finished Product in the Territory for use in the Field, which Commercialization shall be in accordance with the Commercialization Plan and this Agreement.  Sobi shall be responsible for one hundred percent (100%) of the expenses (including Pre-Marketing expenses incurred after the Effective Date and other Commercialization expenses) incurred in connection with the Commercialization of the Finished Product in the Territory for use in the Field.  Without limiting the foregoing, Sobi shall use Commercially Reasonable Efforts to Commercialize the Finished Product for use in the Field in each country in the Territory.

 

6.2                               Commercialization Plan.

 

6.2.1                     Commercialization Plan.  On an annual basis, Sobi shall prepare a commercialization plan with respect to the Commercialization of the Finished Product in the Field in the Territory pursuant to this Agreement (the “Commercialization Plan”).  The initial Commercialization Plan for the Finished Product for the period through December 31, 2013 is attached to this Agreement as Schedule 6.2.1 (the “Initial Commercialization Plan”).

 

6.2.2                     Updates to Commercialization Plan.  On an annual basis no later than October 31st of each year (except as set forth in Section 6.2.1), Sobi shall prepare and submit to the JSC for its review and discussion the Commercialization Plan for the following calendar year.  The Commercialization Plan shall contain a five (5) year rolling annual plan for the Commercialization of the Finished Product in the Territory for use in the Field.  The first year of such plan (except the initial Commercialization Plan as set forth in Section 6.2.1), shall constitute the plan and budget for the first year and the remaining four (4) years shall be for planning purposes only (provided that Sobi shall prepare such four (4) year portion in accordance with its good faith anticipated activities).  Upon review and discussion by the JSC, Sobi shall finalize the Commercialization Plan for the following calendar year.  From time to time during a given calendar year, Sobi may propose written updates to the Commercialization Plan for review and discussion by the JSC.  Sobi shall conduct all Commercialization of the Product in accordance with the Commercialization Plan and this Agreement.

 

6.2.3                     Contents of Commercialization Plan.  Each annual Commercialization Plan shall include and set forth on a country-by-country basis as determined by Sobi, among other things, the following items in connection with the Commercialization of the Product in the Territory for use in the Field:

 

37

 

(a)                                 a description of the short-and long-term vision for the Finished Product and Finished Product positioning; a situation analysis; a Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis; and a description of critical issues, strategic imperatives and tactics by strategic imperative with timelines and budget, all of the foregoing from each of the following perspectives: marketing, sales, reimbursement and distribution;

 

(b)                                 a summary of the level of sales efforts to be dedicated to the promotion of the Finished Product;

 

(c)                                  a forecast of annual sales (in Units and Dollars) for the Finished Product in each country of the Territory;

 

(d)                                 a description of the core Promotional Materials or other materials and campaigns, including publication plans, to be used, subject to Section 6.7.1, in connection with the promotion of the Finished Product in the Field; and

 

(e)                                  a detailed budget for the Commercialization activities (including advertisement, promotion, disease state education, digital efforts, physician injection training, congress support, public relations, life cycle management and publication costs) for the applicable period (the “Commercialization Budget”).

 

6.3                               Sobi’s Performance.

 

6.3.1                     Specific Commercialization Obligations.  Without limiting the generality of the provisions of Section 6.1, in connection with the Commercialization of the Finished Product in the Territory for use in the Field by Sobi hereunder:

 

(a)                                 Sobi shall be solely responsible for (i) receiving, accepting and filling orders for the Finished Product in the Field in the Territory, (ii) handling all returns of the Finished Product in the Field in the Territory, (iii) controlling invoicing, order processing and collection of accounts receivable for the sales of the Finished Product in the Field in the Territory, and (iv) distributing and managing inventory of the Finished Product in the Field in the Territory.

 

(b)                                 Schedule 6.3.1(b) sets forth the annual minimum Finished Product sales commitments of Sobi in the Field in the Territory, it being understood that such minimums are based on assumptions regarding the date of obtaining Regulatory Approval in a given country in the Territory.

 

6.3.2                     Commercialization Plan.  Without limiting obligations of Sobi under Sections 6.3.1, Sobi shall carry out the Commercialization activities in the Commercialization Plan in accordance with the time frames set forth in the Commercialization Plan.

 

6.3.3                     Diligence Failures.  If Sobi fails to satisfy the requirements set forth in Section 6.3.1 with respect to the Commercialization of the Finished Product in the Field in the Territory or Auxilium believes that Sobi is not using Commercially Reasonable Efforts with regards to the Commercialization of the Finished Product in a given country or countries in the Territory, then Auxilium shall raise such issue by notice to Sobi.  If within sixty (60) days 

 

38

 

following Sobi’s receipt of any such notice from Auxilium, Sobi has not remedied the issues identified by Auxilium in such notice, then (i) Sobi shall provide Auxilium with a written response specifying, in reasonable detail, how it is using or has begun to use such Commercially Reasonable Efforts and/or explaining the reason for its failure to satisfy the requirements set forth in Section 6.3.1, (ii) the Parties shall discuss such response at the JSC and (iii) any issues raised by such response and discussion, shall, to the extent appropriate, be submitted to the Dispute Resolution procedures set forth in ARTICLE 15 of this Agreement.

 

6.3.4                     Assignment and Performance of Existing Agreements.   Auxilium hereby assigns and transfer to Sobi, its successors and assigns all of Auxilium’s right, title and interest in and to the contracts set forth on Schedule 6.3.4 (the “Assigned Contracts”) as of the Effective Date.  Sobi hereby assumes all of Auxilium’s rights, obligations, title and interest under the Assigned Contracts accruing from and after the Effective Date, including, but not limited to, the obligations to receive and make all payments due under the Assigned Contracts, and Sobi agrees to be bound by the terms and conditions under the Assigned Contracts accruing from and after the Effective Date.   Sobi shall perform all obligations of Auxilium under the Assigned Contracts and agrees to indemnify Auxilium therefor. Auxilium will effectuate the assignment and transfer of the Assigned Contracts.

 

6.4                               Reports.  Sobi shall update the JSC on a country-by-country basis no less than twice per calendar year regarding its significant Commercialization activities involving the Finished Product.

 

6.5                               Compliance.  Sobi shall, in Commercializing the Finished Product, comply with all Laws, including the U.S. Foreign Corrupt Practices Act and the United Kingdom Bribery Act 2010, and the EU Data Protection Directive 95/46/EC and other laws applicable related to privacy, publicity and data protection, as well as all applicable Regulatory Approvals for the Finished Product.  In addition, Sobi shall not use in any capacity, in connection with its Commercialization of the Finished Product (or Development of the Bulk Product) hereunder, any Person who has been debarred pursuant to Section 306 of the FD&C Act (or similar Laws outside of the U.S.), or who is the subject of a conviction described in such section, and Sobi shall inform Auxilium in writing immediately if it or any Person who is performing services for Sobi hereunder is debarred or is the subject of a conviction described in Section 306 (or similar Laws outside of the U.S.), or if any action, suit, claim, investigation or legal administrative proceeding is pending or, to Sobi’s knowledge, is threatened, relating to the debarment of Sobi or any Person used in any capacity by Sobi in connection with its Commercialization of the Finished Product (or Development, if any, of the Bulk Product) hereunder.

 

6.6                               Sales Representatives.   Sobi shall be solely responsible for (i) any compensation that is payable to its Sales Representatives (including with respect to any employee benefit plan) and (ii) the payment or withholding of any contributions, payroll taxes, or any other payroll-related item by or on behalf of Sobi (or its Affiliates or sublicensees) or any of its Sales Representatives.  Sobi acknowledges and agrees that Auxilium does not and will not maintain or procure any worker’s compensation, healthcare, or other insurance for or on behalf of Sobi’s Sales Representatives, all of which shall be Sobi’s sole responsibility.  For the avoidance of doubt, Sobi shall be solely responsible for any act or omission of its Sales Representatives and for all probationary and termination actions taken by it with respect to its Sales Representatives.

 

39

 

6.7                               Promotional Materials.

 

6.7.1                     Creation of Promotional Materials.  Auxilium shall provide Sobi with existing and new Promotional Materials that are created and Controlled by Auxilium. Sobi will create and develop Promotional Materials for the Territory, which may be based on such Auxilium provided Promotional Materials, in accordance with the Regulatory Approvals and Laws, and shall provide samples thereof and of such other materials to Auxilium for its review and comment (and Sobi shall consider any such comments in good faith) prior to distributing such Promotional Materials.  To the extent Sobi includes any Auxilium trademarks in the Promotional Materials, Sobi shall comply with Auxilium’s then current guidelines for trademark usage, provided such guidelines are made available to Sobi on a timely basis.

 

6.7.2                     Inclusion of Logos on Packaging and Promotional Materials.  Auxilium hereby grants to Sobi a non-exclusive, royalty-free right and license during the Term to utilize the Auxilium housemark (including all trademarks, names and logos) in order to perform the Commercialization activities required to be performed by Sobi hereunder in accordance with the terms of this Agreement.  Sobi shall only use the Auxilium housemark with the necessary trademark designations, and Sobi shall use Auxilium’s housemarks in a manner that does not derogate from Auxilium’s rights in its trademarks, names and logos.  Sobi shall submit representative samples of its use of Auxilium’s housemark for review by the JSC.  Sobi will take no action that will interfere with or diminish Auxilium’s rights in its respective trademarks, names and logos, and if Auxilium reasonably believes that the use of its trademarks, names and logos by Sobi hereunder is interfering with or diminishing its rights, Auxilium shall notify Sobi thereof in writing and Sobi shall promptly cease use of such trademarks, names or logos in such manner.  Sobi agrees that all use of Auxilium’s trademarks, names and logos will inure to the benefit of Auxilium, including all goodwill in connection therewith.

 

6.7.3                     Sobi Ownership of Promotional Materials.  During the Term, Sobi shall own all right, title and interest in and to any Promotional Materials created by Sobi hereunder relating to the Finished Product in the Field in the Territory including copyrights, but excluding trademarks (including the Product Trademark), names, logos and other marks owned by or on behalf of Auxilium or its Affiliates.

 

6.7.4                     Use of Promotional Materials Exclusively for the Product.  The Promotional Materials, and any aspects of those uniquely tied to the Finished Product, shall be used by Sobi exclusively in connection with the Commercialization of the Finished Product in the Field in the Territory in accordance with the terms of this Agreement, and Sobi shall not use, or allow any other Person to use, any such Promotional Materials except in accordance with this Agreement.

 

6.8                               Product Trademarks and Product Trade Dress.

 

6.8.1                     Product Trademark.  Sobi shall use Commercially Reasonable Efforts to Commercialize the Finished Product in the Field in the Territory under the trademark XIAFLEX® or XIAPEX® (and logo) and under the trade dress or such other trademark or trade dress as the Parties mutually agree upon (in each such Party’s sole discretion), including, if applicable, any alternative trademark and any alternative trade dress pursuant to this Section

 

40

 

6.8.1 (the “Product Trademark” and the “Product Trade Dress”, respectively).  Notwithstanding the foregoing, in the event that Sobi believes that the use or registration of the Product Trademark or the use of the Product Trade Dress in a particular country in the Territory would be inappropriate due to such country’s linguistic or cultural particularities or against the Laws of such country, or in conflict with any Third Party’s intellectual property rights in that country, based on a review of market research, regulatory research, legal searches, investigation results, and any other relevant information that may have been collected by either Party that is relevant to the clearance for use and registration of a trademark or for use and registration of a trade dress (it being understood that there is no obligation for either Party to perform any such review or research), Sobi shall present such concern to Auxilium, and Auxilium shall propose an alternative trademark and trade dress to Sobi for use and registration in the country in question without prejudice to Sobi’s right to reasonably refuse to adopt any such alternative trademark or trademark on the aforementioned grounds.  If Sobi accepts such alternative trademark and trade dress, then Auxilium shall perform all necessary activities and bear all costs relating to the creation, legal clearance, filing, registration, and maintenance of the initial alternative trademark and trade dress; provided, that Sobi and Auxilium shall share such costs with respect to each alternative trademark and trade dress after the initial proposal. Sobi may request, and Auxilium shall use Commercially Reasonable Efforts to provide, a reasonable number of alternative trademarks and trade dresses from among which the Parties may agree that the use or registration of such an alternative trademark, or the use of such an alternative trade dress, in a particular country in the Territory would not be inappropriate due to such country’s linguistic or cultural particularities, or against the Laws of such country, or in conflict with any Third Party’s intellectual property rights in that country, based on a review of market research, regulatory research, legal searches, investigation results, and any other relevant information that may have been collected by either Party that is relevant to the clearance for use and registration of a trademark or for use and registration of a trade dress.

 

6.8.2                     Use and Ownership of Product Trademarks and Product Trade Dress.  All uses of the Product Trademark and Product Trade Dress by Sobi (and its Affiliates and sublicensees) to identify and/or in connection with the Commercialization of the Finished Product in the Field in the Territory shall be in accordance with Regulatory Approvals and all Laws and shall be subject to the approval of Auxilium in its reasonable discretion.  Sobi (and its Affiliates and sublicensees) shall only use the Product Trademark and Product Trade Dress pursuant to the terms of this Agreement to identify and in connection with the Commercialization of the Finished Product in the Territory for use in the Field, and Sobi shall not (and shall cause its Affiliates and sublicensees not to) use such Product Trademark or Product Trade Dress to identify or in connection with the marketing of any other product(s).  Auxilium shall own and retain all rights to the Product Trademark and Product Trade Dress (in each case, together with all goodwill associated therewith throughout the Territory), and Sobi shall assign (and shall cause its Affiliates and sublicensees to assign), and hereby does assign to Auxilium, all of its right, title and interest in and to such Product Trademark and Product Trade Dress, if any. Auxilium shall also own rights to any Internet domain names incorporating the Product Trademark or any variation or part of such trademark as its URL address or any part of such address; and Sobi shall not establish any Internet domain name or URL incorporating such trademark without the prior written consent of Auxilium; provided that Sobi shall be responsible for all costs incurred by Auxilium with respect to such Internet domain names or URLs to the extent used for the Commercialization of the Finished Product in the Territory.  The Parties

 

41

 

hereby agree and acknowledge that nothing contained herein shall limit Auxilium’s right to use the Product Trademark or Product Trade Dress outside the Territory.

 

6.8.3                     Maintenance of Product Trademark and Internet Domain Names.  During the Term, Auxilium will use Commercially Reasonable Efforts to establish, maintain, monitor and enforce the Product Trademark in the Territory and internet domain names if any, and will bear all costs and expenses relating thereto.

 

6.8.4                     Infringement of the Product Trademark.  In the event that either Party becomes aware of any infringement of the Product Trademark by a Third Party in the Territory, such Party shall promptly notify the other Party and the Parties shall consult with each other in good faith with respect thereto.  Auxilium shall, at its sole discretion, have the first right to determine how to proceed with respect to such infringement, including by the institution of legal proceedings against such Third Party, in which case all costs and awards relating to such legal proceedings will be borne exclusively by Auxilium.  If requested to do so, Sobi shall reasonably cooperate with any and all action initiated by Auxilium, including by joining legal proceedings as a party at Auxilium’s reasonable expense.  If Auxilium elects not to take action or initiate legal proceedings against an instance of infringement to the Product Trademark in the Territory, Sobi shall have the right at its own and sole discretion to take action or initiate legal proceedings against such instance of infringement to the Product Trademark in the Territory, in which case all costs and awards relating to such legal proceeding will be borne exclusively by Sobi.  If requested to do so, Auxilium shall reasonably cooperate with any and all action initiated by Sobi in connection therewith, including, by joining legal proceedings as a party at Auxilium’s reasonable expense.

 

6.8.5                     Trademark Acknowledgments.  Each Party acknowledges the sole ownership by the other Party and validity of all trademarks, trade dress, logos and slogans owned by the other Party and used or intended to be used in connection with the Commercialization of the Finished Product for the Field in the Territory.  Each Party agrees that it will not at any time during or after the Term assert or claim any interest in, or do anything which may adversely affect the validity or enforceability of, any copyright, trademark, trade dress, logo or slogan owned by the other Party and used or intended to be used on or in connection with the marketing or sale of the Finished Product.  Neither Party will register, seek to register or cause to be registered any copyrights, trademarks, trade dress, logos or slogans owned by the other Party and used or intended to be used on or in connection with the marketing or sale of the Finished Product or any variation thereof, under any Laws providing for registration of copyrights, trademarks, service marks, trade names or fictitious names (including as an Internet domain name) or similar Laws, without the other Party’s prior written consent (in its sole discretion).

 

6.9                               Commercialization Data.  Sobi shall own all marketing and sales data and information resulting from its Commercialization of the Finished Product in the Field in the Territory during the Term (the “Commercialization Data”).  Upon request from Auxilium, Sobi shall provide to Auxilium a copy of such of the Commercialization Data as constitutes promotional materials, marketing strategies and market research data (“Promotional Commercialization Data”).  Auxilium shall have the irrevocable right and license to use all such Promotional Commercialization Data (and the right to grant its Affiliates and Third Parties the right to use such Promotional Commercialization Data) in connection with its 

 

42

 

commercialization of the Finished Product in the Field outside the Territory, which right and license shall survive the expiration or termination of this Agreement.  Notwithstanding the foregoing, Sobi’s obligation to provide Promotional Commercialization Data and Auxilium’s right to use such data shall be performed, or exercised, respectively, in all instances in accordance with all applicable Laws, including, without limiting the foregoing, any data privacy Laws.

 

6.10                        Global Branding Strategy.  Auxilium shall have the right, from time to time during the Term, to implement (and thereafter modify and update) a global branding strategy, including global messaging, for the Finished Product for use in the Field throughout the world (the “Global Branding Strategy”).  To the extent Auxilium determines to utilize such Global Branding Strategy, Sobi shall use Commercially Reasonable Efforts to adhere to the Global Branding Strategy in its Commercialization of the Finished Product, including with respect to any Promotional Materials (it is understood that Sobi will be allowed to Commercialize the Finished Product under the old branding until the stock of Promotional Material and/or Finished Product is used up); provided, that, in the event that Sobi believes that the application of the Global Branding Strategy in a particular country in the Territory would be inappropriate whether because of such country’s linguistic or cultural particularities, because it is against the Laws of such country or because Sobi reasonably determines it would be inconsistent with Sobi’s obligation to use Commercially Reasonable Efforts to Commercialize the Territory, Sobi shall present such concern to Auxilium, and the Parties shall discuss whether appropriate revisions to the Global Branding Strategy may make it appropriate for use in such country.  Nothing in this Section shall be construed to derogate from Sobi’s ultimate right and responsibility to use Commercially Reasonable Efforts to Commercialize the Finished Product in the Territory in accordance with the terms and conditions of this Agreement.

 

6.11                        Compliance with Trade Laws.   Sobi may not (i) sell or distribute any Product to any country (including without limitation Iran, Syria or Sudan) or Person (including without limitation Persons identified on the U.S. list of Specially Designated Nationals) or (ii) file for any Regulatory Approvals with the governments of such country, if such sale, distribution or filing would cause Sobi or Auxillium to violate any applicable export or embargo Laws.

 

43

 

ARTICLE 7
 SUPPLY

 

7.1                               General.  Auxilium will use Commercially Reasonable Efforts to Manufacture (or have Manufactured) and supply requested quantities (taking into consideration Auxilium’s capacity) of the Product for clinical and commercial use in the Field in the Territory, in each case in accordance with the terms of this ARTICLE 7 and the Quality Agreement.

 

7.2                               Development Supply.  Auxilium will use Commercially Reasonable Efforts to Manufacture, or arrange for a Third Party to Manufacture, and supply all of Sobi’s requirements of Units of Product for Development Activities, if any, to be performed by it in accordance with the Development Plan, which supply shall be in accordance with the terms of this ARTICLE 7.  Units of Product shall be ordered and supplied for Development Activities in accordance with the procedures set forth in this ARTICLE 7.  Units of Product (as well as any placebo requested by Sobi) supplied for Development Activities shall be invoiced at [***] (and placebo, if applicable) at the time Sobi issued the relevant Purchase Order (the “Development Supply Price”).

 

7.3                               Commercial Supply.  Auxilium will use Commercially Reasonable Efforts to Manufacture, or arrange for a Third Party to Manufacture, and supply all of Sobi’s requirements of Units of Product for commercial sale in the Field in the Territory pursuant to this Agreement, which supply shall be in accordance with the terms of this ARTICLE 7 and the Quality Agreement.  Units of Product supplied for commercial sale shall be invoiced as follows:  (i) from the Effective Date through [***], all Finished Product shipped by Auxilium shall be invoiced at $[***] per Unit of Product, and (ii) after [***], all Finished Product shipped by Auxilium shall be invoiced at $[***] per Unit of Product (the “Commercial Supply Price”).

 

Auxilium will use Commercially Reasonable Efforts to Manufacture, or arrange for a Third Party to Manufacture, and supply diluent ordered by Sobi in excess of the diluent included in a Unit of Product (“Additional Diluent”).  Such Additional Diluent shall be invoiced at Auxilium’s prevailing Manufacturing Cost of such diluent at the time Sobi issued the relevant Finished Product Designation plus a mark-up of [***] on Auxilium’s prevailing Manufacturing Cost of such diluent (the “Additional Diluent Supply Price”).

 

7.4                               Exclusive Source.  Subject to the provisions of this Agreement, Sobi shall purchase all of its requirements of Product (including Finished Product) exclusively from Auxilium pursuant to the terms of this ARTICLE 7.

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

44

 

7.5                               Packaging and Labeling; Certain Other Manufacturing Activities.

 

7.5.1                     Packaging and Labeling.  Notwithstanding anything to the contrary contained herein, in accordance with the procedures set forth in the Quality Agreement and Section 7.6.3, Auxilium or its designated Third Party shall be responsible (at its sole cost and expense) for all final product labeling and packaging (whether in commercial or clinical packaging presentation), including insertion of materials such as applicators, transfer needles, syringes, patient inserts, patient medication guides, professional inserts and any other written, printed or graphic materials accompanying the Bulk Product, considered to be part of the Finished Product (collectively, “Packaging and Labeling”).  To the extent that Auxilium uses a Third Party to assist with Packaging and Labeling, Auxilium shall be wholly responsible for, and bear all of the costs related to, qualifying such Third Party to perform such activities.  Auxilium or its designated Third Party shall ensure that all such Packaging and Labeling shall comply with Laws, GMPs and the Regulatory Approvals for the Finished Product in the Territory, including the Product Specifications.  Notwithstanding the foregoing, Sobi shall be responsible for reimbursing Auxilium for the cost of preparing any new artwork or labeling not listed on Schedule 7.5.1 or any changes to the artwork or labeling listed on Schedule 7.5.1, at Auxilium’s cost plus [***]. Sobi shall review any new or modified artwork to ensure regulatory compliance in the Territory. Such review shall be made in ten (10) business days.  Sobi shall be permitted to apply Bollini stickers or other similar relabeling for the Product for use in different countries in the Territory at Sobi’s sole expense and risk, provided that Sobi does so in compliance with all applicable Laws and further provided that Sobi indemnifies and holds harmless Auxilium from any liabilities or obligations arising out of such relabeling by Sobi.   For the avoidance of doubt, Sobi shall not be permitted to re-package the Product.

 

7.5.2                     Analytical Release Testing.  Auxilium shall conduct the Analytical Release Testing set forth in Schedule 7.5.2.  To the extent that Analytical Release Testing is required other than as set forth in Schedule 7.5.2, including without limitation qualifying a Third Party to perform such activities, then Sobi shall be responsible for performing such activities and shall be wholly responsible for, and bear one hundred percent (100%) of the costs related to such activities, including qualifying such Third Party to perform such activities.  In the event that a new laboratory for Analytical Release Testing is required to be qualified after the Effective Date in order to obtain or maintain any Regulatory Approvals in any jurisdiction within the Territory, such Manufacturing Development Activities shall be at Sobi’s sole expense.

 

7.5.3                     Post-Delivery Handling and Release.  After delivery of the Finished Product to Sobi in accordance with the terms of this Agreement and the Quality Agreement, any handling, storage, quality control, quality assurance, and the release aspects of Analytical Release Testing and related activities shall be the sole responsibility of Sobi or its designated Third Party, at Sobi’s sole expense.

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

45

 

7.6                               Forecasting and Ordering.

 

7.6.1                     Forecast.  Attached to this Agreement as Schedule 7.6 is the initial forecast of Sobi’s supply requirement of Units of Product.  On or before the tenth day of each calendar month after the Effective Date (each a “Forecast Date”), Sobi shall furnish Auxilium a forecast of quantities of Units of Product for Auxilium to manufacture in order to meet Sobi’s forecast requirements of Units of Product for commercial sale and Units of Product for Development Activities that Sobi expects to be delivered on a monthly basis in each of the twenty-four (24) calendar months beginning from the Forecast Date (each a “Forecast”).  The Forecast for deliveries of Units of Product shall be in full production lots.  The Forecast for deliveries of Units of Product occurring in the calendar months beginning ten months after the Forecast Date and later shall be non-binding.  All Forecasts for Units of Product shall (i) be specified for Units of Product for commercial sale on a monthly basis and (ii) be for full production lots of Units of Product (i.e. between [***] and [***] Units of Product for commercial sale for full production lots of the [***]L Bulk Product Manufacturing environment).  Notwithstanding the immediately preceding sentence, the Parties acknowledge and agree that the Units of Product per full production lot may vary in the future based on changes in yield; provided that, in the event of any such changes, Auxilium shall notify Sobi of such changes from time to time and such notification shall be deemed an amendment of the immediately preceding sentence in satisfaction of Section 16.1 hereof.  The Parties recognize that the foregoing Forecasts may change over time based on commercial and regulatory developments and other factors, and Sobi shall be liable to reimburse Auxilium for Out-of-Pocket Costs incurred by Auxilium as a result of any such changes with respect to the first nine (9) calendar months of the then current Forecast.

 

7.6.2                     Long Range Capacity Planning; Supply Chain Improvements.  In the event Auxilium projects a shortfall in capacity based on the Forecast, the Parties will jointly discuss alternatives to increase such capacity, and the Parties shall promptly meet to discuss a reasonable manner of proceeding.  Unless otherwise agreed to by the Parties during the Term, the Forecast shall be updated by Sobi and reviewed with Auxilium on an annual basis.

 

7.6.3                     Purchase Orders and Finished Product Designations.  On each Forecast Date, in addition to the Forecast specified in Section 7.6.1, Sobi shall for the Term deliver to Auxilium a firm purchase order specifying the quantities of the Units of Product to be delievered nine (9) calendar months in advance (a “Purchase Order”).  Each such Purchase Order shall provide for a numer of lots (if any) for release that is no more than plus or minus one full lot from the previous Forecast unless otherwise agreed upon by the parties in writing.  Unless agreed separately between the Parties, Auxilium shall not be required to make more than two (2) deliveries of Finished Product during any single calendar year.  In the event that Auxilium agrees to make more than two (2) such deliveries during a single calendar year, Sobi shall be responsible for paying all of Auxilium’s costs incurred in preparing any such additional delivery.  Notwithstanding anything in this Agreement to the contrary, Sobi acknowledges and agrees that Auxilium shall not be in breach of this Agreement or its obligations hereunder for Auxilium’s failure to manufacture, supply, or deliver Units of Product during its regularly scheduled manufacturing facility shutdowns, which typically occur in the months of June and

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

46

 

December of each year.  Not less than ninety (90) days prior to the delivery date for any particular Purchase Order, Sobi shall specify in writing the quantities of the Finished Product (including whether such Product is for commercial sale or Development Activities) on a country-by-country basis, and specifying the required artwork and labeling, for delivery (each a “Finished Product Designation”).  Auxilium shall provide written confirmation of such Finished Product Designation to Sobi within ten (10) business days of receipt of such Finished Product Designation (the date of such written confirmation, the “Finished Product Designation Acceptance Date”).  In the event that Sobi fails to issue a Finished Product Designation with respect to all of the Units of Product subject to a Purchase Order at least ninety (90) days prior to the specified delivery date for such Purchase Order, (i) Auxilium shall store the Units of Product for which no Finished Product Designation has been issued in a timely manner at Sobi’s sole risk and expense, (ii) Sobi shall provide an additional Finished Product Designation for any such Units of Product at least ninety (90) days prior to any requested delivery by Auxilium, and (iii) Auxilium shall be relieved of the minimum shelf life requirements set forth in Section 7.8.1 with respect to such Units of Product.

 

7.6.4                     Receipt and Acceptance.  Sobi shall purchase all Units of Product ordered and specified in a Purchase Order.  Purchase Orders and Finished Product Designations may be delivered electronically or by other means to such location as Auxilium shall designate and shall be in a form reasonably acceptable to Auxilium.  Auxilium shall provide written confirmation of such Purchase Order or Finished Product Designation to Sobi within ten (10) business days of receipt of such Purchase Order or Finished Product Designation.  Auxilium will accept any Purchase Order for Units of Product that does not exceed the applicable maximum provided for in the most recent Forecast.  If a Purchase Order, whether or not accepted, exceeds such applicable maximum, the Parties shall seek to agree on a reasonable manner of proceeding.  Auxilium shall use reasonable efforts to supply any amount of Units of Product that Sobi orders pursuant to Section 7.6.3 in excess of the maximum amount deliverable under the ordering and forecasting procedures specified herein, but in any event, such efforts shall not be construed as an obligation hereunder and in no event shall Auxilium be deemed in breach of this Agreement by means of a failure to provide Units of Product in excess of the then current Forecasted amount.  Nothing in any such Purchase Order, Finished Product Designation, or written acceptance shall supersede the terms and conditions of this Agreement or the Quality Agreement, and in the event of a conflict between the terms of such Purchase Order, Finished Product Designation, or written acceptance, as applicable, and the terms of this Agreement (or the Quality Agreement, as applicable), the terms of this Agreement (or the Quality Agreement, as applicable) shall control.  All Purchase Orders, Finished Product Designations, written acceptances of Purchase Orders or Finished Product Designations and other notices contemplated under this Section 7.6 shall be sent to the attention of such persons as each Party may identify to the other in writing from time to time in accordance with Section 16.3.  Notwithstanding any term in Section 7.6.3 or this Section 7.6.4 or elsewhere herein, and notwithstanding any Forecasts given by Sobi, Sobi shall not be obligated to place any Purchase Orders for Units of Product prior to receipt of Regulatory Approval thereof, and Sobi shall have the right to reasonably amend its Forecasts and Purchase Orders in the event of unexpected delays in receipt of any such approval; provided, that Sobi shall be liable to reimburse Auxilium for Out-of-Pocket Costs incurred by Auxilium as a result of any such changes with respect to first nine (9) calendar months of the then current Forecast.

 

47

 

7.7                               Invoicing, and Manufacturing Standard Cost Audit.

 

7.7.1                     Invoice.  Following Auxilium’s completion of the production of Units of Product pursuant to a Finished Product Designation under this Agreement, Auxilium shall deliver to Sobi a Certificate of Analysis for such Units of Product and shall accompany such Certificate of Analysis with an invoice setting forth the Development Supply Price or the Commercial Supply Price, as applicable, for such Units of Product.  Auxilium shall invoice such Units of Product at the Development Supply Price or the Commercial Supply Price, as applicable, and Sobi will issue payment against invoices within thirty (30) days.  Each delivery of Additional Diluent hereunder shall be accompanied by an invoice setting forth the Additional Diluent Supply Price for such delivery.  Auxilium shall invoice such Additional Diluent at the Additional Diluent Supply Price, and Sobi will issue payment against invoices within thirty (30) days.

 

7.7.2                     Manufacturing Standard Cost Audit.  Sobi shall have the right to audit the calculation of Auxilium’s prevailing Manufacturing Standard Cost.  Such audit shall be carried out in the same manner as the audit provisions of Section 8.10 which shall apply mutatis mutandis to both Parties to facilitate such right of audit.

 

7.8                               Shipping and Delivery.

 

7.8.1                     Delivery.  Auxilium shall deliver (or have delivered) to Sobi in accordance with this Section 7.8 the quantity of the Finished Product specified in each accepted Finished Product Designation.  Notwithstanding anything to the contrary contained herein, (i) Sobi will notify Auxilium of the anticipated DAP (Bruchsal, Germany) (Incoterm 2010) date of delivery at least five (5) days prior to such DAP (Bruchsal, Germany) date, which DAP (Bruchsal, Germany) date may occur as many as seven (7) days prior to or seven (7) days after the date that is nine (9) months from the delivery date set forth in the Purchase Order, and such delivery shall be deemed to have been delivered on a timely basis hereunder, and (ii) in order to allow for Bulk Product Manufacturing variances, Auxilium shall be entitled to deliver quantities of Finished Product as much as ten percent (10%) above or as little as ten percent (10%) below the amount of the Finished Product specified by Sobi in the applicable Finished Product Designation, provided however that the aggregate difference in any twelve (12) month period does not exceed ten percent (10%) in the aggregate for all such Finished Product ordered for such period and such delivery shall be deemed to have been delivered in satisfaction of Auxilium’s obligations hereunder.  At the time that Auxilium provides a Certificate of Analysis with respect to any Units of Product ordered by Sobi under this Agreement, the shelf life of such Units of Product shall not be consumed with more than six (6) months.

 

7.8.2                     Delivery Terms.  Finished Product shall be supplied to Sobi DAP (Incoterms 2010), Sobi’s warehouse in Bruchsal, Germany.  Delivery shall occur, and title and risk of loss will pass to Sobi, when each order of Finished Product is placed at the disposal of Sobi at such Facility.  The Finished Product shall be shipped via a carrier identified by Sobi in the applicable Finished Product Designation; provided, that in the event that Sobi fails to identify a carrier, Auxilium may choose a carrier at its own reasonable discretion.

 

48

 

7.8.3                     Retention.  Unless the Parties agree otherwise, Auxilium will maintain analytical samples of Bulk Product from which Units of Product for commercial sale delivered to Sobi hereunder are derived in storage for a time period based upon Auxilium’s sample retention policy.

 

7.9                               Quality and Compliance.

 

7.9.1                     Quality Agreement.  The Quality Agreement will set forth the Parties’ quality and compliance obligations with respect to Manufacture and acceptance of the Product.  Sobi and Auxilium agree to comply with the requirements and provisions set forth in the Quality Agreement.  The Quality Agreement will set forth in greater detail many of the responsibilities and obligations set forth herein.  In the event of a conflict between the terms of the Quality Agreement and the terms of this Agreement, the terms of this Agreement shall prevail.  The Parties shall execute the Quality Agreement prior to the first delivery of Product under this Agreement.

 

7.9.2                     Notice of Non-Conformance.

 

(a)                                 Auxilium will supply to Sobi the applicable batch number for the Bulk Product and the Finished Product as well as such other information as the Parties may set forth in the Quality Agreement with respect to the Manufacture of the Bulk Product and the Finished Product (a “Certificate of Analysis”) for all Units of Product manufactured by Auxilium pursuant to orders placed by Sobi hereunder.  Sobi shall promptly on receipt of each shipment of Units of Product hereunder inspect, or cause to have inspected, each shipment of Units of Product for any damage, defect or shortage and within a reasonable period of time give Auxilium written notice of any such damaged, defective or short shipment (a “Notice of Non-Conformance”).

 

(b)                                 Latent Defects shall be communicated to Auxilium, together with appropriate detail, via a Notice of Non-Conformance, without undue delay after such Latent Defect is first discovered by Sobi (or Sobi otherwise is notified of such Latent Defect), but in all cases within two (2) business days of the date on which such Latent Defect was first discovered by Sobi or was notified to Sobi by the relevant Person discovering the defect, and thereafter such Latent Defect shall be handled as set forth in the remainder of this Section 7.9 and/or the Quality Agreement, as applicable.  For purposes of this Section 7.9.2(b), “Latent Defects” shall mean those defects that could not be discovered by inspection by Sobi or its designee as described in Section 7.9.2(a).

 

7.9.3                     Notification of significant quality issues.  As set forth in the Quality Agreement (including on timing set forth therein), the Parties shall notify each other of the occurrence of a confirmed out-of specification (“OOS”) result or major process deviation relating to the Finished Product whether inside the Territory or outside the Territory.  The Parties agree to consult on all quality decisions regarding any OOS result or major process deviations involving the Finished Product.

 

7.9.4                     Audits.  Sobi shall have access to Auxilium Facilities associated with the Drug Substance or Finished Product at a mutually agreeable time for the sole purpose of auditing

 

49

 

the Facilities for operational compliance with cGMPs and the content of the respective Quality Agreement.  The right to audit also includes any testing Facility (for EU testing) related to the Drug Substance or Finished Product.  To the extent a Third Party’s facilities are the subject of an audit pursuant to this Section 7.9.4, Sobi shall (a) perform such audit in conjunction with Auxilium, subject to any limitations set forth in the agreement between Auxilium and such Third Party, and in accordance with this Agreement and any related Quality Agreement and (b) bear any costs charged by such Third Party associated with such audit.  Sobi shall not have more than three (3) individual persons present during any such audit conducted under this Section 7.9.4.  For clarity, Auxilium shall have the right to accompany Sobi on any such audit of a Third Party Facility.

 

7.10                        Disputes and Remedies.

 

7.10.1              Disputes.  If Sobi delivers a Notice of Non-Conformance in respect of all or any part of a shipment of Units of Product, and Auxilium does not agree with Sobi’s determination that any such Units of Product fails to meet the Product Specifications (or there is a short shipment), the Parties shall in good faith attempt to resolve such dispute.  Auxilium and Sobi shall have thirty (30) days, unless otherwise agreed in writing by the Parties, from the date of Auxilium’s receipt of a Notice of Non-Conformance to resolve such dispute regarding whether all or any part of such shipment of Units of Product was Manufactured in conformance with the Product Specifications (or there is otherwise a short shipment).  If the dispute regarding whether all or any part of a shipment of Units of Product rejected by Sobi was Manufactured in conformance with the Product Specifications (or there is a short shipment) is not resolved in such thirty (30) day period, then Auxilium shall prepare an investigative report concerning such alleged non-conformance and such investigative report and Sobi’s original Notice of Non-Conformance shall be submitted to an independent consultant.  The consultant shall be mutually agreed upon in writing by the Parties.  The results of the consultant’s determination shall be based on Auxilium’s investigative report and Sobi’s original Notice of Non-Conformance and shall be final and binding on the Parties, and if such Units of Product are determined to meet the Product Specifications (or is otherwise determined not to be a short shipment, as applicable) in all material respects, then Sobi shall pay for the costs of such consultant; otherwise Auxilium shall pay for such costs.

 

7.10.2              Remedies.  In the event any shipment of Units of Product is rejected pursuant to Section 7.10.1 (or as a result of an uncontested Notice of Non-Conformance) and/or the Quality Agreement, as applicable, solely as a result of any act or omission of Auxilium, then (i) Sobi shall, at the direction of Auxilium, either (a) destroy such rejected Units of Product at Auxilium’s reasonable expense (in accordance with Laws) or (b) return such Units of Product to Auxilium, at a location designated by Auxilium and at Auxilium’s reasonable expense, and (ii) Auxilium, at no expense to Sobi, shall, either (a) use its Commercially Reasonable Efforts to promptly replace such non-conforming Units of Product (or short shipment) or (b) give Sobi a credit in an amount equal to the amount paid or payable by Sobi with respect to such rejected Units Product (or short shipment) as reasonably agreed between the Parties.  In the event that any shipment of Units of Product is rejected for any other reason, Auxilium shall have no liability to Sobi in connection therewith, and Sobi shall, at its sole cost, destroy such rejected Units of Product in compliance with Laws.  AUXILIUM’S LIABILITY IN RESPECT OF ANY

 

50

 

REJECTION (INCLUDING ANY SHORT SHIPMENT) SHALL BE LIMITED TO THE REMEDIES PROVIDED IN THIS SECTION 7.10.2.

 

7.11                        Shortages.  In the event that the materials and/or Manufacturing capacity required to Manufacture and deliver Units of Product to Sobi in a timely manner are in short supply, Auxilium shall notify Sobi of such shortage and, the Parties shall promptly meet to discuss the shortage.  Auxilium shall provide a written plan of action stating in reasonable detail the root cause of the shortage and proposed measures to remedy the shortage and the date such shortage is expected to end.  Notwithstanding anything to the contrary contained herein, the situation where the commercial success of the Finished Product in the Territory is the reason for such shortage (which situation is addressed in Section 7.6.2) shall not constitute a “shortage” or mean that Auxilium is “unable to supply” for purposes of this Section 7.11 (provided, that Auxilium is using Commercially Reasonable Efforts to supply all of Sobi’s Purchase Orders in accordance with this Agreement.  Auxilium shall use its Commercially Reasonable Efforts to minimize the duration of any shortage.  During any such shortage, Auxilium shall allocate the materials and resources used in the supply of Units of Product between Auxilium (and any other Third Parties), on the one hand, and Sobi, on the other hand (subject to pre-existing obligations to Third Parties), in an appropriate and commercially reasonable manner.

 

7.12                        Manufacturing Supply Assurance.  Auxilium shall use its Commercially Reasonable Efforts, as the exclusive supplier of Units of Product, to ensure for the duration of the Term of the Agreement that a reasonable measure of supply assurance be maintained.

 

7.13                        Product Specification and Manufacturing Changes.  Product Specification and Manufacturing changes, including those resulting from a request received by a Party from a Governmental Authority, or any changes that Auxilium may make, shall be dealt with pursuant to the Quality Agreement; provided that all applicable Regulatory Materials shall be prepared and filed by the Parties in accordance with the provisions of ARTICLE 5.

 

7.14                        Termination of Supply Obligations.  Notwithstanding anything to the contrary contained herein, the obligations of Auxilium under this ARTICLE 7, including the obligations to Manufacture and supply Units of Product to Sobi hereunder, and Sobi’s obligations to purchase solely from Auxilium, may continue after the end of the Royalty Term, or terminate (on a country-by-country and Finished Product-by-Finished Product basis) from and after the end of the Royalty Term with respect to such Finished Product in such country.  The Parties will negotiate in good faith the terms and conditions upon which Auxilium might continue to Manufacture and supply, and Sobi might continue to purchase, requirements of Units of Product from Auxilium pursuant to a distinct manufacturing and supply agreement which shall be amendable to include additional countries of the Territory as the Royalty Term expires in such countries.

 

7.15                        Auxilium Notice.  Auxilium shall provide Sobi with verbal notice as soon as practicable after it becomes aware, confirmed in writing within three (3) business days thereafter, of any significant condition or incident, which shall include any event, occurrence, or circumstance, including any governmental or private action, which could reasonably be expected to materially impact Auxilium’s ability to perform its obligations under this Agreement.

 

51

 

ARTICLE 8
 PAYMENTS

 

8.1                               Milestone Payments.  Sobi shall pay to Auxilium the milestone payments (the “Milestone Payments”) described in this Section 8.1 following achievement (first occurrence) of the corresponding milestone event.  Sobi shall promptly notify Auxilium in writing, but in no event later than five (5) days after, of the achievement of each such milestone event (each, a “Milestone Notification Notice”) achieved by Sobi.  Sobi shall pay the applicable milestone payment by wire transfer of immediately available funds into an account designated by Auxilium as per Section 8.7 of this Agreement; provided, however, that in no event shall a failure to deliver a Milestone Notification Notice relieve Sobi of its obligation to pay Auxilium the milestone payments described in this Section 8.1.  Each such milestone payment is nonrefundable and noncreditable against any other payments due hereunder.

 

	
Milestone Event
    	
 
    	
Milestone Payment
    	
 
    
	
Sales Based Milestones
    	
 
    	
 
    	
 
    
	
1.   The first time aggregate Net Sales of Finished Product in the Territory equal   or exceed [***] Dollars ($[***]) for any calendar year. 
    	
 
    	
[***] Dollars ($[***])
    	
 
    
	
2.   The first time aggregate Net Sales of Finished Product in the Territory equal   or exceed [***] Dollars ($[***]) for any calendar year.
    	
 
    	
[***] Dollars ($[***])
    	
 
    
	
3.   The first time aggregate Net Sales of Finished Product in the Territory equal   or exceed [***] Million ($[***]) for any calendar year.
    	
 
    	
[***] Dollars ($[***])
    	
 
    
	
4.   The first time aggregate Net Sales of Finished Product in the Territory equal   or exceed [***] Dollars ($[***]) for any calendar year.
    	
 
    	
[***] Dollars ($[***])
    	
 
    

 

8.1.1                     Each of the Sales Based Milestones shall be payable only once during the Term.

 

8.2                               Royalties.

 

8.2.1                     Royalty Rate During Term.  As further consideration for the rights granted to Sobi under this Agreement, Sobi shall pay to Auxilium tiered royalty payments (“Royalty Payments”) at the following rates (the “Royalty Rates”) based on aggregate annual Net Sales of Finished Product in the Territory for all or any portion of a calendar year falling within the Royalty Term as set forth below:

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

52

 

From the Effective Date through the earlier of (a) June 30, 2016, and (b) six (6) months after [***]:

 

	
Calendar Year Net Sales
    	
 
    	
Royalty Rate
    	
 
    
	
For that portion of   aggregate annual Net Sales equal to or less than [***]   Dollars ($[***])
    	
 
    	
[***]
    	
%
    
	
For that portion of   aggregate annual Net Sales greater than [***]   Dollars ($[***]) but less than or equal to   [***] Dollars ($[***])
    	
 
    	
[***]
    	
%
    
	
For that portion of   aggregate annual Net Sales greater than [***] Dollars   ($[***])
    	
 
    	
[***]
    	
%
    

 

From the earlier of (a) July 1, 2016, and (b) six (6) months after the [***] and until the expiration of the Term:

 

	
Calendar Year Net Sales
    	
 
    	
Royalty Rate
    	
 
    
	
For that portion of   aggregate annual Net Sales less than or equal to [***]   Dollars ($[***])
    	
 
    	
[***]
    	
%
    
	
For that portion of   aggregate annual Net Sales greater than [***] Dollars   ($[***]) but less than or equal to [***] Dollars ($[***])
    	
 
    	
[***]
    	
%
    
	
For that portion of   aggregate annual Net Sales greater than [***] Dollars   ($[***])
    	
 
    	
[***]
    	
%
    

 

Also, for the purposes of clarity, aggregate Net Sales levels from the Territory shall be computed using the exchange rate in effect at the time for the calculation of the quarterly royalty payments and then summed to determine whether an aggregate sales milestone has been reached.

 

8.2.2                     Sobi Success Compensation.  Sobi shall be entitled to reduce the Royalty Payments payable to Auxilium under this Agreement by the following amounts (each a “Success Amount”) and based on the successful achievement of the following events (each a “Success Event”):

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

53

 

	
Success Event
    	
 
    	
Success Amount
    	
 
    
	
1.   Receipt by Sobi of (I) first Pricing Approval of the Product for any   indication in the Field in Germany on or before December 31, 2016 and   (II) at a price at or above the top 25th percentile of the average price received by   Sobi in each country of the European Union in which the Product is sold for   such indication.
    	
 
    	
[***] Dollars ($[***])
    	
 
    
	
2.   Receipt by Sobi of (I) first Pricing Approval of the Product for any   indication in the Field in France on or before December 31, 2016 and   (II) at a price at or above the top 25th percentile of the average price received by   Sobi in each country of the European Union in which the Product is sold for   such indication.
    	
 
    	
[***] Dollars ($[***])
    	
 
    

 

Each such Success Event can only be achieve on one occasion, and each Success Amount is payable only once.  In the event that a Success Event is achieved, then the next quarterly Royalty Payment payable by Sobi under Section 8.2 shall be reduced by the Success Amount; provided that the Royalty Payment will in no event be reduced below zero.  In the event that the Success Amount can not be paid to Sobi in full due to the Royalty Payment being reduced to zero, the balance of the unpaid Success Amount will reduce future Royalty Payments payable under Section 8.2 until the Success Amount is fully paid.

 

8.2.3                     The date of “receipt by Sobi of first Pricing Approval” shall mean, as the case may be, the date on which Sobi has received notice from the relevant Governmental Authority related thereto.

 

8.3                               Royalty Reports and Payments.  Within fifteen (15) days of the end of each calendar quarter Sobi shall provide Auxilium with a royalty report that includes: (i) a statement of the amount of gross sales of the Finished Product, on an indication-by-indication basis, (a) in the Territory as a whole and (b) on a country-by-country and month-by-month basis during the applicable calendar quarter (including such amounts expressed in local currency and as converted to Dollars), (ii) an itemized calculation of Net Sales (a) in the Territory as a whole and (b) on a country-by-country and month-by-month basis, showing for both (a) and (b) deductions provided for in the definition of “Net Sales” during such calendar quarter and (iii) the total Royalty Payment payable to Auxilium pursuant to Section 8.2 with respect to Net Sales during such calendar quarter less the aggregate amount of the Commercial Supply Price paid by Sobi for all Finished Product to which the Net Sales for such calendar quarter relate (the “Aggregate Quarterly Supply Price”), which amount shall be converted to Dollars at such time in accordance with Section 8.6.  Without limiting the generality of the foregoing, Sobi shall require its Affiliates and sublicensees (and any distributors) to account for its Net Sales and to provide such reports with respect thereto as if such sales were made by Sobi.  In the event that the amount of the Royalty Payment payable to Auxilium with respect to any calendar quarter is less than the Commercial Supply Price paid by Sobi for all Finished Product to which the Net Sales for such calendar quarter relate, Sobi shall be entitled to offset the amount by which such

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

54

 

aggregate Commercial Supply Price exceeds the Royalty Payment for such calendar quarter against future Royalty Payments owed by Sobi.

 

8.4                               Third Party Royalties and Other Payments.

 

8.4.1                     Certain Existing Obligations.  Auxilium shall be solely responsible for the payment of any royalties, sublicense revenues, milestones or other payments due to Third Parties under the BTC License Agreement on account of the sale of the Finished Product by Sobi hereunder.

 

8.4.2                     Licenses to New Necessary Patents.  If Sobi determines that it is necessary to obtain a license under any Patent of a Third Party that would be infringed by the sale by Sobi of the Finished Product, as the Bulk Product exists on the Effective Date (excluding, for the avoidance of doubt, any additional technology that may be combined or incorporated therewith, or any future improvements or enhancements to the Bulk Product) in the Territory (as in existence on the Effective Date) for use in the Field (as defined on the Effective Date), other than those described in Section 8.4.1 necessary to make, use or import the Bulk Product or use, sell or offer for sale the Finished Product for sale in the Field in the Territory, then (x) the Parties shall meet to discuss such determination and Auxilium shall consider Sobi’s comments in good faith and (y) if Auxilium determines that it is still necessary to obtain such license, Auxilium will be primarily responsible for the negotiation and execution of the corresponding license agreement; provided, however, that, notwithstanding the foregoing, Auxilium shall have the sole right to obtain a license, and negotiate and execute a license agreement, in connection with the Manufacture of the Bulk Product or with respect to any intellectual property applicable to the Bulk Product or Finished Product on a worldwide basis (and, provided, that at the request of Auxilium, any such license from a Third Party shall include a license to Auxilium (including without limitation with the right to sublicense) with respect to the Bulk Product and Finished Product outside the Territory (and/or outside the Field)).  Any amounts due under such Third Party license agreement with respect to sale of the Finished Product in the Field in the Territory will be borne by Sobi; provided, that Sobi shall be entitled to deduct up to fifty percent (50%) of the royalties payable to such Third Party (on account of the sale of the Finished Product in the Field in the Territory) from the Royalty Payments thereafter made by Sobi to Auxilium hereunder; provided, however, that the Royalty Payments payable under Section 8.2.1 shall not be reduced in any such event below fifty percent (50%) of the amounts set forth in Section 8.2.1.  In no event shall a license be deemed to be “necessary” on a Third Party Patent that is not granted or issued, literally infringed or has genuine issues of fact that raise a reasonable defense that such Patent is invalid or unenforceable.

 

8.4.3                     Licenses to Other Patents.  Except as provided in Sections 8.4.1 and 8.4.2, if Sobi desires to obtain a license under any Third Party’s Patents that are otherwise useful for the Development of the Bulk Product or Commercialization of the Finished Product in the Field in the Territory, then Sobi shall notify the JSC.  To the extent that both Parties determine (in each such Party’s sole discretion) to pursue such a license, then Sobi shall be primarily responsible for the negotiation and execution of the corresponding license agreement and the Parties shall share equally (unless otherwise mutually agreed or as provided in the next sentence) all payments associated with any license fees, royalties and other amounts owed to the applicable Third Party for such license.  Notwithstanding the foregoing, at the time a license opportunity is

 

55

 

presented to the JSC, Auxilium may elect not to participate in the costs of such joint licensing opportunity with respect to the Development of the Bulk Product or Commercialization of the Finished Product in the Field in the Territory.  In such event Sobi may pursue such licensing opportunity and shall be responsible for one hundred percent (100%) of all payments associated with any license fees, royalties and other amounts owed to the applicable Third Party for such license, with no right to invoice Auxilium or offset such amounts against any amounts owed to Auxilium under this Agreement; provided that, in the event that Sobi decides to pursue such license within the Territory, then Auxilium will not be entitled to opt out of the obligation to contribute equally to all costs of such licensing opportunity within the Territory if Auxilium pursues the licensing of such opportunity outside of the Territory.

 

8.5                               Taxes and Withholding.

 

8.5.1                     VAT.  The Parties agree to cooperate with one another and use reasonable efforts to ensure that value added tax or similar payment (“VAT”) in respect of any payments made by Sobi to Auxilium under this Agreement does not represent an unnecessary cost in respect of payments made under this Agreement.  For purposes of clarity, all sums payable under this Agreement shall be exclusive of VAT.  In the event that any VAT is owing in any jurisdiction in respect of any such payment, Sobi shall pay such VAT, and (i) if such VAT is owing as a result of any action by Sobi, including any assignment or sublicense (including, without limitation, assignment to, or payment hereunder by, another Sobi-related entity or Affiliate), or any failure on the part of Sobi or its Affiliates to comply with applicable tax Laws or filing or record retention requirements, that has the effect of modifying the tax treatment of the Parties hereto, then the payment in respect of which such VAT is owing shall be made without deduction for or on account of such VAT to ensure that Auxilium receives a sum equal to the sum which it would have received had such VAT not been due or (ii) otherwise, such payment shall be made after deduction of such VAT.  For the sake of clarity, any increase in payments to Auxilium under this Section 8.5 shall reflect only the incremental increase in VAT directly resulting from clause (i) above.  In the event that any VAT is owing in any jurisdiction in respect of any such payment, Auxilium will provide to Sobi tax invoices showing the correct amount of VAT in respect of such payments hereunder.

 

8.5.2                     Withholding Tax Matters.  If Sobi is required to make a payment to Auxilium subject to a deduction of tax or withholding tax, the sum payable by Sobi (in respect of which such deduction or withholding is required to be made) shall be made to Auxilium after deduction of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted in accordance with Laws.  Any such withholding taxes required under Laws to be paid or withheld shall be an expense of, and borne solely by Auxilium, subject to Section 8.5.1 and the obligation of Sobi to assume the responsibility of such expense in the event that such expense arises as a result of any action by Sobi.

 

8.5.3                     Tax Cooperation.  To the extent Sobi is required to deduct and withhold taxes on any payments to Auxilium, Sobi shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Auxilium an official tax certificate or other evidence of such withholding sufficient to enable Auxilium to claim such payments of taxes.  Auxilium shall provide to Sobi any tax forms that may be reasonably necessary in order for Sobi not to withhold tax or to withhold tax at a reduced rate under an

 

56

 

applicable bilateral income tax treaty.  Auxilium shall use reasonable efforts to provide any such tax forms to Sobi at least thirty (30) days prior to the due date for any payments for which Auxilium desires that Sobi apply a reduced withholding rate.  Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Laws, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or VAT.

 

8.6                               Currency Conversion.  All payments hereunder shall be made in U.S. Dollars.  For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than U.S. Dollars), any amount expressed in a foreign currency shall be converted into U.S. Dollars in a manner consistent with such Party’s normal practices used to prepare its audited financial statements for external reporting purposes, provided that such practices use a widely accepted source of published exchange rates.

 

8.7                               General Payment Procedures.  The receiving Party shall invoice the paying Party for all amounts due to such receiving Party under this Agreement, and such payments shall be made within thirty (30) days following the receipt by the paying Party of an invoice from the receiving Party specifying the amount due.

 

8.8                               Late Payments.  Any amount required to be paid by a Party hereunder which is not paid on the date due shall bear interest at a rate equal to the thirty (30) day U.S. dollar LIBOR rate effective for the date that payment was first due as reported by The Wall Street Journal plus two percent (2%).  Such interest shall be computed on the basis of a year of three hundred sixty (360) days for the actual number of days payment is delinquent.

 

8.9                               Legal Restrictions.  If at any time legal restrictions prevent the remittance by Sobi of all or any part of amounts due under this Agreement in any country, Sobi will have the right and option to make such payment by depositing the amount thereof in local currency to an account in the name of Auxilium in a bank or other depository in such country as directed by Auxilium.  Sobi will consult with Auxilium regarding, and promptly notify Auxilium of, any and all such arrangements.  Under such circumstances Sobi shall not be liable for any late fees to the extent the subject payment is deposited in a bank or other depository in such country as directed by Auxilium prior to the date such payment is otherwise due hereunder.

 

8.10                        Records; Audits.  Sobi and its Affiliates, its sublicensees and subcontractors shall keep full, true and accurate records and books of account containing all particulars that may be necessary for the purpose of confirming the accuracy of, and calculating, as applicable, all Royalty Payments and other amounts payable to Auxilium hereunder (including records of Net Sales), and any other records reasonably required to be maintained with respect to Sobi’s obligations under this Agreement, for a minimum period of two (2) years or such longer period as required by Laws.  Auxilium shall have a right to request an audit of Sobi in order to confirm the accuracy of the foregoing (an “Audit”); provided, however, that Auxilium shall only have the right to request such Audit one time during any given calendar year.  Upon the written request by Auxilium to Audit Sobi, Auxilium shall have the right to engage an independent, internationally recognized accounting firm to perform a review as is reasonably necessary to enable such accounting firm to calculate or otherwise confirm the accuracy of any of the

 

57

 

foregoing for the calendar year(s) requested by Auxilium; provided that (i) such accountants shall be given access to, and shall be permitted to examine and copy such books and records of Sobi upon five (5) business days’ prior written notice to Sobi, and at all reasonable times on such business days, (ii) prior to any such examination taking place, such accountants shall enter into a confidentiality agreement with Sobi reasonably acceptable to Sobi in order to keep all information and data contained in such books and records strictly confidential and shall not disclose such information or copies of such books and records to any third person including Auxilium, but shall only use the same for the purpose of the reviews and/or calculations which they need to perform in order to determine any amounts being reviewed, and (iii) such accountants shall use reasonable efforts to minimize any disruption to Sobi’s business.  Sobi shall make personnel reasonably available during regular business hours to answer queries on all such books and records required for the purpose of the Audit.  The accountants shall deliver a copy of their findings to each of the Parties within ten (10) business days of the completion of the review, and, in the absence of fraud or manifest error, the findings of such accountant shall be final and binding on each of the Parties.  Any underpayments by Sobi shall be paid to Auxilium within ten (10) business days of notification of the results of such inspection.  Any overpayments made by Sobi shall be refunded by Auxilium within ten (10) business days of notification of the results of such inspection.  The cost of the accountants shall be the responsibility of Auxilium unless the accountants’ calculation shows that the actual royalties payable, Net Sales, and/or any other applicable amount Audited hereunder to be different, by more than ten percent (10%), than the amounts as previously calculated by Sobi.

 

ARTICLE 9
 INTELLECTUAL PROPERTY MATTERS

 

9.1                               Ownership of Intellectual Property.

 

9.1.1                     General.  Subject to the provisions of this Section 9.1.1 and except as expressly set forth otherwise in this Agreement, (i) Auxilium shall solely own, and it alone shall have the right to apply for, Patents within and outside of the Territory Covering any Auxilium Invention (“Auxilium Collaboration Patents”), and (ii) Sobi shall solely own, and it alone shall have the right to apply for, Patents within and outside of the Territory Covering any Sobi Invention (“Sobi Collaboration Patents”).  With respect to any Joint Invention and any Patents claiming such Joint Invention (“Joint Collaboration Patents”), Sobi shall assign (and shall cause its Affiliates, sublicensees and subcontractors to assign), and hereby does assign, any and all of Sobi’s (and its Affiliates’, its sublicensees’ and subcontractors’) right, title and interest in and to such Joint Inventions and Joint Collaboration Patents to Auxilium, such that Auxilium shall solely own such Joint Inventions and Joint Collaboration Patents and thereafter, any Confidential Information contained therein shall be deemed “Confidential Information” of Auxilium.  Each Party shall promptly disclose to the other Party all Auxilium Inventions, Sobi Inventions and Joint Inventions, as applicable, made by it during the Term.  The determination of inventorship for such Inventions shall be made in accordance with applicable Laws relating to inventorship set forth in the patent Laws of the United States (Title 35, United States Code).

 

9.1.2                     Employees.  Each Party will require all of its and its Affiliates’ employees to assign all Inventions that are developed, made or conceived by such employees according to the ownership principles described in Section 9.1.1 free and clear of all liens, encumbrances,

 

58

 

charges, security interests, mortgages or other similar restrictions.  Each Party will also use its Commercially Reasonable Efforts to require any agents, independent contractors or sublicensees performing an activity pursuant to this Agreement to assign all Inventions that are developed, made or conceived by such agents, independent contractors or sublicensees to Auxilium and/or Sobi according to the ownership principles described in Section 9.1.1 free and clear of all liens, encumbrances, charges, security interests, mortgages or other similar restrictions.

 

9.2                               Disclosures; Disputes Regarding Inventions.  Each Party shall, before filing a new Patent application (including provisionals and continuations-in-part) claiming an Invention, promptly disclose such Invention to the other Party and shall provide the other Party with a copy of the proposed patent application at least ten (10) business days before filing such application or such shorter time as may be required to preserve Patent rights, including the avoidance of a statutory bar or prior publication.  If the non-filing Party believes that the filing Party’s proposed Patent application discloses Confidential Information of the non-filing Party, the non-filing Party shall so notify the filing Party within such ten (10) business days after receipt thereof, and the filing Party shall amend its proposed application to comply with the confidentiality provisions of this Agreement.  If the Parties are in agreement as to the designation of the Invention as an Auxilium Invention, Joint Invention or Sobi Invention, as applicable, they can continue as set forth in Section 9.3.  If the Parties disagree as to whether an Invention is an Auxilium Invention, Joint Invention or Sobi Invention, and are unable to reach agreement within thirty (30) days after commencing discussions, then the provisions of ARTICLE 15 shall apply to such dispute.

 

9.3                               Patent Filings, Prosecution and Maintenance.

 

9.3.1                     Auxilium Patents.  Subject to, and without limiting Sobi’s rights under, Section 9.4 of this Agreement, Auxilium shall have the first right to prepare, file, prosecute and maintain (i) Auxilium Collaboration Patents and (ii) all other Auxilium Patents, at its own cost and expense.  Auxilium shall keep Sobi informed of the status of Auxilium Patents and will provide Sobi with copies of all substantive documentation submitted to, or received from, the patent offices in connection therewith.  With respect to any substantive submissions that Auxilium is required to or otherwise intends to submit to a patent office with respect to an Auxilium Patent, Auxilium shall provide a draft of such submission to Sobi at least sixty (60) days) (or such time as is possible) prior to the deadline for, or the intended filing date of, such submission, whichever is earlier (or as soon as reasonably possible if Auxilium has less than sixty (60) days notice of a deadline for submission).  Sobi shall have the right to review and comment upon any such submission by Auxilium to a patent office, and will provide such comments within twenty (20) days after receiving such submission (provided, that if no comments are received within such twenty (20) day period, then Auxilium may proceed with such submission).  Auxilium shall consider in good faith any suggestions or recommendations of Sobi concerning the preparation, filing, prosecution and maintenance thereof.  The Parties shall cooperate reasonably in the prosecution of all Auxilium Patents and shall share all material information relating thereto promptly after receipt of such information.  If, during the Term, Auxilium (a) intends to allow any Auxilium Patent to which Sobi has a license under this Agreement to expire or intends to otherwise abandon any such Auxilium Patent, or (b) decides not to prepare or file patent applications covering Auxilium Inventions in the Territory to which Sobi would otherwise have a license under this Agreement, Auxilium shall notify Sobi of such intention or decision at least thirty (30) days (or as soon as possible if less than thirty (30) days)

 

59

 

prior to any filing or payment due date, or any other date that requires action, in connection with such Auxilium Patent, and Sobi shall thereupon have the right, but not the obligation, to assume responsibility for the preparation, filing, prosecution or maintenance thereof in the Territory at its sole cost and expense (provided that Sobi may thereafter at any time decide not to pursue any such Auxilium Patent and Auxilium hereby agrees to reasonably cooperate with Sobi in order to enable Sobi to cease such preparation, filing, prosecution or maintenance), in the name of Auxilium; provided that, with respect to any international Patent applications included in the Auxilium Patents described in the foregoing sentence, Auxilium shall not allow such an international Patent application to expire or otherwise be abandoned until such international Patent application is about to enter the national stage, at which time Auxilium shall notify Sobi of such intention or decision at least thirty (30) days (or as soon as possible if less than thirty (30) days) prior to any filing or payment due date, or any other date that requires action, in connection with such international Patent application in a country or region in the Territory that is designated in such international Patent, and Sobi shall have the right to, but not the obligation, to assume responsibility for the preparation, filing, prosecution or maintenance of the national phase of such an international Patent in the Territory at its sole cost and expense, in the name of Auxilium (rendering such international Patent, an “Sobi Funded Patent Rights”).  Auxilium agrees to use Commercially Reasonable Efforts with respect to any decision to allow an Auxilium Patent to expire or to otherwise go abandoned, or with respect to any decision not to prepare or file patent applications covering Auxilium Inventions.

 

9.3.2                     Joint Collaboration Patents.  Subject to, and without limiting Sobi’s rights under, Section 9.4 of this Agreement, Auxilium shall have the first right to prepare, file, prosecute and maintain Joint Collaboration Patents at its own cost and expense.  Auxilium shall keep Sobi informed of the status of Joint Collaboration Patents and will provide Sobi with copies of all substantive documentation submitted to, or received from, the patent offices in connection therewith.  With respect to any substantive submissions that Auxilium is required to or otherwise intends to submit to a patent office with respect to a Joint Collaboration Patent, Auxilium shall provide a draft of such submission to Sobi at least sixty (60) days (or such time as is possible) prior to the deadline for, or the intended filing date of, such submission, whichever is earlier (or as soon as reasonably possible if Auxilium has less than sixty (60) days notice of a deadline for submission).  Sobi shall have the right to review and comment upon any such submission by Auxilium to a patent office, and will provide such comments within twenty (20) days after receiving such submission (provided, that if no comments are received within such twenty (20) day period, then Auxilium may proceed with such submission).  Auxilium shall consider in good faith any suggestions or recommendations of Sobi concerning the preparation, filing, prosecution and maintenance thereof.  The Parties shall cooperate reasonably in the prosecution of all Joint Collaboration Patents and shall share all material information relating thereto promptly after receipt of such information.  If Auxilium (i) intends to allow any Joint Collaboration Patent to expire or intends to otherwise abandon any such Joint Collaboration Patent (“Abandoned Collaboration Patents”), or (ii) decides not to prepare or file patent applications covering Joint Inventions (“Abandoned Joint Inventions”) Auxilium shall notify Sobi of such intention or decision at least thirty (30) days (or as soon as possible if less than thirty (30) days) prior to any filing or payment due date, or any other date that requires action, in connection with such Abandoned Collaboration Patent or Abandoned Joint Invention, and Sobi shall thereupon have the right, but not the obligation, to assume responsibility for the preparation, filing, prosecution or maintenance thereof at its sole cost and expense, in the name of Sobi.

 

60

 

9.3.3                     Sobi Collaboration Patents and Sobi Applied Patents.  Sobi shall have the first right to prepare, file, prosecute and maintain (i) Sobi Collaboration Patents and (ii) Sobi Applied Patents, at its own cost and expense.  Sobi shall keep Auxilium informed of the status of Sobi Collaboration Patents and Sobi Applied Patents and will provide Auxilium with copies of all substantive documentation submitted to, or received from, the patent offices in connection therewith.  With respect to any substantive submissions that Sobi is required to or otherwise intends to submit to a patent office with respect to a Sobi Collaboration Patents and Sobi Applied Patent, Sobi shall provide a draft of such submission to Auxilium at least sixty (60) days (or such time as is possible) prior to the deadline for, or the intended filing date of, such submission, whichever is earlier (or as soon as reasonably possible if Sobi has less than sixty (60) days notice of a deadline for submission).  Auxilium shall have the right to review and comment upon any such submission by Sobi to a patent office, and will provide such comments within twenty (20) days after receiving such submission (provided, that if no comments are received within such twenty (20) day period, then Sobi may proceed with such submission).  Sobi shall consider in good faith any suggestions or recommendations of Auxilium concerning the preparation, filing, prosecution and maintenance thereof.  The Parties shall cooperate reasonably in the prosecution of all Sobi Collaboration Patents and Sobi Applied Patents and shall share all material information relating thereto promptly after receipt of such information.  If, during the Term, Sobi (a) intends to allow any Sobi Collaboration Patents or Sobi Applied Patent to which Auxilium has a license under this Agreement to expire or intends to otherwise abandon any such Sobi Collaboration Patents or Sobi Applied Patent, or (b) decides not to prepare or file patent applications covering Sobi Applied Know-How or Sobi Inventions to which Auxilium would otherwise have a license under this Agreement, Sobi shall notify Auxilium of such intention or decision at least thirty (30) days (or as soon as possible if less than thirty (30) days) prior to any filing or payment due date, or any other date that requires action, in connection with such Sobi Applied Patent, and Auxilium shall thereupon have the right, but not the obligation, to assume responsibility for the preparation, filing, prosecution or maintenance thereof at its sole cost and expense, in the name of Auxilium and Sobi shall, and hereby does, assign to Auxilium Sobi’s entire right, title and interest in and to any such Sobi Applied Patents (rendering, for clarity, such Sobi Applied Patent an Auxilium Patent hereunder).  Sobi agrees to use Commercially Reasonable Efforts with respect to any decision to allow a Sobi Applied Patent to expire or to otherwise go abandoned, or with respect to any decision not to prepare or file patent applications covering Sobi Inventions.

 

9.3.4                     Cooperation.  The Parties agree to cooperate in the preparation, filing, prosecution and maintenance of all Patents under this Section 9.3, including obtaining and executing necessary powers of attorney and assignments by the named inventors, providing relevant technical reports to the filing Party concerning the Invention disclosed in such Patent, obtaining execution of such other documents which are needed in the filing and prosecution of such Patent, and, as requested by a Party, updating each other regarding the status of such Patent, and shall cooperate with the other Party so far as reasonably necessary with respect to furnishing all information and data in its possession reasonably necessary to obtain or maintain such Patents.

 

9.3.5                     Patent Expenses.  Any expenses incurred by a Party in connection with the preparation, filing, prosecution and maintenance of any Auxilium Patents, Joint

 

61

 

Collaboration Patents or Sobi Applied Patents, as applicable, shall be borne by the Party incurring such expenses.

 

9.4                               Defense and Enforcement of Patents.

 

9.4.1                     Infringement of Third Party Patents.  Each of the Parties shall promptly, but in any event no later than ten (10) days after receipt of notice thereof, notify the other Party in writing in the event of any claims by a Third Party of alleged patent infringement by Sobi or Auxilium or any of their respective Affiliates or sublicensees with respect to the research, development, manufacture, use, sale, offer for sale or importation of, as applicable, the Product, Bulk Product or Finished Product (each, an “Infringement Claim”).  With respect to any Infringement Claim in the Field in the Territory, the Parties shall attempt to negotiate in good faith a resolution with respect thereto.  If the Parties cannot settle such Infringement Claim with the appropriate Third Parties within thirty (30) days after the receipt of the notice pursuant to this Section 9.4.1, then the following shall apply:

 

(a)                                 In the case of any such claim against either Party with respect to the Product, Auxilium shall be deemed to be the “Controlling Party” for purposes of such Infringement Claim.    Sobi shall reasonably assist Auxilium in its role as the Controlling Party.

 

(b)                                 The Controlling Party shall assume control of the defense of such Infringement Claim.  The non-Controlling Party, upon request of the Controlling Party, agrees to join in any such litigation at the Controlling Party’s expense, and in any event to reasonably cooperate with the Controlling Party at the Controlling Party’s expense.  The non-Controlling Party will have the right to consult with the Controlling Party concerning such Infringement Claim and to participate in and be represented by independent counsel in any litigation in which such non-Controlling Party is a party at its own expense.  The Controlling Party shall have the exclusive right to settle any Infringement Claim without the consent of the other Party, unless such settlement shall have a material adverse impact on the other Party (in which case the consent of such other Party shall be required).  For purposes of this Section 9.4.1(b), any settlement that would involve the waiver of rights (including the rights to receive payments) of such other Party shall be deemed a material adverse impact and shall require the consent of such other Party, such consent not to be unreasonably withheld.

 

(c)                                  If a Party shall become engaged in or participate in any suit described in this Section 9.4.1, the other Party shall cooperate, and shall cause its and its Affiliates’ employees to cooperate, with such Party in all reasonable respects in connection therewith, including giving testimony and producing documents lawfully requested, and using its reasonable efforts to make available to the other, at no cost to the other (other than reimbursement of actually incurred, reasonable out-of-pocket travel and lodging expenses), such employees who may be helpful with respect to such suit, investigation, claim or other proceeding.

 

9.4.2                     Prosecution of Infringers.

 

(a)                                 Notice.  If either Party (i) receives notice of any patent nullity actions, any declaratory judgment actions or any alleged or threatened infringement of patents or

 

62

 

patent applications or misappropriation of intellectual property in the Territory comprising the (w) Joint Inventions, (x) Auxilium Patents, Auxilium Inventions or Auxilium Know-How or (y) Sobi Applied Patents, Sobi Inventions or Sobi Applied Know-How, or (ii) learns that a Third Party is infringing or allegedly infringing any Patent within the Auxilium Patents or Sobi Applied Patents in each case, in the Territory, or if any Third Party claims that any such Patent is invalid or unenforceable, in each case, with respect to the Field in the Territory, it will promptly notify the other Party thereof, including providing evidence of infringement or the claim of invalidity or unenforceability reasonably available to such Party.

 

(b)                                 Enforcement of Patents.

 

(i)                                     As between Auxilium and Sobi, Auxilium will have the first right (but not the obligation) to take the appropriate steps to enforce or defend any Patent within the Auxilium Patents and Joint Collaboration Patents against infringement by a Third Party that is conducting the manufacture, sale, use, offer for sale or import of any pharmaceutical product in the Field in the Territory.  Auxilium may take steps including the initiation, prosecution and control of any suit, proceeding or other legal action by counsel of its own choice.  Auxilium shall bear the costs of such enforcement or defense, as applicable.  Notwithstanding the foregoing, Sobi will have the right, at its own expense, to be represented in any such action by counsel of its own choice.

 

(ii)                                  If, pursuant to Section 9.4.2(b)(i), Auxilium fails to institute such litigation or otherwise take steps to remedy the infringement of an Auxilium Patent or a Joint Collaboration Patent within one hundred eighty (180) days of the date one Party has provided notice to the other Party pursuant to Section 9.4.2(a) of such infringement or claim, then Sobi will have the right (but not the obligation), at its own expense, to bring any such suit, action or proceeding by counsel of its own choice and Auxilium will have the right, at its own expense, to be represented in any such action by counsel of its own choice. Notwithstanding anything to the contrary contained herein, in no event shall Sobi have any right to bring any suit, action or proceeding with respect to any matter involving infringement of an Auxilium Manufacturing Patent, or a Patent outside the Territory or outside the Field.

 

(c)                                  Cooperation; Damages.

 

(i)                                     If one Party brings any suit, action or proceeding under Section 9.4.2(b), the other Party agrees to be joined as party plaintiff if necessary to prosecute the suit, action or proceeding and to give the first Party reasonable authority to file and prosecute the suit, action or proceeding; provided, however, that neither Party will be required to transfer any right, title or interest in or to any property to the other Party or any other party to confer standing on a Party hereunder.

 

(ii)                                  The Party not pursuing the suit, action or proceeding hereunder will provide reasonable assistance to the other Party, including by providing access to relevant documents and other evidence and making its employees available, subject to the other Party’s reimbursement of any Out of Pocket Costs incurred by the non-enforcing or defending Party in providing such assistance.

 

63

 

(iii)                               Sobi shall not, without the prior written consent of Auxilium (in its sole discretion), enter into any compromise or settlement relating to any claim, suit or action that it brought under Section 9.4.2 involving an Auxilium Patent (including any Joint Collaboration Patent), that admits the invalidity or unenforceability of any Auxilium Patent (including any Joint Collaboration Patent), or requires Auxilium to pay any sum of money, or otherwise adversely affects the rights of Auxilium with respect to such Patents, the Product or Auxilium’s rights hereunder (including the rights to receive payments).

 

(iv)                              Any settlements, damages or other monetary awards (a “Recovery”) recovered pursuant to a suit, action or proceeding brought pursuant to Section 9.4.2(b) will be allocated first to the costs and expenses of the Party taking such action, and second, to the costs and expenses (if any) of the other Party, with any remaining amounts (if any) to be allocated as follows: (i) to the extent that such Recovery is a payment for lost sales of the Product in the Field in the Territory, the Parties will negotiate in good faith the distribution of Recovery, which negotiations either can initiate at any time, including prior to any Recovery, and (ii) all remaining Recoveries shall be payable to the Party taking such action to the extent such remaining Recoveries relate solely to the Product in the Field in the Territory (and, for purposes of clarity, all remaining Recoveries related to the Product outside the Field or outside the Territory shall be payable to Auxilium).

 

(d)                                 Infringement and Defense of Auxilium Patents Outside of the Territory or Outside the Field.  For clarity, with respect to any and all infringement or defense of any Auxilium Patent (including any Joint Collaboration Patent) anywhere outside of the Territory or outside the Field, Auxilium (or its designee) shall have the sole and exclusive right to bring an appropriate suit or other action against any Person engaged in such infringement or defense of any such Auxilium Patents (including any Joint Collaboration Patents), in its sole discretion and Sobi shall have no rights with respect thereto.

 

9.5                               Patent Term Extensions.  As between Auxilium and Sobi, Auxilium shall have the exclusive right, but not the obligation, to seek, in Sobi’s name if so required, Patent Term Extensions (including any supplemental protection certificates and the like available under applicable Laws) in any country in the Territory in relation to the Auxilium Patents (including Joint Collaboration Patents).  Sobi and Auxilium shall cooperate in connection with all such activities.  Auxilium, its agents and attorneys will give due consideration to all suggestions and comments of Sobi regarding any such activities, but in the event of a disagreement between the Parties, Auxilium will have the final decision making authority.

 

9.6                               Patent Marking.  Sobi shall mark the Finished Product marketed and sold by Sobi (or its Affiliate or distributor) hereunder with appropriate patent numbers or indicia, to the extent not prohibited by Laws in a given country in the Territory.

 

ARTICLE 10
 REPRESENTATIONS, WARRANTIES AND COVENANTS

 

10.1                        Mutual Representations and Warranties.  Each Party hereby represents and warrants (as applicable) to the other Party as follows, as of the Effective Date:

 

64

 

10.1.1              Corporate Existence and Power.  It is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it hereunder.

 

10.1.2              Authority and Binding Agreement.  (i) It has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder, and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, except as enforcement may be affected by bankruptcy, insolvency or other similar laws and by general principles of equity.

 

10.1.3              No Conflicts.  The execution, delivery and performance of this Agreement by it does not (i) conflict with any agreement, instrument or understanding, oral or written, to which it is a party and by which it may be bound, subject in all cases to the rights of BTC under the BTC License Agreement or (ii) violate any Laws of any Governmental Authority having jurisdiction over it.

 

10.1.4              All Consents and Approvals Obtained.  Except with respect to Regulatory Approvals for the Development and Manufacturing of Bulk Product or Commercialization of the Finished Product or as otherwise described in this Agreement, (i) all necessary consents, approvals and authorizations of, and (ii) all notices to, and filings by such Party with, all Governmental Authorities and other Persons required to be obtained or provided by such Party as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained and provided, except for those approvals, if any, not required at the time of execution of this Agreement.

 

10.2                        Additional Representations, Warranties and Covenants of Auxilium.  Auxilium hereby represents, warrants and covenants to Sobi that, as of the Effective Date:

 

10.2.1              To its knowledge, Auxilium is the owner or licensee of the Auxilium Patents, Auxilium Know-How, Product Trademark and all other rights necessary to make and use the Bulk Product and use and sell the Finished Product.

 

10.2.2              Neither Auxilium nor its Affiliates, nor, to Auxilium’s knowledge, its subcontractors, has received any notice in writing or otherwise has knowledge of any facts which have led Auxilium to believe that any of the Regulatory Approvals relating to the Finished Product are not currently in good standing with the FDA, the EMA or their foreign equivalents.

 

10.2.3              Neither Auxilium nor, to the knowledge of Auxilium, its subcontractors, has received written notice of any proceedings pending before or threatened by any Regulatory Authority with respect to the Product or any Facility where the Drug Substance or Bulk Product is Manufactured.

 

65

 

10.2.4              To the knowledge of Auxilium, (a) the issued patents encompassed within the Auxilium Patents are valid and enforceable patents, and (b) there are no facts which would render the patent applications encompassed within the Auxilium Patents, if and when issued, invalid or unenforceable. To the knowledge of Auxilium, no Third Party (i) is infringing any such Auxilium Patents or has misappropriated any Auxilium Technology or (ii) has challenged the ownership, scope, duration, validity, enforceability, priority, or Auxilium’s right to use or license any Auxilium Technology.

 

10.2.5              Schedule 1.7 contains a complete and correct list of the Auxilium Patents that are Controlled by Auxilium (or its Affiliates) as of the Effective Date.

 

10.2.6              Auxilium (or its Affiliate) is the exclusive owner of the trademark registrations for XIAFLEX® and XIAPEX® as displayed on Schedule 10.2.6.  It has no knowledge of any trademarks or other rights which would prevent the use or registration of the XIAFLEX® or XIAPEX® mark in any of the countries of the Territory.

 

10.2.7              Other than as set forth in Schedule 10.2.7 there are no claims, judgments or settlements against or owed by Auxilium, nor any pending reissue, reexamination, interference, opposition or similar proceedings with respect to Auxilium’s Trademark XIAFLEX® and XIAPEX® or Auxilium Technology, and Auxilium has not received notice as of the Effective Date of any threatened claims or litigation or any reissue, reexamination, interference, opposition or similar proceedings seeking to invalidate or otherwise challenge the Auxilium Patent rights, Auxilium’s Trademark XIAFLEX® and XIAPEX® or Auxilium Know-How.

 

10.2.8              To the knowledge of Auxilium, the use, sale, offer for sale, or importation by Auxilium or Sobi (or their respective Affiliates), as applicable, of the Finished Product, (i) does not infringe any issued patent of any Third Party and (ii) does not misappropriate any Know-How of any Third Party and (iii) will not infringe any claim, if and when issued, within any patent application of any Third Party published as of the Effective Date.

 

10.2.9              All Finished Product Manufactured and supplied hereunder by, or under authority of, Auxilium shall be Manufactured and supplied such that:

 

(a)                                 The Finished Product furnished by Auxilium to Sobi under this Agreement:

 

(i)                                     shall be manufactured, handled, stored and shipped by Auxilium, in accordance with, and shall conform to, the applicable Product Specifications;

 

(ii)                                  shall be manufactured, handled, stored and shipped by Auxilium in compliance with all Laws including, GMPs and GDPs; and

 

(iii)                               shall, at the time delivered by Auxilium, not contain any material that would cause the Finished Product to be adulterated or misbranded within the meaning of applicable Laws.

 

66

 

(b)                                 In the course of the Development of the Bulk Product, to its knowledge, Auxilium has not used any employee that is debarred by the FDA under the Generic Drug Enforcement Act of 1992 (or by any analogous agency or under any analogous Laws in the Territory).

 

10.2.10       To its knowledge, Auxilium has complied with all Laws in all material respects, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Auxilium Patents owned by Auxilium in the Territory.

 

10.2.11       None of the rights of Auxilium or its Affiliates under the Auxilium Patents owned by Auxilium were developed with federal funding from the United States government or any other Governmental Authority.

 

10.2.12       Auxilium has obtained assignments from the inventors of all inventorship rights relating to the Auxilium Patents which are owned by Auxilium, and all such assignments of inventorship rights relating to such Auxilium Patents are valid and enforceable. With respect to the Auxilium Patents that are the subject of the BTC License Agreement, to the knowledge of Auxilium, BTC has obtained assignments from the inventors of all inventorship rights relating to such Patents, and to the knowledge of Auxilium, all such assignments are valid and enforceable.

 

10.2.13       Each of the Assigned Contracts is legal, valid and in full force and effect, and enforceable in accordance with its terms by Auxilium against the other parties thereto. Auxilium has performed all material obligations required to be performed by such party under the Assigned Contracts and is not in material Default under any Assigned Contract and, to the knowledge of Auxilium, no other party to any Assigned Contract in material Default thereunder. Neither Auxilium, any of its Affiliates, nor, to Auxilium’s knowledge, any other party to any of the Assigned Contracts has waived any of its material rights thereunder or modified any material terms thereof. Complete and correct copies of all Assigned Contracts and amendments thereto have been disclosed to Sobi. For the purpose of this subsection 10.2.13, “Default” means (i) breach, default or violation, (ii) the occurrence of an event that with or without the passage of time or the giving of notice, or both, would constitute a breach, default or violation or cause a claim or any other encumbrance to arise, or (iii) with respect to any commitments, undertakings or other agreements, the occurrence of an event that with or without passage of time or the giving of notice or both, would give rise to a right of termination, modification, renegotiation, cancellation, or a right to receive damages or a payment of penalties.

 

10.3                        Additional Representations, Warranties and Covenants of Sobi as of the Effective Date.  Sobi hereby represents, warrants and covenants to Auxilium that, as of the Effective Date:

 

10.3.1              Sobi is solvent and has the ability to pay and perform all of its obligations as and when such obligations become due, including payment obligations and other obligations under this Agreement.

 

10.3.2              Sobi’s compensation programs for its Sales Representatives do not, and will not, provide financial incentives for the promotion, sales, and marketing of the Finished Product in violation of any Laws or any professional requirements.

 

67

 

10.3.3              Sobi’s medical, regulatory and legal teams will review all training materials and programs prior to use by Sobi to ensure that all training materials and programs are in accordance with the Commercialization Plan, the Regulatory Approvals and applicable Laws.

 

10.3.4              All Finished Product Commercialized by, or under authority of, Sobi:

 

(a)                                 shall be handled, stored and shipped by Sobi, in accordance with, and shall conform to, the applicable Product Specifications;

 

(b)                                 shall be handled, stored and shipped by Sobi in compliance with all applicable Laws including, GMPs and GDP’s; and

 

(c)                                  shall, from and after the time delivered by Auxilium hereunder, not contain any material that would cause the Finished Product to be adulterated or misbranded within the meaning of Laws.

 

10.3.5              Sobi shall conduct its Development, Commercialization and all other activities related to this Agreement and the Finished Product, as applicable, in compliance with Laws and Regulatory Approvals including but not limited to anti-corruption Laws, including the U.S. Foreign Corrupt Practices Act and the UK Bribery Act 2010, and privacy laws, including the EU Data Protection Directive 95/46/EC.

 

10.4                        Additional Covenants of Sobi.  Sobi hereby covenants to Auxilium that to the extent that any Sobi Applied Patents are incorporated in the Bulk Product during the Term, Sobi shall ensure that:

 

(a)                                 To the knowledge of Sobi, no claim or demand of any Person has been asserted in writing to Sobi that challenges the rights of Sobi to use or license any of the Sobi Applied Technology.

 

(b)                                 To the knowledge of Sobi, Sobi has complied with all Laws, in all material respects, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Sobi Applied Patents owned by Sobi in the Territory.

 

(c)                                  To the knowledge of Sobi, none of the rights of Sobi or its Affiliates under the Sobi Applied Patents owned by Sobi were developed with federal funding from the United States government or any other Governmental Authority.

 

(d)                                 Sobi has obtained assignments from the inventors of all inventorship rights relating to the Sobi Applied Patents which are owned by Sobi, and, to the knowledge of Sobi, all such assignments of inventorship rights relating to such Sobi Applied Patents are valid and enforceable.

 

10.5                        Disclaimer.  Auxilium makes no warranties except as set forth in this ARTICLE 10 concerning the Auxilium Technology.  Sobi understands and acknowledges that the Product, including Bulk Product and Finished Product, are the subject of ongoing clinical research and development and that Auxilium cannot ensure the safety or usefulness of the Product of that the Finished Product receive Regulatory Approvals in any jurisdiction where such Regulatory

 

68

 

Approvals have not already been obtained or that the Finished Product will be able to maintain any such Regulatory Approvals in the Field in any other countries within the Territory.

 

10.6                        No Other Representations or Warranties.  EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY.  EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.

 

ARTICLE 11
 LIABILITY AND INDEMNIFICATION

 

11.1                        Indemnification by Auxilium.  Subject to the terms and condition of this Agreement, and to the extent finally determined pursuant to ARTICLE 15, Auxilium hereby shall be held liable for and agrees to save, indemnify, defend and hold Sobi, its Affiliates, and their respective directors, officers, agents and employees harmless from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) arising in connection with any and all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions by a Third Party (each a “Claim”) resulting or otherwise arising from (i) any breach by Auxilium of any of its representations, warranties, covenants or obligations pursuant to this Agreement, (ii) the negligence or willful misconduct by Auxilium or its Affiliates or their respective officers, directors, employees, agents or consultants in performing any obligations under this Agreement or (iii) any matter related to the Development or Manufacturing of the Finished Product hereunder (including, for clarity, product liability Losses including defects in design and failure to warn, in each case resulting therefrom) by Auxilium or its Affiliates or their respective officers, directors, employees, agents, consultants or sublicensees; in each case except to the extent that such Losses are subject to indemnification by Sobi pursuant to Section 11.2.

 

11.2                        Indemnification by Sobi.  Subject to the terms and condition of this Agreement, and to the extent finally determined pursuant to ARTICLE 15, Sobi hereby shall be held liable for and agrees to save, indemnify, defend and hold Auxilium, its Affiliates, and their respective directors, agents and employees harmless from and against any and all Losses arising in connection with any and all Claims resulting or otherwise arising from (i) any breach by Sobi of any of its representations, warranties, covenants or obligations pursuant to this Agreement, (ii) the negligence or willful misconduct by Sobi or its Affiliates or their respective officers, directors, employees, agents, consultants or sublicensees in performing any obligations under this Agreement, or (iii) any matter related to the Commercialization of the Finished Product hereunder (including, for clarity, product liability Losses including defects in design and failure to warn, in each case resulting therefrom) by Sobi or its Affiliates or their respective officers, directors, employees, agents or consultants; in each case except to the extent that such Losses are subject to indemnification by Auxilium pursuant to Section 11.1.

 

69

 

11.3                        Indemnification Procedures.

 

11.3.1              Notice of Claim.  All indemnification claims in respect of any indemnitee seeking indemnity under Section 11.1 or 11.2, as applicable (collectively, the “Indemnitees” and each an “Indemnitee”) will be made solely by the corresponding Party (the “Indemnified Party”).  The Indemnified Party will give the indemnifying Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses and any legal proceeding initiated by a Third Party against the Indemnified Party as to which the Indemnified Party intends to make a request for indemnification under Section 11.1 or 11.2, as applicable, but in no event will the Indemnifying Party be liable for any Losses that result from any delay in providing such notice which materially prejudices the defense of such proceeding.  Each Indemnification Claim Notice shall contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time).  Together with the Indemnification Claim Notice, the Indemnified Party will furnish promptly to the Indemnifying Party copies of all notices and documents (including court papers) received by any Indemnitee in connection with the Claim.

 

11.3.2              Control of Defense.  At its option, the Indemnifying Party may assume the defense of any Claim subject to indemnification as provided for in Section 11.1 or 11.2, as applicable, by giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice.  Upon assuming the defense of a Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Claim any legal counsel it selects, and such Indemnifying Party shall thereafter continue to defend such Claim in good faith.  Should the Indemnifying Party assume the defense of a Claim (and continue to defend such Claim in good faith), the Indemnifying Party will not be liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Claim, unless the Indemnifying Party has failed to assume the defense and employ counsel in accordance with this Section 11.3.

 

11.3.3              Right to Participate in Defense.  Without limiting Section 11.3.2, any Indemnitee will be entitled to participate in the defense of a Claim for which it has sought indemnification hereunder and to employ counsel of its choice for such purpose; provided, however, that such employment will be at the Indemnitee’s own expense unless (i) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (ii) the Indemnifying Party has failed to assume the defense (or continue to defend such Claim in good faith) and employ counsel in accordance with this Section 11.3, in which case the Indemnified Party will be allowed to control the defense.

 

11.3.4              Settlement.  With respect to any Losses relating solely to the payment of money damages in connection with a Claim and that will not result in the Indemnitee becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its reasonable discretion, will deem appropriate (provided, however, that such terms shall include a complete and unconditional

 

70

 

release of the Indemnified Party from all liability with respect thereto), and will transfer to the Indemnified Party all amounts which said Indemnified Party will be liable to pay prior to the time of the entry of judgment.  With respect to all other Losses in connection with Claims, where the Indemnifying Party has assumed the defense of the Claim in accordance with Section 11.3.2, the Indemnifying Party will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, provided it obtains the prior written consent of the Indemnified Party (which consent will be at the Indemnified Party’s reasonable discretion).  The Indemnifying Party that has assumed the defense of (and continues to defend) the Claim in accordance with Section 11.3.2 will not be liable for any settlement or other disposition of a Loss by an Indemnitee that is reached without the written consent of such Indemnifying Party.  Regardless of whether the Indemnifying Party chooses to defend or prosecute any Claim, no Indemnitee will admit any liability with respect to, or settle, compromise or discharge, any Claim without first offering to the Indemnifying Party the opportunity to assume the defense of the Claim in accordance with Section 11.3.2.

 

11.3.5              Cooperation.  If the Indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party will, and will cause each other Indemnitee to, cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection with such Claim.  Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket expenses incurred in connection with such cooperation.

 

11.3.6              Expenses of the Indemnified Party.  Except as provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Claim will be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.

 

11.4                        Limitation of Liability.  NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY CONSEQUENTIAL, INCIDENTAL, LOST PROFITS, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.  EXCEPT AS EXPRESSLY SET FORTH IN ANY REPRESENTATION OR WARRANTY IN ARTICLE 10, SOBI ACKNOWLEDGES AND AGREES THAT AUXILIUM HAS MADE NO REPRESENTATIONS OR WARRANTIES WITH RESPECT TO, AND SOBI SHALL HAVE NO CLAIM OR RIGHT (INCLUDING WITH RESPECT TO INDEMNIFICATION PURSUANT TO THIS ARTICLE 11 (OR OTHERWISE)) WITH RESPECT TO, ANY INFORMATION, DOCUMENTS OR MATERIALS FURNISHED TO OR FOR SOBI BY AUXILIUM, ANY OF ITS AFFILIATES, OR ANY OF ITS OR THEIR OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR ADVISORS, INCLUDING THE CONFIDENTIAL INFORMATION PACKAGE REGARDING THE PRODUCT, BULK

 

71

 

PRODUCT OR FINISHED PRODUCT PROVIDED TO SOBI AND ANY INFORMATION, DOCUMENTS OR MATERIAL MADE AVAILABLE TO SOBI IN ANY “DATA ROOM”, MANAGEMENT PRESENTATION OR ANY OTHER FORM IN EXPECTATION OF THE TRANSACTION AND COLLABORATION CONTEMPLATED HEREBY.

 

11.5                        Insurance.  Each Party shall (provided that either Party shall be allowed to self-insure) procure and maintain insurance, including clinical trials insurance and product liability insurance, adequate to cover its obligations hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which the Product is being clinically tested in human subjects or commercially distributed or sold by such Party pursuant to this Agreement, and the clinical trials insurance coverage shall in no event be less than Ten Million Dollars ($10,000,000) per loss occurrence and Ten Million Dollars ($10,000,000) in the aggregate, and product liability insurance coverage shall in no event be less than Twenty-five Million Dollars ($25,000,000) per loss occurrence and Twenty-five Million Dollars ($25,000,000) in the aggregate.  It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this ARTICLE 11.  Each Party shall provide the other Party with written evidence of such insurance prior to commencement of this Agreement and upon expiration of any one coverage.  Each Party shall promptly provide the other Party with written notice regarding the cancellation, nonrenewal or material change (but in any event within thirty (30) days of such cancellation, nonrenewal or material change) in such insurance or self-insurance which materially adversely affects the rights of the other Party hereunder.

 

ARTICLE 12
 CONFIDENTIALITY

 

12.1                        Confidential Information.  As used in this Agreement, the term “Confidential Information” means all information, whether it be written or oral, including all production schedules, lines of products, volumes of business, processes, new product developments, product designs, formulae, technical information, laboratory data, clinical data, patent information, know-how, trade secrets, financial and strategic information, marketing and promotional information and data, and other material relating to any products, projects or processes of one Party (the “Disclosing Party”) that is provided to, or otherwise obtained by, the other Party (the “Receiving Party”) in connection with this Agreement (including information exchanged prior to the date hereof in connection with the transactions set forth in this Agreement, including any information disclosed by either Party pursuant to the Confidentiality Agreement between the Parties dated February 5, 2013).  Notwithstanding the foregoing sentence, Confidential Information shall not include any information or materials that:

 

(a)                                 were already known to the Receiving Party (other than under an obligation of confidentiality), at the time of disclosure by the Disclosing Party, to the extent such Receiving Party has documentary evidence to that effect;

 

(b)                                 were generally available to the public or otherwise part of the public domain at the time of disclosure thereof to the Receiving Party;

 

72

 

(c)                                  became generally available to the public or otherwise part of the public domain after disclosure or development thereof, as the case may be, and other than through any act or omission of a Party in breach of such Party’s confidentiality obligations under this Agreement;

 

(d)                                 were disclosed to a Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others; or

 

(e)                                  were independently discovered or developed by or on behalf of the Receiving Party without the use of the Confidential Information belonging to the other Party, to the extent such Receiving Party has documentary evidence to that effect.

 

12.2                        Confidentiality Obligations.  Each of Sobi and Auxilium shall keep all Confidential Information received from or on behalf of the other Party with the same degree of care with which it maintains the confidentiality of its own Confidential Information, but in all cases no less than a reasonable degree of care.  Neither Party shall use such Confidential Information for any purpose other than in performance of this Agreement or disclose the same to any other Person other than to such of its and its Affiliates’ directors, managers, employees, independent contractors, agents, consultants or, its sublicensees who in each case have a need to know such Confidential Information to implement the terms of this Agreement or enforce its rights under this Agreement; provided, however, that a Receiving Party shall advise any of its and its Affiliates’ directors, managers, employees, independent contractors, agents, consultants or sublicensees who receives such Confidential Information of the confidential nature thereof and of the obligations contained in this Agreement relating thereto, and the Receiving Party shall ensure (including, in the case of a Third Party, by means of a written agreement with such Third Party having terms at least as protective as those contained in this ARTICLE 12) that all such directors, managers, employees, independent contractors, agents, consultants or sublicensees comply with such obligations.  Upon termination of this Agreement, the Receiving Party shall return or destroy all documents, tapes or other media containing Confidential Information of the Disclosing Party that remain in the possession of the Receiving Party or its directors, managers, employees, independent contractors, agents, consultants or sublicensees, except that the Receiving Party may keep one copy of the Confidential Information in confidential files of the Receiving Party, solely for archival purposes and subject at all times to the obligations of confidentiality and non-use described herein.  Such archival copy shall be deemed to be the property of the Disclosing Party, and shall continue to be subject to the provisions of this ARTICLE 12.

 

12.3                        Permitted Disclosure and Use.  Notwithstanding Section 12.2, (i) either Party may disclose Confidential Information belonging to the other Party only to the extent such disclosure is reasonably necessary to: (a) comply with or enforce any of the provisions of this Agreement; or (b) comply with Laws; and (ii) Auxilium may disclose Confidential Information belonging to Sobi related to a Product only to the extent such disclosure is reasonably necessary to obtain or maintain regulatory approval of a Product, as applicable, to the extent such disclosure is made to a Governmental Authority.  If a Party deems it necessary to disclose Confidential Information of the other Party pursuant to this Section 12.3, such Party shall give reasonable advance written notice of such disclosure to the other Party to permit such other Party

 

73

 

sufficient opportunity to object to such disclosure or to take measures to ensure confidential treatment of such information, including seeking a protective order or other appropriate remedy.  Notwithstanding Section 12.2, Auxilium may also disclose Confidential Information belonging to Sobi related to the Bulk Product or Finished Product (X) to BTC pursuant to the BTC License Agreement and (Y) to Third Parties in connection with the development or commercialization of the Bulk Product or Finished Product outside of the Field or outside of the Territory (provided that such Third Parties are bound by written agreements having terms at least as protective as those contained in this ARTICLE 12 with respect to keeping such Confidential Information confidential).

 

12.4                        Notification.  The Receiving Party shall notify the Disclosing Party promptly upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information, and will cooperate with the Disclosing Party in any reasonably requested fashion to assist the Disclosing Party to regain possession of such Confidential Information and to prevent its further unauthorized use or disclosure.

 

12.5                        Publicity; Filing of this Agreement.

 

12.5.1              Publicity.  The press release to be issued in connection with the transactions is set forth on Schedule 12.5.1.  Except as otherwise provided in this Section 12.5, each Party shall maintain the confidentiality of all provisions of this Agreement, and without the prior written consent of the other Party, which consent shall not be unreasonably withheld, neither Party nor its respective Affiliates shall make any press release or other public announcement of or otherwise disclose the provisions of this Agreement, except for: (i) disclosure to those of its directors, officers, employees, accountants, attorneys, auditors, underwriters, lenders and other financing sources, potential strategic partners, advisors, agents and sublicensees whose duties reasonably require them to have access to this Agreement, provided that such directors, officers, employees, accountants, attorneys, underwriters, lenders and other financing sources, potential strategic partners, advisors, agents or sublicensees are required to maintain the confidentiality of this Agreement, (ii) disclosures required by Nasdaq regulation or any listing agreement with a national securities exchange, in which case the disclosing Party shall provide the nondisclosing Party with at least forty eight (48) hours’ notice unless otherwise not practicable, but in any event no later than the time the disclosure required by such Nasdaq regulation or listing agreement is made, (iii) disclosures as may be required by Laws, in which case the disclosing Party shall provide the nondisclosing Party with prompt advance notice of such disclosure and cooperate with the nondisclosing Party to seek a protective order or other appropriate remedy, including a request for confidential treatment in the case of a filing with the Securities and Exchange Commission, (iv) the report on Form 8-K, which may be filed by Auxilium or an Affiliate of Auxilium setting forth the press release referred to above, and/or the Redacted Agreement (as defined in Section 12.5.2), and the report on Form 10-K or Form 10-Q, which may be filed by Auxilium or an Affiliate of Auxilium setting forth the Redacted Agreement, (v) disclosures that are consistent with or complementary to those described in clause (iv) but which do not contain any Confidential Information of the other Party; and (vi) other disclosures for which consent has previously been given.  A Party may publicly disclose without regard to the preceding requirements of this Section 12.5 any information that was previously publicly disclosed pursuant to this Section 12.5.

 

74

 

12.5.2              Redacted Agreement.  Auxilium shall prepare a redacted copy of this Agreement (“Redacted Agreement”) which it shall provide to Sobi for comments, which comments Auxilium shall consider in good faith; provided, that Auxilium shall have final discretion with regards to the content of the Redacted Agreement.  In the event Sobi is obligated to file this Agreement it shall file the Redacted Agreement as filed by Auxilium.

 

12.6                        Publication.  Sobi shall submit copies of each proposed academic, scientific, medical and other publication or presentation that contains or refers to the Auxilium Patents, Auxilium Know-How or otherwise relates to the Bulk Product or Finished Product or any research, Development Activities, or Commercialization under this Agreement to Auxilium at least thirty (30) days in advance of submitting such proposed publication or presentation to a publisher or other Third Party.  Auxilium shall have the right to review, comment on and consent to each such proposed publication or presentation at its sole discretion.  Auxilium shall have the right to remove any of its Confidential Information prior to submission for publication or presentation.  Sobi shall redact or otherwise modify the proposed publication or presentation to remove any such Confidential Information of Auxilium.  In addition, in the event that the document includes data, information or material generated by Auxilium’s scientists, and professional standards for authorship would be consistent with including Auxilium’s scientists as co-authors of the document, the names of such scientists will be included as co-authors.

 

12.7                        Use of Names.  Except as otherwise set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld; provided, however, that subject to Section 12.5, either Party may use the name of the other Party in any document filed with or required to be released by any Regulatory Authority or Governmental Authority, including the Securities and Exchange Commission.

 

12.8                        Survival.  The obligations and prohibitions contained in this ARTICLE 12 as they apply to Confidential Information shall survive the expiration or termination of this Agreement for a period of ten (10) years.

 

ARTICLE 13
 TERM AND TERMINATION

 

13.1                        Term.  This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this ARTICLE 13, shall remain in effect, on a country-by-country and Finished Product-by-Finished Product basis, until the expiration of the Royalty Term in such country with respect to such Finished Product in the Territory (the “Term”).

 

13.2                        Termination for Material Breach.  Either Party may, without prejudice to any other remedies available to it at law or in equity, terminate this Agreement upon written notice to the other Party in the event that the other Party (the “Breaching Party”) shall have materially breached or defaulted in the performance of any of its obligations.  The Breaching Party shall have sixty (60) days (thirty (30) days in the event of non-payment) after written notice thereof was provided to the Breaching Party by the non-breaching Party to remedy such default.  Unless the Breaching Party has cured any such breach or default prior to the expiration of such sixty

 

75

 

(60) day period (thirty (30) day period for non-payment), such Termination shall become effective upon receipt of the written notice of termination by the Breaching Party to be given within ten (10) days of the end of the sixty (60) day period (thirty (30) day period for non-payment).

 

13.3                        Termination as a Result of Bankruptcy.  Each Party shall have the right to terminate this Agreement upon written notice as a result of the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided that such termination shall be effective only if such proceeding is not dismissed within ninety (90) days after the filing thereof.

 

13.4                        Termination by Auxilium.  Without limitation of its other rights under this ARTICLE 13, Auxilium will be permitted to terminate this Agreement: (A) in its entirety upon written notice to Sobi, effective upon receipt, if Sobi or any of its Affiliates or subcontractors, directly or indirectly, (i) initiate or request an interference or opposition proceeding with respect to, (ii) make, file or maintain any claim, demand, lawsuit or cause of action to challenge the validity or enforceability of, or (iii) oppose any extension of, or the grant of a supplementary protection certificate with respect to, any Auxilium Patent or Auxilium Manufacturing Patent (each of clause (i) or (ii), a “Patent Challenge”); (B) in its entirety or on a country-by-country basis, as applicable, pursuant to the provisions of Sections 5.2.2(a) and 5.8; (C) in its entirety if after 2013, for two (2) consecutive years, Sobi has not reached at least [***] of the minimum Finished Product sales reflected in Schedule 6.3.1(b); and (D) commencing with the year ending December 31, 2016 in its entirety if (I) the sum of (i) the aggregate of the Commercial Supply Price paid to Auxilium for the Finished Product delivered during any calendar year plus (ii) the aggregate of all Royalty Payments paid to Auxilium with respect to such calendar year, divided by (II) the aggregate number of Finished Product sold by Sobi during such calendar year is less than the average Manufacturing Standard Cost for such calendar year.

 

13.5                        Termination by Sobi.  Sobi may terminate this Agreement in whole, or on a country by country basis, for any reason with prior written notice of one (1) year; provided that such notice may not be given prior to the fourth (4th) anniversary of the Effective Date without any termination payments or other compensation payable to Auxilium.  In the event of any termination by Sobi, and in addition to any such termination payments or other compensation, Sobi shall pay or reimburse Auxilium for all of the reasonable costs incurred to transition the sale of the Products to Auxilium or its designee.

 

*** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

76

 

ARTICLE 14
 EFFECTS OF TERMINATION

 

14.1                        Effects of Termination.  Without limiting any other legal or equitable remedies that a Party may have, if this Agreement is terminated prior to its natural expiration, then the following provisions shall apply:

 

14.1.1              Termination of Licenses.  All rights and licenses granted to Sobi hereunder shall immediately terminate and be of no further force and effect and Sobi shall cease any Development Activities, if any, and Commercializing the Finished Product (except as otherwise set forth in Section 14.1.4).

 

14.1.2              Assignments.  Sobi will promptly upon Auxilium’s request, in each case within sixty (60) days after receipt of Auxilium’s request, and at no cost to Auxilium:

 

(a)                                 assign to Auxilium all of Sobi’s right, title and interest in and to any agreements between Sobi and Third Parties that relate solely to Development Activities or Commercialization of the Finished Product;

 

(b)                                 assign to Auxilium all of Sobi’s right, title and interest in and to any (i) Promotional Materials and (ii) copyrights and trademarks (including the Product Trademarks), including any goodwill associated therewith, and any registrations and design patents for the foregoing, and (iii) any Internet domain name registrations for such trademarks and slogans, all to the extent solely related to the Finished Product; provided, however, in the event Auxilium exercises such right to have assigned such Promotional Materials, Sobi shall grant, and hereby does grant, a royalty-free right and license to any housemarks, trademarks, names and logos of Sobi contained therein for a period of twelve (12) months in order to use such Promotional Materials in connection with the Commercialization of the Finished Product;

 

(c)                                  assign to Auxilium, the management and continued performance of any clinical trials for the Bulk Product ongoing hereunder, if any, as of the effective date of such termination in respect of which Auxilium shall assume full financial responsibility from and after the effective date of such termination;

 

(d)                                 transfer to Auxilium all of, if any, Sobi’s right, title and interest in and to any and all regulatory filings, Regulatory Approvals and other Regulatory Materials for the Finished Product in respect of which Auxilium shall assume full financial responsibility;

 

(e)                                  transfer to Auxilium all of Sobi’s right, title and interest in and to any and all Development Data and Promotional Commercialization Data Controlled by Sobi for the Bulk Product or Finished Product, as the case may be; and

 

(f)                                   provide a copy of (i) the material tangible embodiments of the foregoing and (ii) any other material books, records, files and documents Controlled by Sobi solely to the extent related to the Bulk Product or Finished Product, as the case may be, and which may be redacted to exclude Confidential Information of Sobi;

 

77

 

(g)                                  provided, however, that to the extent that any agreement or other asset described in this Section 14.1.2 is not assignable by Sobi or if the Parties mutually determine that it is not practicable to assign such agreement or other asset to Auxilium, then such agreement or other asset will not be assigned, and upon the request of Auxilium, Sobi will take such steps as may be reasonably necessary to allow Auxilium to obtain and to enjoy the benefits of such agreement or other asset.  For purposes of clarity, (1) Auxilium shall have the right to request that Sobi take any or all of the foregoing actions in whole or in part, or with respect to all or any portion of the assets set forth in the foregoing provisions and (2) to the extent Auxilium requests Sobi to transfer its right, title and interest in the items set forth in this Section 14.1.2 to Auxilium, Sobi shall also cause its Affiliates and sublicensees to transfer and assign to Auxilium all of such Affiliates’ and sublicensees’ right, title and interest in and to the foregoing items set forth in this Section 14.1.2.

 

14.1.3              Disclosure and Delivery.  Sobi will promptly transfer to Auxilium copies of any physical embodiment of any Sobi Applied Know-How, to the extent then used in connection with the Development of the Bulk Product or Commercialization of the Finished Product; such transfer shall be effected by the delivery of material documents, to the extent such Sobi Applied Know-How is embodied in such documents, and to the extent that Sobi Applied Know-How is not fully embodied in such documents, Sobi shall make its employees and agents who have knowledge of such Sobi Applied Know-How in addition to that embodied in documents available to Auxilium for interviews, demonstrations and training to effect such transfer in a manner sufficient to enable Auxilium to practice such Sobi Applied Know-How but only in a manner as set out as follows in this Section.  The appropriate technical teams at Auxilium and Sobi will meet to plan transfer for the Sobi Applied Know-How as follows: (a) Sobi’s designated representative(s) for the Bulk Product will meet with representatives from Auxilium to answer questions with respect to the Sobi Applied Know-How and establish a plan for the transfer for such Sobi Applied Know-How; (b) Sobi will allocate adequate appropriately qualified representatives to work with Auxilium to review the Sobi Applied Know-How to enable the completion of the transfer within thirty (30) days of the completion of the initial transfer planning meetings to the extent reasonable, but in any event no longer than sixty (60) days thereafter.

 

14.1.4              Disposition of Inventory.  Sobi and its Affiliates will be entitled, during the period ending on the last day of the sixth (6th) full month following the effective date of such termination, to sell any inventory of Finished Product affected by such termination that remains on hand as of the effective date of the termination, so long as Sobi pays to Auxilium the Royalty Payments and other amounts payable hereunder (including milestones) applicable to said subsequent sales, with respect to sales in the Territory, as applicable, in accordance with the terms and conditions set forth in this Agreement and otherwise complies with the terms set forth in this Agreement.

 

14.1.5              Disposition of Commercialization Related Materials.  Sobi will promptly deliver to Auxilium in electronic, sortable form (a) a list identifying all wholesalers and other distributors involved in the Commercialization of the Finished Product in the Territory as well as any customer lists (e.g., purchasers, trained physicians, and end-user physicians, upon obtaining necessary consents to comply with applicable privacy laws) related to the Commercialization of the Finished Product in the Territory, and (b) all Promotional Materials

 

78

 

and other materials such as market research, disease state and educational materials, as well as any items bearing the Product Trademark and/or any trademarks or housemarks otherwise associated with the Finished Product or Auxilium.

 

14.2                        Sobi Rights In Lieu of Termination.  Without limiting any other legal or equitable remedies that Sobi may have, if Sobi has the right to terminate this Agreement in accordance with Section 13.2 because Auxilium is the breaching Party, then Sobi shall have the option, in its sole discretion, to allow this Agreement to remain in full force and effect in lieu of exercising such termination right.

 

14.3                        Accrued Rights.  Termination or expiration of this Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of a Party prior to the effective date of such termination.  Such termination will not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement.

 

14.4                        Survival.  Notwithstanding anything to the contrary contained herein, the following provisions shall survive any expiration or termination of this Agreement: Articles: 11, 12 and 16 and Sections: 14.1, 14.2, 14.3, 14.4 and 14.5.  Except as set forth in this ARTICLE 14 or otherwise expressly set forth herein, upon termination or expiration of this Agreement all other rights and obligations of the Parties shall cease.

 

14.5                        Rights in Bankruptcy.  All rights and licenses granted under or pursuant to this Agreement by Auxilium and Sobi are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code.  The Parties agree that each Party, as licensee of certain rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code.  The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party (such Party, the “Bankrupt Party”) under the U.S. Bankruptcy Code, (a) the other Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any intellectual property licensed to such other Party and all embodiments of such intellectual property, which, if not already in such other Party’s possession, shall be promptly delivered to it (x) upon any such commencement of a bankruptcy proceeding upon such other Party’s written request therefore, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement or (y) if not delivered under clause (x), following the rejection of this Agreement by the Bankrupt Party upon written request therefore by the other Party and (b) the Bankrupt Party shall not unreasonably interfere with the other Party’s rights to intellectual property and all embodiments of intellectual property, and shall assist and not unreasonably interfere with the other Party in obtaining intellectual property and all embodiments of intellectual property from another entity.  The “embodiments” of intellectual property includes all tangible, intangible, electronic or other embodiments of rights and licenses hereunder, including all compounds and products embodying intellectual property, Bulk Product, Finished Product, filings with Regulatory Authorities and related rights and Auxilium Know-How in the case that Auxilium is the Bankrupt Party and Sobi Applied Know-How in the case Sobi is the Bankrupt Party.

 

14.6                        Continuing Obligations.  In the event of a termination of this Agreement pursuant to Section 13.4(D), Auxilium shall continue to supply Units of Product and Finished

 

79

 

Product under any previously accepted Purchase Orders (and related Packaging and Labeling Orders), but Auxilium shall not be required to accept any new Purchase Orders.

 

ARTICLE 15
 DISPUTE RESOLUTION

 

15.1                        Disputes.  The Parties recognize that, from time to time during the Term, disputes may arise as to certain matters which relate to either Party’s rights and/or obligations hereunder.  It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation.  To accomplish this objective, the Parties agree to follow the procedures set forth in this ARTICLE 15 to resolve any controversy or claim arising out of, relating to or in connection with any provision of this Agreement (other than a dispute addressed in Section 3.4).

 

15.2                        Arising Between the Parties.  With respect to all disputes arising between the Parties and not from the JSC, including any alleged failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, if the Parties are unable to resolve such dispute within thirty (30) days after such dispute is first identified by either Party in writing to the other, the Parties shall refer such dispute to the Chief Executive Officers of each of the Parties, or a designee from senior management with decision-making authority (the Chief Executive Officer or such designee, the “Executive Officer”) for attempted resolution by good-faith negotiations within thirty (30) days after such notice is received.

 

15.3                        Dispute Resolutions.  If the Executive Officers are not able to resolve such dispute referred to them under Section 15.2 within such thirty (30) day period, then either Party shall have right to pursue any legal or equitable remedy available to it under Laws; provided that any litigation arising under this Agreement shall be brought in the United States Court for the Southern District of New York.  Each Party hereby agrees to the exclusive jurisdiction of such court and waives any objections as to the personal jurisdiction or venue of such court.

 

15.4                        Patent and Trademark Dispute Resolution.  Any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any patent rights covering the manufacture or use of any Finished Product or of any trademark rights relating to any Finished Product shall be submitted to a court of competent jurisdiction in the Territory in which such patent or trademark rights were granted or arose.

 

15.5                        Injunctive Relief.  Nothing herein may prevent either Party from seeking a preliminary injunction or temporary restraining order, in any court of competent jurisdiction, so as to prevent any Confidential Information from being disclosed in violation of this Agreement.

 

ARTICLE 16
 MISCELLANEOUS

 

16.1                        Entire Agreement; Amendment.  This Agreement, including the Exhibits and Schedules hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date,

 

80

 

all prior agreements and understandings between the Parties with respect to the subject matter hereof, including the Confidential Disclosure Agreement between the Parties dated February 5, 2013 (which shall remain effective prior to the Effective Date).  There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized representative of each Party.

 

16.2        Force Majeure.  A Party shall be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party.  Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party makes reasonable efforts to remove the condition.  For purposes of this Agreement, force majeure shall include conditions beyond the control of the Parties, which might include, without limitation, an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, and non-performance by Third Party suppliers or subcontractors.  Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of force majeure affecting such Party.

 

16.3        Notices.  Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 16.3, and shall be deemed to have been given for all purposes (i) when delivered, if hand-delivered or sent by facsimile on a business day, (ii) on the next business day if sent by a reputable international overnight courier service, or (iii) five (5) business days after mailing, if mailed by first-class certified or registered airmail, postage prepaid, return receipt requested.  Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below:

 

	
If to Auxilium:
    	
Auxilium   Pharmaceuticals, Inc.
    
	
 
    	
640 Lee Road
    
	
 
    	
Chesterbrook,   Pennsylvania 19087
    
	
 
    	
U.S.A.
    
	
 
    	
Attention: Andrew I.   Koven, Chief Administrative Officer & General Counsel
    
	
 
    	
Fax: 1-484-321-5996
    
	
 
    	
 
    
	
With a copy to:
    	
Holland &   Knight LLP
    
	
 
    	
701 Brickell Avenue,   Suite 3000
    
	
 
    	
Miami, FL 33143
    
	
 
    	
U.S.A.
    
	
 
    	
Attn: Rodney H. Bell
    
	
 
    	
Fax: 1-305-789-7799
    

 

81

 

	
If to Sobi:
    	
Swedish Orphan   Biovitrum AB (publ)
    
	
 
    	
SE-112 76 Stockholm
    
	
 
    	
Sweden
    
	
 
    	
 
    
	
 
    	
Delivery address:
    
	
 
    	
Tomtebodavägen 23a, 171 65 Solna
    
	
 
    	
Attention: General Counsel
    
	
 
    	
Fax: +46 8 697 30   56
    
	
 
    	
 
    
	
With a copy to:
    	
Swedish Orphan   Biovitrum AB (publ)
    
	
 
    	
SE-112 76 Stockholm
    
	
 
    	
Sweden
    
	
 
    	
Attn: Head of   Marketing & Sales
    

 

16.4        No Strict Construction; Interpretation.  This Agreement has been prepared jointly and shall not be strictly construed against either Party.  Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.  The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section.

 

16.5        Assignment.  Without limiting Sobi’s rights under Section 2.4.2, neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other, which consent shall not be unreasonably withheld, except that Auxilium may make such an assignment without Sobi’s consent to (a) Affiliates or (b) a successor to substantially all of the business of Auxilium to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other transaction.  Any permitted assignment shall be binding on the successors of the assigning Party.  Any assignment or attempted assignment by either Party in violation of the terms of this Section 16.5 shall be null, void and of no legal effect.

 

16.6        Further Actions.  Each Party agrees to execute, acknowledge and deliver such further instruments, and to perform all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

16.7        Severability.  If any one or more of the provisions of this Agreement are held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, such provision or provisions shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.  The Parties shall make a good-faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.

 

16.8        No Waiver.  Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.

 

82

 

16.9        Independent Contractors.  Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way.  Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties.

 

16.10      English Language; Governing Law.  This Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement.  This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed under the laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state.

 

16.11      Counterparts.  This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

[No Further Text on This Page]

 

83

 

IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives as of the date first written above.

 

 

	
SWEDISH   ORPHAN BIOVITRUM AB (PUBL)
    	
AUXILIUM   UK LTD
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/   Anders Edvell
    	
 
    	
By:
    	
/s/   Michael J. Purvis
    
	
Name:
    	
Anders   Edvell
    	
Name:
    	
Michael   J. Purvis
    
	
Title:
    	
VP   Sobi Partner Products
    	
Title:
    	
Director
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/   Alan Raffensperger
    	
 
    	
 
    
	
Name:
    	
Alan   Raffensperger
    	
 
    
	
Title:
    	
COO/SVP
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
AUXILIUM INTERNATIONAL HOLDINGS, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   James Englund
    
	
 
    	
Name:
    	
James   Englund
    
	
 
    	
Title:
    	
President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]